




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07H 19/01; A61K 31/70		A1	(11) International Publication Number: WO 93/05058
			(43) International Publication Date: 18 March 1993 (18.03.93)
(21) International Application Number: PCT/US92/07508 (22) International Filing Date: 2 September 1992 (02.09.92) (30) Priority data: 756,946 9 September 1991 (09.09.91) US 921,851 5 August 1992 (05.08.92) US (71) Applicant: MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (72) Inventors: SINCLAIR, Peter, J. ; 92 Maple Court, Highland Park, NJ 08904 (US). WONG, Frederick ; 16 High Street, Glen Ridge, NJ 07028 (US). GOULET, Joung ; GOULET, Mark ; 719 Hanford Place, Westfield, NJ 07090 (US). PARSONS, Williams, H. ; 2171 Oliver Street, Rahway NJ 07065 (US). WYVRATT, Matthew, J. ; 1130 Puddingstone Road, Mountainside, NJ 07092 (US).			(74) Agent: THIES, J., Eric; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (81) Designated States: BG, CS, FI, HU, NO, PL, RO, RU. Published With international search report.

(54) Title: O-HETEROARYL, O-ALKYLHETEROARYL, O-ALKENYLHETEROARYL AND O-ALKYNYLHETEROARYLMACROLIDES



(57) Abstract

O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides of general structural formula (I) have been prepared from suitable precursors by alkylation and/or arylation at C-3'' and/or C-4'' of the cyclohexyl ring. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases, the prevention of rejection of foreign organ transplants and/or related afflictions, diseases and illnesses.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	MN	Mongolia
AU	Australia	FR	France	MR	Mauritania
BB	Barbados	GA	Gabon	MW	Malawi
BE	Belgium	GB	United Kingdom	NL	Netherlands
BF	Burkina Faso	GN	Guinea	NO	Norway
BG	Bulgaria	GR	Greece	NZ	New Zealand
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	PT	Portugal
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	RU	Russian Federation
CG	Congo	KP	Democratic People's Republic of Korea	SD	Sudan
CH	Switzerland	KR	Republic of Korea	SE	Sweden
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovak Republic
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CS	Czechoslovakia	LU	Luxembourg	SU	Soviet Union
CZ	Czech Republic	MC	Monaco	TD	Chad
DE	Germany	MG	Madagascar	TG	Togo
DK	Denmark	MI	Mali	UA	Ukraine
ES	Spain			US	United States of America

5

- 1 -

10

TITLE OF THE INVENTION

O-HETEROARYL, O-ALKYLHETEROARYL, O-ALKENYLHETEROARYL
AND O-ALKYNYLHETEROARYLMACROLIDES

15

SUMMARY OF THE INVENTION

This application is a continuation-in-part
of copending application Serial No. 07/756,946, filed
September 9, 1991.

20

The present invention is related to
O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl
and O-alkynylheteroarylmacrolides which are useful in
a mammalian host for the treatment of autoimmune
diseases (such as juvenile-onset diabetes mellitus,
25 multiple sclerosis and rheumatoid arthritis),
immunodepression, infectious diseases and/or the
prevention of rejection of foreign organ transplants
(e.g. bone marrow and heart transplants and xeno
transplants) and are also useful in the topical
30 treatment of inflammatory and hyperproliferative skin
diseases and cutaneous manifestations of
immunologically-mediated illnesses (such as:
psoriasis, atypical dermatitis, contact

- 2 -


dermatitis and further eczematous dermatitises,
seborrhoeic dermatitis, Lichen planus, Pemphigus,
bullous Pemphigoid, Epidermolysis bullosa, urticaria,
angioedemas, vasculitides, erythemas, cutaneous
5 eosinophilias, Lupus erythematosus, Alopecia areata),
male pattern alopecia, alopecia senilis, reversible
obstructive airways disease, particularly asthma,
alopecia, inflammation of mucosa and blood vessels,
cytomegalovirus infection, multidrug resistance,
10 idiopathic thrombocytopenic purpura, Behcet's
syndrome, conjunctivitis, Crohn's disease, Mooren's
ulcer, uveitis, severe intraocular inflammation,
and/or hepatic injury associated with ischemia. In
addition, some of the compounds of this invention may
15 have antagonistic properties and so have utility in
the reversal of immunosuppressive activity and/or
diminishing the toxicity of other immunosuppressive
agents.

20 More particularly, this invention relates to
compounds of the general structural formula I:

25

30

- 3 -



I

- 4 -

wherein R¹, R², R³, R⁴, R⁵, R¹⁰, W and n are hereinafter defined.

5 This invention also relates to pharmaceutical compositions containing the compounds and to a method of use of the present compounds and other agents for the treatment of and prevention of certain afflictions, diseases and illnesses.

BRIEF DESCRIPTION OF DISCLOSURES IN THE ART

10 Fujisawa United States, European and Japanese patents and applications (U.S. Patent No. 4,894,366, issued January 16, 1990, EPO Publication No. 0,184,162 and PBJ Disclosure 63-17884) and publications (J. Am. Chem. Soc., 1987, 109, 5031 and
15 J. Antibiotics 1987, 40, 1249) disclose 17-allyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (FR-900506), (FK-506),
20 (L-679,934), 17-ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (FR-900520) and related compounds which are
25 the starting materials for the preparation of the compounds described. The synthetic preparation of the aforementioned starting material (FR-900506) has recently been reported (J. Am. Chem. Soc., 1989, 111, 1157). A Sandoz European patent application (EPO
30 Publication No. 0,356,399) discloses stereoisomers of FR-900506 and derivatives at the 17-position. Fisons European and WIPO patent applications (EPO Publication No. 0,323,042 and PCT Publication No. WO

- 5 -

89/05304) discloses various derivatives of FR-900506, FR-900520 and related compounds. A Sandoz European Patent application (EPO Publication No. 0.437.680) discloses chloro, bromo, iodo and azido derivatives of FR-900506, FR-900520 and related compounds. A Merck European Patent application (EPO Publication No. 0.428.365) discloses various amino derivatives of FR-900506, FR-900520 and related compounds. A Fujisawa patent application (UK Publication No. GB 2.245.891-A) discloses various derivatives of FR-900506 bearing a heterocyclic group.

Fujisawa United States patents (U.S. Patent No. 4.929.611, issued May 29, 1990, U.S. Patent No. 4.956.352, issued Sept. 11, 1990 and U.S. Patent No. 5.110.811, issued May 5, 1992) discloses the use of FK-506-type compounds in treating resistance to transplantation. A Sandoz European patent application (EPO Publication No. 0.315.978) discloses the use of FR-900506 and related compounds in the topical treatment of inflammatory and hyperproliferative skin diseases and of cutaneous manifestations of immunologically-mediated illness. A Fisons WIPO patent application (PCT Publication No. WO 91/04025) discloses the use of various derivatives of FR-900506 in the treatment of immunodepression. A Fisons WIPO patent application (PCT Publication WO 90/14826) discloses the use of FR-900506 and related compounds in the treatment of reversible obstructive airways disease, particularly asthma. A Fujisawa European patent application (EPO Publication No. 0.423.714) discloses the use of FK-506 and derivatives as hair revitalizing agents. Various studies have suggested the efficacy of FK-506 in the treatment of a number of ailments, including

- 6 -

rheumatoid arthritis (C. Arita, et al., Clinical exp. Immunol., 1990, 82, 456-461; N. Inamura, et al., Clin. Immunol. Immunopathol. 1988, 46, 82-90), recent-onset diabetes (N. Murase, et al., Diabetes, 1990, 39, 1584-86; N. Murase, et al., Lancet, 1990, 336, 373-74), posterior uveitis (H. Kawashima, Invest. Ophthalmol. Vis. Sci., 1988, 29, 1265-71), hepatic injury associated with ischemia (M. Sakr, et al., Life Sci., 1990, 47, 687-91) allergic encephalomyelitis (K. Deguchi, et al., Brain Nerve, 1990, 42, 391-97), glomerulonephritis (J. McCauley, et al., Lancet, 1990, 335, 674) and systemic lupus erythematosus (K. Takabayashi, et al., Clin. Immunol. Immunopathol., 1989, 51, 110-117) multidrug resistance (M. Naito, et al., Cancer Chemother. Pharmacol., 1992, 29, 195-200), inflammation of mucosa and blood vessels (PCT Publication WO 91/17754), cytomegalovirus infection (UK Publication GB 2,247,620A), and idiopathic thrombocytopenic purpura and Basedow's disease (PCT Publication WO 91/19495).

BACKGROUND OF THE INVENTION

Immunoregulatory abnormalities have been shown to exist in a wide variety of "autoimmune" and chronic inflammatory diseases, including systemic lupus erythematosus, chronic rheumatoid arthritis, type I and II diabetes mellitus, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis and other disorders such as Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, ichthyosis, and Graves ophthalmopathy. Although the underlying pathogenesis of each of these

- 7 -

conditions may be quite different, they have in common the appearance of a variety of autoantibodies and self-reactive lymphocytes. Such self-reactivity may be due, in part, to a loss of the homeostatic controls under which the normal immune system operates.


Similarly, following a bone-marrow or an organ transplantation, the host lymphocytes recognize the foreign tissue antigens and begin to produce antibodies which lead to graft rejection.

One end result of an autoimmune or a rejection process is tissue destruction caused by inflammatory cells and the mediators they release. Antiinflammatory agents such as NSAID's and corticosteroids act principally by blocking the effect or secretion of these mediators but do nothing to modify the immunologic basis of the disease. On the other hand, cytotoxic agents such as cyclophosphamide, act in such a nonspecific fashion that both the normal and autoimmune responses are shut off. Indeed, patients treated with such nonspecific immunosuppressive agents are as likely to succumb from infection as they are from their autoimmune disease.

Cyclosporin A which was approved by the US FDA in 1983 is currently the leading drug used to prevent rejection of transplanted organs. The drug acts by inhibiting the body's immune system from mobilizing its vast arsenal of natural protecting agents to reject the transplant's foreign protein. Though cyclosporin A is effective in fighting transplant rejection, it is nephrotoxic and is known

Newer, safer drugs exhibiting less side effects are constantly being searched for in the field.

The 23-membered tricyclo-macrolide immunosuppressant, tacrolimus, FR-900506, FK-506,



- 9 -

(17-allyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]-octacos-18-ene-2,3,10,16-tetraone) and related compounds which were isolated and characterized by Tanaka, Kuroda, and co-workers at Fujisawa Pharmaceutical Co. in Japan, see J. Am. Chem. Soc., 1987, 109, 5031, and U.S. Patent No. 4,894,366, issued January 16, 1990) have been shown to possess exceptional immunosuppressive activity. Fujisawa United States patents (U.S. Patent No. 4,929,611, issued May 29, 1990, U.S. Patent No. 4,956,352, issued September 11, 1990 and U.S. Patent No. 5,110,811, issued May 5, 1992) disclose the use of FK-506-type compounds in treating resistance to transplantation. In particular, the compound FR-900506 has been reported to be 100 times more effective than cyclosporin in the suppression of in vitro immune systems (J. Antibiotics 1987, 40, 1256). In addition, these compounds are reputed to possess topical activity in the treatment of inflammatory and hyperproliferative skin diseases and cutaneous manifestations of immunologically-mediated illnesses (EPO Pub. No. 0,315,978).

The compound FK-506 and related compounds further have been suggested to be useful in the treatment of obstructive airways disease, particularly asthma (PCT Publication WO 90/14826), male pattern alopecia or alopecia senilis (EPO Publication No. 0,423,714), rheumatoid arthritis (C. Arita, et al., Clinical exp. Immunol., 1990, 82,

- 10 -

456-461; N. Inamura, et al., Clin. Immunol. Immunopathol. 1988, 46, 82-90), recent-onset diabetes (N. Murase, et al., Diabetes, 1990, 39, 1584-86; N. Murase, et al., Lancet, 1990, 336, 373-74), posterior uveitis (H. Kawashima, Invest. Ophthalmol. Vis. Sci., 1988, 29, 1265-71), hepatic injury associated with ischemia (M. Sakr, et al., Life Sci., 1990, 47, 687-91) allergic encephalomyelitis (K. Deguchi, et al., Brain Nerve, 1990, 42, 391-97), glomerulonephritis (J. McCauley, et al., Lancet, 1990, 335, 674), systemic lupus erythematosus (K. Takabayashi, et al., Clin. Immunol. Immunopathol., 1989, 51, 110-117) multidrug resistance (M. Naito, et al., Cancer Chemother. Pharmacol., 1992, 29, 195-200), inflammation of mucosa and blood vessels (PCT Publication WO 92/17754), cytomegalovirus infection (UK Publication GB 2.247.620A), and idiopathic thrombocytopenic purpura and Basedow's disease (PCT Publication WO 91/19495).

DETAILED DESCRIPTION OF THE INVENTION

A. Scope of the Invention

The novel compound of this invention has structural Formula I:


- 11 -

5

10

15

20



I

or a pharmaceutically acceptable salt thereof,
wherein:

25

R¹ is selected from:

30

- (1) heteroaryl;
- (2) substituted heteroaryl in which the
substituents are X, Y and Z;
- (3) heteroaryl-C₁₋₁₀alkyl;

- 12 -

- (4) substituted heteroaryl-C₁₋₁₀alkyl in which the heteroaryl group is substituted by X, Y and Z and the alkyl portion may be substituted with one or more of the substituent(s) selected from:
- (a) hydroxy,
 - (b) oxo,
 - (c) C₁₋₆-alkoxy,
 - (d) aryl-C₁₋₃alkoxy,
 - (e) substituted aryl-C₁₋₃alkoxy, in which the substituents on aryl are X, Y and Z,
 - (f) unsubstituted or substituted aryloxy, in which the substituents on aryl are X, Y and Z,
 - (g) -OCO-C₁₋₆alkyl,
 - (h) -NR⁶R⁷, wherein R⁶ and R⁷ are independently selected from
 - (i) hydrogen,
 - (ii) C₁₋₁₀alkyl unsubstituted or substituted with one or more of the substituent(s) selected from:
 - (a') aryl, which is unsubstituted or substituted with X, Y and Z,
 - (b') heteroaryl, which is unsubstituted or substituted with X, Y and Z,
 - (c') -OH,
 - (d') C₁₋₆alkoxy,
 - (e') -CO₂H,
 - (f') -CO₂-C₁₋₆alkyl,

- 13 -

(g') -C₃₋₇cycloalkyl, and

(h') -OR¹¹,

(iii) C₃₋₁₀alkenyl unsubstituted or substituted with one or more of the substituent(s) selected from:

(a') aryl, which is unsubstituted or substituted with X, Y and Z,

(b') heteroaryl, which is unsubstituted or substituted with X, Y and Z,

(c') -OH,

(d') C₁₋₆alkoxy,

(e') -CO₂H,

(f') -CO₂-C₁₋₆alkyl,

(g') -C₃₋₇cycloalkyl, and

(h') -OR¹¹,

(iv) or where R⁶ and R⁷ and the N to which they are attached may form an unsubstituted or substituted 3-7-membered heterocyclic ring which may include one or two additional heteroatoms independently selected from the group consisting of O, S(O)_p, NR¹⁴, wherein R¹⁴ is hydrogen or C₁₋₆ alkyl unsubstituted or substituted by phenyl, and p is 0, 1 or 2, such as morpholine, thiomorpholine, piperidine, or piperazine,

- 14 -

- (i) $-\text{NR}^6\text{CO}-\text{C}_{1-6}\text{alkyl}-\text{R}^7$, wherein R^6 and R^7 are as defined above,
- (j) $-\text{NR}^6\text{CO}_2-\text{C}_{1-6}\text{alkyl}-\text{R}^7$,
- (k) $-\text{NR}^6\text{CONR}^6\text{R}^7$,
- 5 (l) $-\text{OCONR}^6\text{R}^7$,
- (m) $-\text{COOR}^6$,
- (n) $-\text{CHO}$,
- (o) aryl,
- (p) substituted aryl in which the substituents are X, Y and Z,
- 10 (q) $-\text{OR}^{11}$, and
- (r) $-\text{S}(\text{O})_p-\text{C}_{1-6}\text{alkyl}$;
- (5) heteroaryl- $\text{C}_{1-10}\text{alkyl}$ wherein one or more of the alkyl carbons is replaced by a group selected from: $-\text{NR}^6-$, $-\text{O}-$, $-\text{S}(\text{O})_p-$, $-\text{CO}_2-$, $-\text{O}_2\text{C}-$, $-\text{CONR}^6-$, $-\text{NR}^6\text{CO}-$, $-\text{NR}^6\text{CONR}^7-$;
- 15 (6) substituted heteroaryl- $\text{C}_{1-10}\text{alkyl}$ wherein one or more of the alkyl carbons is replaced by a group selected from: $-\text{NR}^6-$, $-\text{O}-$, $-\text{S}(\text{O})_p-$, $-\text{CO}_2-$, $-\text{O}_2\text{C}-$, $-\text{CONR}^6-$, $-\text{NR}^6\text{CO}-$, and $-\text{NR}^6\text{CONR}^7-$, the heteroaryl group is substituted with X, Y, and Z, and the alkyl group may be substituted with one or more of the substituent(s) selected from:
- 20 (a) hydroxy,
- (b) oxo,
- (c) $\text{C}_{1-6}\text{alkoxy}$,
- (d) aryl- $\text{C}_{1-3}\text{alkoxy}$,
- 25 (e) substituted aryl- $\text{C}_{1-3}\text{alkoxy}$, in which the substituents on aryl are X, Y and Z,
- 30

- 15 -

- (f) unsubstituted or substituted aryloxy,
in which the substituents on aryl are
X, Y and Z,
- (g) $-\text{OCO}-\text{C}_{1-6}\text{alkyl}$,
- 5 (h) $-\text{NR}^6\text{R}^7$, wherein R^6 and R^7 are as
defined above,
- (i) $-\text{NR}^6\text{CO}-\text{C}_{1-6}\text{alkyl}-\text{R}^7$,
- (j) $-\text{NR}^6\text{CO}_2-\text{C}_{1-6}\text{alkyl}-\text{R}^7$,
- (k) $-\text{NR}^6\text{CONR}^6\text{R}^7$,
- 10 (l) $-\text{OCONR}^6\text{R}^7$,
- (m) $-\text{COOR}^6$,
- (n) $-\text{CHO}$,
- (o) aryl,
- (p) substituted aryl in which the
15 substituents are X, Y and Z,
- (q) $-\text{OR}^{11}$, and
- (r) $-\text{S}(\text{O})_p-\text{C}_{1-6}\text{alkyl}$;
- (7) heteroaryl- $\text{C}_{3-10}\text{alkenyl}$ wherein alkenyl
contains one to four double bonds;
- 20 (8) heteroaryl- $\text{C}_{3-10}\text{alkenyl}$ wherein alkenyl
contains one to four double bonds and
wherein one or more of the alkyl carbons is
replaced by a group selected from: $-\text{NR}^6-$,
 $-\text{O}-$, $-\text{S}(\text{O})_p-$, $-\text{CO}_2-$, $-\text{O}_2\text{C}-$, $-\text{CONR}^6-$,
25 $-\text{NR}^6\text{CO}-$, and $-\text{NR}^6\text{CONR}^7-$;
- (9) substituted heteroaryl- $\text{C}_{3-10}\text{alkenyl}$ wherein
alkenyl contains one to four double bonds
and wherein one or more of the alkyl carbons
may be replaced by a group selected from:
30 $-\text{NR}^6-$, $-\text{O}-$, $-\text{S}(\text{O})_p-$, $-\text{CO}_2-$, $-\text{O}_2\text{C}-$, $-\text{CONR}^6-$,
 $-\text{NR}^6\text{CO}-$, and $-\text{NR}^6\text{CONR}^7$, the heteroaryl group

- 16 -

is substituted with X, Y, and Z, and the alkyl group may be substituted with one or more of the substituent(s) selected from:

- (a) hydroxy,
- (b) oxo,
- (c) C₁₋₆alkoxy,
- (d) aryl-C₁₋₃alkoxy,
- (e) substituted aryl-C₁₋₃alkoxy, in which the substituents on aryl are X, Y and Z,
- (f) unsubstituted or substituted aryloxy, in which the substituents on aryl are X, Y and Z,
- (g) -OCO-C₁₋₆alkyl,
- (h) -NR⁶R⁷, wherein R⁶ and R⁷ as defined above,
- (i) -NR⁶CO-C₁₋₆alkyl, wherein R⁶ is as defined above,
- (j) -NR⁶CO₂-C₁₋₆alkyl,
- (k) -NR⁶CONR⁶R⁷,
- (l) -OCONR⁶R⁷,
- (m) -COOR⁶,
- (n) -CHO,
- (o) aryl,
- (p) substituted aryl in which the substituents are X, Y and Z, and
- (q) -OR¹¹, and
- (r) -S(O)_p-C₁₋₆alkyl;

R² is selected from:

- (1) the definitions of R¹;
- (2) hydrogen;
- (3) phenyl;

- 17 -

- (4) substituted phenyl in which the substituents are X, Y and Z;
- (5) 1- or 2-naphthyl;
- 5 (6) substituted 1- or 2-naphthyl in which the substituents are X, Y and Z;
- (7) biphenyl;
- (8) substituted biphenyl in which the substituents are X, Y and Z;
- (9) C₁₋₁₀alkyl;
- 10 (10) substituted-C₁₋₁₀alkyl in which one or more substituent(s) is(are) selected from:
- (a) hydroxy,
- (b) oxo,
- (c) C₁₋₆alkoxy,
- 15 (d) aryl-C₁₋₃alkoxy,
- (e) substituted aryl-C₁₋₃alkoxy, in which the substituents on aryl are X, Y and Z,
- (f) unsubstituted or substituted aryloxy, in which the substituents on aryl are
- 20 X, Y and Z,
- (g) -OCO-C₁₋₆alkyl,
- (h) -NR⁶R⁷, wherein R⁶ and R⁷ are as defined above
- (i) -NR⁶CO-C₁₋₆alkyl-R⁷, wherein R⁶ and R⁷ are as defined above,
- 25 (j) -COOR⁶, wherein R⁶ is as defined above,
- (k) -CHO,
- (l) phenyl,
- (m) substituted phenyl in which the substituents are X, Y and Z,
- 30 (n) 1- or 2-naphthyl,
- (o) substituted 1- or 2-naphthyl in which the substituents are X, Y and Z,

- 18 -

- (p) biphenyl,
(q) substituted biphenyl in which the substituents are X, Y and Z,
(r) $-OR^{11}$, and
5 (s) $-S(O)_p-C_{1-6}alkyl$;
(11) $C_{3-10}alkenyl$;
(12) substituted $C_{3-10}alkenyl$ in which one or more substituent(s) is(are) selected from:
(a) hydroxy,
10 (b) oxo,
(c) $C_{1-6}alkoxy$,
(d) phenyl- $C_{1-3}alkoxy$,
(e) substituted phenyl- $C_{1-3}alkoxy$, in which the substituents on phenyl are
15 X, Y and Z,
(f) $-OCO-C_{1-6}alkyl$,
(g) $-NR^6R^7$, wherein R^6 and R^7 are as defined above
(h) $-NR^6CO-C_{1-6}alkyl$, wherein R^6 is as defined above,
20 (i) $-COOR^6$, wherein R^6 is as defined above,
(j) $-CHO$,
(k) phenyl,
(l) substituted phenyl in which the substituents are X, Y and Z,
25 (m) 1- or 2-naphthyl,
(n) substituted 1- or 2-naphthyl in which the substituents are X, Y and Z,
(o) biphenyl,
30 (p) substituted biphenyl in which the substituents are X, Y and Z,
(q) $-OR^{11}$, and
(r) $-S(O)_p-C_{1-6}alkyl$;

- 19 -

(13) C₃₋₁₀alkynyl;(14) substituted C₃₋₁₀alkynyl in which one or more substituent(s) is(are) selected from:

(a) hydroxy,

(b) oxo,

(c) C₁₋₆alkoxy,(d) phenyl-C₁₋₃alkoxy,(e) substituted phenyl-C₁₋₃alkoxy, in which the substituents on phenyl are

X, Y and Z,

(f) -OCO-C₁₋₆alkyl,(g) -NR⁶R⁷, wherein R⁶ and R⁷ are as defined above,(h) -NR⁶CO-C₁₋₆alkyl, wherein R⁶ is as defined above,(i) -COOR⁶, wherein R⁶ is as defined above,

(j) -CHO,

(k) phenyl,

(l) substituted phenyl in which the substituents are X, Y and Z,

(m) 1- or 2-naphthyl,

(n) substituted 1- or 2-naphthyl in which the substituents are X, Y and Z,

(o) biphenyl,

(p) substituted biphenyl in which the substituents are X, Y and Z,

(q) -OR¹¹; and(15) -R¹¹;R³ is hydrogen, hydroxy, -OR¹¹, or C₁₋₆alkoxy;R⁴ is hydrogen, or R³ and R⁴ taken together form a double bond;R⁵ is methyl, ethyl, propyl or allyl;R¹⁰ is hydrogen, hydroxy, -OR¹¹ or fluoro;

- 20 -

R¹¹ is selected from:

- (a) $-\text{PO}(\text{OH})\text{O}^-\text{M}^+$, wherein M^+ is a positively charged inorganic or organic counterion,
- (b) $-\text{SO}_3^-\text{M}^+$,
- (c) $-\text{CO}(\text{CH}_2)_q\text{CO}_2^-\text{M}^+$, wherein q is 1-3, and
- (d) $-\text{CO}-\text{C}_{1-6}\text{alkyl}-\text{NR}^6\text{R}^7$, wherein R^6 and R^7 are as defined above and the alkyl is unsubstituted or substituted with one or more substituents selected from:
- (i) hydroxy,
- (ii) $\text{C}_{1-6}\text{alkoxy}$,
- (iii) $-\text{NR}^{16}\text{R}^{17}$, wherein R^{16} and R^{17} are independently selected from:
- (a') hydrogen, and
- (b') $\text{C}_{1-6}\text{alkyl}$,
- (iv) $-\text{COOR}^6$, wherein R^6 is as defined above,
- (v) phenyl,
- (iv) substituted phenyl in which the substituents are X, Y and Z,
- (vii) heteroaryl,
- (viii) $-\text{SH}$, and
- (ix) $-\text{S}-\text{C}_{1-6}\text{alkyl}$;

W is O or (H, OH);

X, Y and Z independently are selected from:

- (a) hydrogen,
- (b) $\text{C}_{1-10}\text{alkyl}$, unsubstituted or substituted with one or more substituents selected from:
- (i) aryl,
- (ii) substituted aryl in which the substituents are X', Y' and Z',
- (iii) heteroaryl,

- 21 -

- (iv) substituted heteroaryl in which the substituents are X', Y', and Z',
- (v) unsubstituted or substituted aryloxy, in which the substituents on aryl are X', Y' and Z',
- (vi) $-OR^6$,
- (vii) $-OR^{11}$,
- (viii) $-OCOR^6$,
- (ix) $-OCO_2R^6$,
- (x) $-NR^6R^7$,
- (xi) $-CHO$,
- (xii) $-NR^6COC_{1-6}alkyl-R^7$,
- (xiii) $-NR^6CO_2C_{1-6}alkyl-R^7$,
- (xiv) $-NR^6CONR^6R^7$,
- (xv) $-OCONR^6R^7$,
- (xvi) $-CONR^6R^7$,
- (c) $C_{1-10}alkyl$ wherein one or more of the alkyl carbons is replaced by a group selected from $-NR^6-$, $-O-$, $-S(O)_p-$, $-CO_2-$, $-O_2C-$, $-CONR^6-$, $-NR^6CO-$, $-NR^6CONR^7-$, $-CO-$, $-CH(OH)-$, alkenyl or alkynyl and the alkyl may be unsubstituted or substituted with one or more substituents selected from:
- (i) aryl,
- (ii) substituted aryl in which the substituents are X', Y' and Z',
- (iii) heteroaryl,
- (iv) substituted heteroaryl in which the substituents are X', Y', and Z',

- 22 -

- (v) unsubstituted or substituted aryloxy, in which the substituents on aryl are X', Y', and Z',
- (vi) $-OR^6$,
- 5 (vii) $-OR^{11}$,
- (viii) $-OCOR^6$,
- (ix) $-OCO_2R^6$,
- (x) $-NR^6R^7$,
- (xi) $-CHO$
- 10 (xii) $-NR^6COC_{1-6}alkyl-R^7$,
- (xiii) $-NR^6CO_2C_{1-6}alkyl-R^7$,
- (xiv) $-NR^6CONR^6R^7$,
- (xv) $-OCONR^6R^7$,
- (xvi) $-CONR^6R^7$,
- 15 (d) halogen,
- (e) $-NR^6R^7$,
- (f) $-CN$,
- (g) $-CHO$,
- 20 (h) $-CF_3$,
- (i) $-SR^8$, wherein R^8 is hydrogen, $C_{1-6}alkyl$, trifluoromethyl, or phenyl,
- (j) $-SOR^8$,
- (k) $-SO_2R^8$,
- 25 (l) $-CONR^6R^7$,
- (m) $R^9O(CH_2)_m-$ wherein R^9 is hydrogen, $C_{1-6}alkyl$, hydroxy- $C_{2-3}alkyl$, $-CF_3$, phenyl, R^{11} or naphthyl and m is 0, 1, 2, or 3,
- 30 (n) $-CH(OR^{12})(OR^{13})$, wherein R^{12} and R^{13} are $C_{1-3}alkyl$ or taken together form an ethyl or propyl bridge,

- 23 -

(o) $R^9 \overset{O}{\parallel} CO(CH_2)_m-$ wherein R^9 and m are as defined above,

(p) $R^9 \overset{O}{\parallel} OC(CH_2)_m-$ wherein R^9 and m are as defined above, and

(q) $-R^{11}$;

or any two of X, Y and Z may be joined to form a saturated ring having 5, 6 or 7 ring atoms, said ring atoms comprising 1 or 2 oxygen atoms, the remaining ring atoms being carbon, such as dioxolanyl or dioxanyl;

X', Y' and Z' independently are selected from:

(a) hydrogen,

(b) C_{1-7} alkyl,

(c) C_{2-6} alkenyl,

(d) halogen,

(e) $-(CH_2)_m-NR^6R^7$, wherein R^6 , R^7 , and m are as defined above,

(f) $-CN$,

(g) $-CHO$,

(h) $-CF_3$,

(i) $-SR^8$, wherein R^8 is hydrogen, C_{1-6} alkyl, trifluoromethyl, or phenyl,

(j) $-SOR^8$, wherein R^8 is as defined above,

(k) $-SO_2R^8$, wherein R^8 is as defined above,

(l) $-CONR^6R^7$, wherein R^6 and R^7 are as defined above,

(m) $R^9O(CH_2)_m-$ wherein R^9 and m are as defined above,

(n) $-CH(OR^{12})(OR^{13})$, wherein R^{12} and R^{13} are as defined above,

(o) $R^9 \overset{O}{\parallel} CO(CH_2)_m-$ wherein R^9 and m are as defined above,

- 24 -

- (p) $R^9 \overset{\text{O}}{\parallel} \text{C}(\text{CH}_2)_m -$ wherein R^9 and m are as defined above, and
(q) $-R^{11}$;

5

n is 1 or 2.

10 The compounds of the present invention have asymmetric centers and this invention includes all of the optical isomers and mixtures thereof.

In addition compounds with carbon-carbon double bonds may occur in Z- and E- forms with all isomeric forms of the compounds being included in the present invention.

15

When any variable (e.g., alkyl, aryl, R^6 , R^7 , R^8 , R^9 , R^{10} , R^{11} , X, Y, Z, etc.) occurs more than one time in any variable or in Formula I, its definition on each occurrence is independent of its definition at every other occurrence.

20

As used herein, the term "alkyl" includes those alkyl groups of a designated number of carbon atoms of either a straight, branched, or cyclic configuration. Examples of "alkyl" include methyl, ethyl, propyl, isopropyl, butyl, sec- and tert-butyl, 25 pentyl, hexyl, heptyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, and the like. "Alkoxy" represents an alkyl group of indicated number of carbon atoms attached through an oxygen bridge, such as methoxy, ethoxy, propoxy, 30 butoxy and pentoxy. "Alkenyl" is intended to include hydrocarbon chains of a specified number of carbon atoms of either a straight- or branched- configuration and at least one unsaturation,

- 25 -

which may occur at any point along the chain, such as ethenyl, propenyl, butenyl, pentenyl, dimethylpentyl, and the like, and includes E and Z forms, where applicable; and "heteroarylalkyl" represents heteroaryl groups as herein defined which are attached through a straight or branched chain alkyl group of from one to ten carbon atoms. "Halogen", as used herein, means fluoro, chloro, bromo and iodo.

As will be understood by those skilled in the art, pharmaceutically acceptable salts include, but are not limited to salts with inorganic acids such as hydrochloride, sulfate, phosphate, diphosphate, hydrobromide, and nitrate or salts with an organic acid such as malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, p-toluenesulfonate or palmoate, salicylate and stearate. Similarly pharmaceutically acceptable cations include, but are not limited to sodium, potassium, calcium, aluminum, lithium and ammonium (especially ammonium salts with amines of the formula HNR^6R^7).

The heteroaryl group as used herein includes acridine, carbazole, cinnoline, dibenzofuran, dibenzothiophene, quinoxaline, pyrazole, indole, benzotriazole, furan, benzofuran, quinoline, isoquinoline, pyrazine, pyridazine, pyridine, pyrimidine, pyrrole which are optionally substituted.

In the compounds of Formula I the heteroaryl group may be optionally substituted with X, Y and Z at any available carbon atom or nitrogen atom (if present), but compounds bearing certain of X, Y and Z directly substituted to a nitrogen atom of the heteroaryl ring may be relatively unstable and are not preferred.

- 26 -

The term "heteroaryl" as utilized herein is intended to include the following heteraromatic groups which may include X, Y and Z substitution as indicated and wherein Q is -N(X)-, -O-, -S-, -SO-, or -SO₂-:

5

10

15


20

25


30

- 27 -


5




10




15



20




25




30

- 28 -


5




10



15



20



25

30



- 29 -

The aryl or aromatic group may include phenyl or naphthyl which are optionally substituted by from one- to three-members independently selected from the group consisting of: alkyl, alkenyl, halogen, carboxyl, CHO, amino, mono-alkylamino, di-alkylamino, aminoalkyl, mono-alkylaminoalkyl, di-alkylaminoalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, trifluoromethyl, amido, mono-alkylamido, dialkylamido, hydroxy, hydroxyalkyl, R¹¹O-alkyl, alkoxy, alkoxyalkyl, formamido, alkyl-CO₂-, formamidoalkyl, alkyl-CO₂-alkyl-, carboxyl, alkyl-CO₂H, alkyl-O₂C-, alkyl-O₂C-alkyl-, and OR¹¹.



- 30 -

In the compound of formula I it is preferred that heteroaryl is selected from the group consisting of:



5






10





15



20





25





30

- 31 -

5




10




15

20



and



25

wherein X is as defined above.

30

- 32 -

In the compound of formula I it is also preferred that:

R^2 is selected from:

- 5 (1) hydrogen,
- (2) methyl,
- (3) ethyl,
- (4) propyl,
- (5) allyl,
- 10 (6) R^{11} ,
- (7) $-C_{2-3}alkyl-OH$; and
- (8) $-C_{2-3}alkyl-OR^{11}$;

R^3 is selected from:

- (1) hydrogen,
- 15 (2) hydroxy,
- (3) $-OR^{11}$, or

R^3 and R^4 taken together form a double bond;

R^{10} is hydrogen, hydroxy, fluoro, or $-OR^{11}$;

W is O; and


20 n is 2.

25

30

- 33 -

In one embodiment of the present invention, heteroaryl is indole, which may be represented by:



wherein X, Y and Z are as defined above,

15 Preferred compounds of the present invention are the compounds identified as follows:

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2-furanyl)methoxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
20 [22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2-furanyl)methoxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
25 [22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-(2-furanyl)methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
30

- 34 -

- 5 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2-thiophene)-methoxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 10 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2-thiophene)-methoxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 15 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(3-thiophene)-methoxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 20 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-(2-thiophene)methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 25 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-(3-thiophene)methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 30

- 35 -

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2-thiophene)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

5

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2-benzothienyl)-oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

10

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

15

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

20

17-Ethyl-1,14,20-trihydroxy-12-[2'-(4''-(5-indolyl)-oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

25

17-Ethyl-1,20-dihydroxy-12-[2'-(4''-(5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

30

- 36 -

- 17-Ethyl-1-hydroxy-12-[2'-(4''-(5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 5 17-Allyl-1,14-dihydroxy-12-[2'-(4''-(5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 10 17-Allyl-1,14-dihydroxy-12-[2'-(4''-(5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 15 17-Allyl-1,14,20-trihydroxy-12-[2'-(4''-(5-indolyl)-oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 20 17-Allyl-1,20-dihydroxy-12-[2'-(4''-(5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 25 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(5-indolyl)oxy-3''-ethoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 30

- 37 -

17-Allyl-1,14-dihydroxy-12-[2'-(4''-(5-indolyl)oxy-3''-ethoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

5

17-Allyl-1-hydroxy-12-[2'-(4''-(5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

10

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

15

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

20

17-Ethyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

25

17-Ethyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

30

- 38 -

17-Ethyl-1,20-dihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Ethyl-1,20-dihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Allyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Allyl-1,20-dihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

- 39 -

17-Ethyl-1-hydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)-
oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-
dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-
5 tricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-methyl-5-
indolyl)oxy-3''-ethoxycyclohexyl)-1'-methylvinyl]-
23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-
10 4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone;

17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-methyl-5-
indolyl)oxy-3''-ethoxycyclohexyl)-1'-methylvinyl]-
15 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-ethyl-5-
indolyl)oxy-3''-ethoxycyclohexyl)-1'-methylvinyl]-
20 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone;

17-Allyl-1-hydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)-
oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-
dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-
tricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
25 tetraone;

30

- 40 -

5 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-allyloxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

10 17-Ethyl-1-hydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)-oxy-3''-allyloxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

15 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-n-propyloxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

20 17-Ethyl-1-hydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)-oxy-3''-n-propyloxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

25 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-i-propyloxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

30

- 41 -

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-ethyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-
23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
5 tetraone;

17-Ethyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-ethyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-
23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
10 azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone;

17-Ethyl-1,20-dihydroxy-12-[2'-(4''-(1-N-ethyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-
15 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-ethyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-
20 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone;

17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-ethyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-
25 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-
4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
30 tetraone;

- 42 -

- 5 17-Allyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-ethyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 10 17-Allyl-1,20-dihydroxy-12-[2'-(4''-(1-N-ethyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 15 17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-ethyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 20 17-Ethyl-1-hydroxy-12-[2'-(4''-(1-N-ethyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 25 17-Allyl-1-hydroxy-12-[2'-(4''-(1-N-ethyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 30

- 43 -

5 17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-ethyl-5-indolyl)oxy-3''-ethoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

10 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-propyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

15 17-Ethyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-propyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

20 17-Ethyl-1,20-dihydroxy-12-[2'-(4''-(1-N-propyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

25 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-propyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

30

- 44 -

5 7-Ethyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-propyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

10 17-Ethyl-1,20-dihydroxy-12-[2'-(4''-(1-N-propyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

15 17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-propyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

20 17-Allyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-propyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

25 17-Allyl-1,20-dihydroxy-12-[2'-(4''-(1-N-propyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

30

- 45 -

17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-propyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-
23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-
5 4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Ethyl-1-hydroxy-12-[2'-(4''-(1-N-propyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-
10 dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

~~17-Allyl-1-hydroxy-12-[2'-(4''-(1-N-propyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-~~
15 ~~dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;~~

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-propyl-5-indolyl)oxy-3''-ethoxycyclohexyl)-1'-methylvinyl]-
20 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

25 ~~17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-propyl-5-indolyl)oxy-3''-ethoxycyclohexyl)-1'-methylvinyl]-~~
~~23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-~~
30 ~~4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;~~

- 46 -

5 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-allyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

10 17-Ethyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-allyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

15 17-Ethyl-1,20-dihydroxy-12-[2'-(4''-(1-N-allyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

20 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-allyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

25 17-Ethyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-allyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

30

- 47 -

17-Ethyl-1,20-dihydroxy-12-[2'-(4''-(1-N-allyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-
23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-
4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
5 tetraone;

17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-allyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-
23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-
10 4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Allyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-allyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-
15 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Allyl-1,20-dihydroxy-12-[2'-(4''-(1-N-allyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-
20 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

25 17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-allyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-
23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
30 tetraone;

- 48 -

17-Ethyl-1-hydroxy-12-[2'-(4''-(1-N-allyl-5-indolyl)-
oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-
dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-
tricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
5 tetraone;

17-Allyl-1-hydroxy-12-[2'-(4''-(1-N-allyl-5-indolyl)-
oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-
dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-
10 tricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-allyl-5-
indolyl)oxy-3''-ethoxycyclohexyl)-1'-methylvinyl]-
15 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-
4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone;

17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-allyl-5-
indolyl)oxy-3''-ethoxycyclohexyl)-1'-methylvinyl]-
20 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-
4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-2-hydroxy-
ethyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methyl-
vinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-
dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-
25 2,3,10,16-tetraone;

30

- 49 -

17-Ethyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-2-hydroxy-ethyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methyl-vinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-
5 2,3,10,16-tetraone;

17-Ethyl-1,20-dihydroxy-12-[2'-(4''-(1-N-2-hydroxy-ethyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methyl-vinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-
10 2,3,10,16-tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-2-hydroxy-ethyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methyl-vinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-
15 2,3,10,16-tetraone;

17-Ethyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-2-hydroxy-ethyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methyl-vinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-
20 2,3,10,16-tetraone;

17-Ethyl-1,20-dihydroxy-12-[2'-(4''-(1-N-2-hydroxy-ethyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methyl-vinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-
25 2,3,10,16-tetraone;
30

- 50 -

17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-2-hydroxy-ethyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-hydroxyethyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-benzyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Ethyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-benzyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Ethyl-1,20-dihydroxy-12-[2'-(4''-(1-N-benzyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

- 51 -

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-benzyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Ethyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-benzyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Ethyl-1,20-dihydroxy-12-[2'-(4''-(1-N-benzyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-benzyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Allyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-benzyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

- 52 -

5 17-Allyl-1,20-dihydroxy-12-[2'-(4''-(1-N-benzyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

10 17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-benzyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

15 17-Ethyl-1-hydroxy-12-[2'-(4''-(1-N-benzyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

20 17-Allyl-1-hydroxy-12-[2'-(4''-(1-N-benzyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

25 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-benzyl-5-indolyl)oxy-3''-ethoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

30

-53-

17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-benzyl-5-indolyl)oxy-3''-ethoxycyclohexyl)-1'-methylvinyl]-
23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-
4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
5 tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-cyclopropyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-
23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-
10 4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-cyclopropyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-
15 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-
4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone;

17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-cyclopropyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-
20 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone;

17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-cyclopropyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-
25 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone;

30

-54-

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-cyclopropyl-5-indolyl)oxy-3''-ethoxycyclohexyl)-1'-methylvinyl]-
23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
5 tetraone;

17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-cyclopropyl-5-indolyl)oxy-3''-ethoxycyclohexyl)-1'-methylvinyl]-
23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
10 azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone;

17-Ethyl-1-hydroxy-12-[2'-(4''-(1-N-cyclopropyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-
15 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone;

17-Allyl-1-hydroxy-12-[2'-(4''-(1-N-cyclopropyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-
20 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-
4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone;

25 17-Ethyl-1-hydroxy-12-[2'-(4''-methoxy-N-tryptophanyl-carbonylmethoxy-3''-methoxycyclohexyl)-1'-methylvinyl]-
23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone;

30

-55-

17-Ethyl-1-hydroxy-12-[2'-(4''-(3-indolyl)ethylamino-
carbonylmethoxy-3''-methoxycyclohexyl)-1'-methylvinyl]-
23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
5 tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-(3-hydroxy-
propyl)indol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methyl-
vinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-
10 dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-
2,3,10,16-tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(3''-hydroxy-4''-(1-
hydroxyethylindol-5-yl)oxycyclohexyl)-1'-methylvinyl]-
15 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-hydroxyethyl-
20 indol-6-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-
23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone;

25 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-methylindol-6-
yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-
dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-
tricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone;

30

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-dibenzyl-
phosphonoxy-ethylindol-5-yl)oxy-3''-methoxycyclohexyl)-
1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetra-

-56-

methyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

5 Monopotassium salt of 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-phosphonoxy-ethylindol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

10 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-(N,N-dimethylglycyloxy)ethylindol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

15 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-succinyloxyethylindol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

20 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-methyl-3-phenylindol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

25 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-methyl-3-(2-hydroxyethyl)indol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

-57-

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1,3-dimethylindol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(9'-methylcarbazol-3'-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2''''-(3''''-diethylaminopropionyloxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2''''-(3''''-dimethylaminopropionyloxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2''''-(3''''-aminopropionyloxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

30

-58-

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2'''-(3''''-benzyloxycarbonyl-2''''-benzyloxycarbonylamino-propionyloxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-octacos-18-ene-2,3,10,16-tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2'''-(aspartyl-oxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2'''-(1''''-imidazolylcarbonyloxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2'''-(1''''-piperazinocarbonyloxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-(2''''-hydroxy)ethylaminocarbonyloxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

-59-

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-(
(isopropylaminocarbonyloxy)ethyl)indol-5'''-yl)oxy-3''-
methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
5 [22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-(
(1''''''-piperidinocarbonyloxy)ethyl)indol-5'''-yl)oxy-
3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
10 13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-(
(1''''''-morpholinocarbonyloxy)ethyl)indol-5'''-yl)oxy-
15 3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-(
20 (diphenylaminocarbonyloxy)ethyl)indol-5'''-yl)oxy-3''-
methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-(
25 (diethylaminocarbonyloxy)ethyl)indol-5'''-yl)oxy-3''-
methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

30

-60-

5 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-methanesulfonyloxyethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-octacos-18-ene-2,3,10,16-tetraone;

10 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-azidoethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-octacos-18-ene-2,3,10,16-tetraone;

15 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-aminoethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-octacos-18-ene-2,3,10,16-tetraone;

20 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-t-butylidimethylsilyloxyethoxyethylindol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-octacos-18-ene-2,3,10,16-tetraone;

25 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-hydroxyethoxyethylindol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-octacos-18-ene-2,3,10,16-tetraone;

30

-61-

17-Ethyl-1,14-dihydroxy-12-[2'-(3"-methoxy-4"-(1'''-
(1'''-oxoprop-3'''-yl)indol-5'''-yl)oxycyclohexyl)-
1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetra-
methyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-
5 18-ene-2,3,10,16-tetraone; and


17-Ethyl-1,14-dihydroxy-12-[2'-(3"-methoxy-4"-(1'''-
(1'''-carboxyeth-2'''-yl)indol-5'''-yl)oxycyclo-
hexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-
10 tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-
octacos-18-ene-2,3,10,16-tetraone.

Representative compounds of the present
invention include the compounds of Formula X, XI, XII
15 and XIII:


20

25

30



10



15.


20

25

X

30


-63-




XI

30

-64-



XII



XIII

wherein R^{6a} is H or CH_3 and the definitions of R^2 , R^3 , R^5 , R^6 and R^7 are selected from the following groups of substituents:

R^6	R^7	R^2	R^3	R^5
phenyl	phenyl	CH_3	OH	ethyl
phenyl	H	CH_3	OH	ethyl
benzyl	H	CH_3	OH	ethyl
4- HO_2C -benzyl	H	CH_3	OH	ethyl

SUBSTITUTE SHEET

-66-

	4-H ₂ NCO-benzyl	H	CH ₃	OH	ethyl
	4-CH ₃ O-benzyl	H	CH ₃	OH	ethyl
	4-HO-benzyl	H	CH ₃	OH	ethyl
	4-Cl-benzyl	H	CH ₃	OH	ethyl
5	4-(CH ₃) ₂ N-benzyl	H	CH ₃	OH	ethyl
	3-HO ₂ C-benzyl	H	CH ₃	OH	ethyl
	3-H ₂ NCO-benzyl	H	CH ₃	OH	ethyl
	3-CH ₃ O-benzyl	H	CH ₃	OH	ethyl
	3-HO-benzyl	H	CH ₃	OH	ethyl
10	3-Cl-benzyl	H	CH ₃	OH	ethyl
	3-(CH ₃) ₂ N-benzyl	H	CH ₃	OH	ethyl
	4-pyridyl	H	CH ₃	OH	ethyl
	3-pyridyl	H	CH ₃	OH	ethyl
	2-pyridyl	H	CH ₃	OH	ethyl
15	4-pyridylmethyl	H	CH ₃	OH	ethyl
	3-pyridylmethyl	H	CH ₃	OH	ethyl
	2-pyridylmethyl	H	CH ₃	OH	ethyl
	phenyl	phenyl	CH ₃	H	ethyl
	phenyl	H	CH ₃	H	ethyl
20	benzyl	H	CH ₃	H	ethyl
	4-HO ₂ C-benzyl	H	CH ₃	H	ethyl
	4-H ₂ NCO-benzyl	H	CH ₃	H	ethyl
	4-CH ₃ O-benzyl	H	CH ₃	H	ethyl
	4-HO-benzyl	H	CH ₃	H	ethyl
25	4-Cl-benzyl	H	CH ₃	H	ethyl
	4-(CH ₃) ₂ N-benzyl	H	CH ₃	H	ethyl
	3-HO ₂ C-benzyl	H	CH ₃	H	ethyl
	3-H ₂ NCO-benzyl	H	CH ₃	H	ethyl
	3-CH ₃ O-benzyl	H	CH ₃	H	ethyl
30	3-HO-benzyl	H	CH ₃	H	ethyl
	3-Cl-benzyl	H	CH ₃	H	ethyl
	3-(CH ₃) ₂ N-benzyl	H	CH ₃	H	ethyl

-67-

	4-pyridyl	H	CH ₃	H	ethyl
	3-pyridyl	H	CH ₃	H	ethyl
	2-pyridyl	H	CH ₃	H	ethyl
	4-pyridylmethyl	H	CH ₃	H	ethyl
5	3-pyridylmethyl	H	CH ₃	H	ethyl
	2-pyridylmethyl	H	CH ₃	H	ethyl
	phenyl	phenyl	CH ₃	OH	allyl
	phenyl	H	CH ₃	OH	allyl
	benzyl	H	CH ₃	OH	allyl
10	4-HO ₂ C-benzyl	H	CH ₃	OH	allyl
	4-H ₂ NCO-benzyl	H	CH ₃	OH	allyl
	4-CH ₃ O-benzyl	H	CH ₃	OH	allyl
	4-HO-benzyl	H	CH ₃	OH	allyl
	4-Cl-benzyl	H	CH ₃	OH	allyl
15	4-(CH ₃) ₂ N-benzyl	H	CH ₃	OH	allyl
	3-HO ₂ C-benzyl	H	CH ₃	OH	allyl
	3-H ₂ NCO-benzyl	H	CH ₃	OH	allyl
	3-CH ₃ O-benzyl	H	CH ₃	OH	allyl
	3-HO-benzyl	H	CH ₃	OH	allyl
20	3-Cl-benzyl	H	CH ₃	OH	allyl
	3-(CH ₃) ₂ N-benzyl	H	CH ₃	OH	allyl
	4-pyridyl	H	CH ₃	OH	allyl
	3-pyridyl	H	CH ₃	OH	allyl
	2-pyridyl	H	CH ₃	OH	allyl
25	4-pyridylmethyl	H	CH ₃	OH	allyl
	3-pyridylmethyl	H	CH ₃	OH	allyl
	2-pyridylmethyl	H	CH ₃	OH	allyl
	CH ₃	H	CH ₃	OH	ethyl
	CH ₃ CH ₂	H	CH ₃	OH	ethyl
30	CH ₃ CH ₂ CH ₂	H	CH ₃	OH	ethyl
	(CH ₃) ₂ CH	H	CH ₃	OH	ethyl
	HO ₂ CCH ₂ CH ₂	H	CH ₃	OH	ethyl

-68-

	H ₂ NCOCH ₂ CH ₂	H	CH ₃	OH	ethyl
	HOCH ₂ CH ₂	H	CH ₃	OH	ethyl
	HOCH ₂ CH ₂ CH ₂	H	CH ₃	OH	ethyl
	CH ₃	CH ₃	CH ₃	OH	ethyl
5	CH ₃ CH ₂	CH ₃ CH ₂	CH ₃	OH	ethyl
	CH ₃ CH ₂ CH ₂	CH ₃ CH ₂ CH ₂	CH ₃	OH	ethyl
	HOCH ₂ CH ₂	HOCH ₂ CH ₂	CH ₃	OH	ethyl
	HOCH ₂ CH ₂ CH ₂	HOCH ₂ CH ₂ CH ₂	CH ₃	OH	ethyl
	CH ₃	H	CH ₃	H	ethyl
10	CH ₃ CH ₂	H	CH ₃	H	ethyl
	CH ₃ CH ₂ CH ₂	H	CH ₃	H	ethyl
	(CH ₃) ₂ CH	H	CH ₃	H	ethyl
	HO ₂ CCH ₂ CH ₂	H	CH ₃	H	ethyl
	H ₂ NCOCH ₂ CH ₂	H	CH ₃	H	ethyl
15	HOCH ₂ CH ₂	H	CH ₃	H	ethyl
	HOCH ₂ CH ₂ CH ₂	H	CH ₃	H	ethyl
	CH ₃	CH ₃	CH ₃	H	ethyl
	CH ₃ CH ₂	CH ₃ CH ₂	CH ₃	H	ethyl
	CH ₃ CH ₂ CH ₂	CH ₃ CH ₂ CH ₂	CH ₃	H	ethyl
20	HOCH ₂ CH ₂	HOCH ₂ CH ₂	CH ₃	H	ethyl
	HOCH ₂ CH ₂ CH ₂	HOCH ₂ CH ₂ CH ₂	CH ₃	H	ethyl
	CH ₃	H	H	OH	ethyl
	CH ₃ CH ₂	H	H	OH	ethyl
	CH ₃ CH ₂ CH ₂	H	H	OH	ethyl
25	(CH ₃) ₂ CH	H	H	OH	ethyl
	HO ₂ CCH ₂ CH ₂	H	H	OH	ethyl
	H ₂ NCOCH ₂ CH ₂	H	H	OH	ethyl
	HOCH ₂ CH ₂	H	H	OH	ethyl
	HOCH ₂ CH ₂ CH ₂	H	H	OH	ethyl
30	CH ₃	CH ₃	H	OH	ethyl
	CH ₃ CH ₂	CH ₃ CH ₂	H	OH	ethyl
	CH ₃ CH ₂ CH ₂	CH ₃ CH ₂ CH ₂	H	OH	ethyl

-69-

	HOCH ₂ CH ₂	HOCH ₂ CH ₂	H	OH	ethyl
	HOCH ₂ CH ₂ CH ₂	HOCH ₂ CH ₂ CH ₂	H	OH	ethyl
	-CH ₂ CH ₂ OCH ₂ CH ₂ -	CH ₃	H	ethyl	
5	-CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ -	CH ₃	H	ethyl	
	-CH ₂ CH ₂ OCH ₂ CH ₂ -	CH ₃	OH	ethyl	
	-CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ -	H	OH	ethyl	
	-CH ₂ CH ₂ OCH ₂ CH ₂ -	H	OH	ethyl	
	-CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ -	H	OH	ethyl	
10	-CH ₂ CH ₂ OCH ₂ CH ₂ -	CH ₃	H	allyl	
	-CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ -	CH ₃	H	allyl	
	-CH ₂ CH ₂ OCH ₂ CH ₂ -	CH ₃	OH	allyl	
	-CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ -	H	OH	allyl	
	-CH ₂ CH ₂ OCH ₂ CH ₂ -	H	OH	allyl	
15	-CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ -	H	OH	allyl.	


Representative compounds of the present invention include the compounds of formula XIV, XV, XVI and XVII:

20

25


30

-70-




XIV


-71-



XV



10.



15

20

25

XVI

30

-73-

5


10

15

20

25

30



XVII

-74-

wherein R^{6a} is H or CH_3 and R^2 , R^3 , R^5 and R^6 are selected from the following groups of substituents:

	<u>R^6</u>	<u>R^2</u>	<u>R^3</u>	<u>R^5</u>
5	H	CH_3	OH	ethyl
	CH_3	CH_3	OH	ethyl
	CH_3CH_2	CH_3	OH	ethyl
	$CH_2=CHCH_2$	CH_3	OH	ethyl
10	$CH_3CH_2CH_2$	CH_3	OH	ethyl
	$(CH_3)_2CH$	CH_3	OH	ethyl
	$HO_2CCH_2CH_2$	CH_3	OH	ethyl
	$H_2NCOCH_2CH_2$	CH_3	OH	ethyl
	$HOCH_2CH_2$	CH_3	OH	ethyl
15	$HOCH_2CH_2CH_2$	CH_3	OH	ethyl
	$(CH_3)_2CH_2$	CH_3	OH	ethyl
	phenyl	CH_3	OH	ethyl
	4-pyridyl	CH_3	OH	ethyl
	3-pyridyl	CH_3	OH	ethyl
20	2-pyridyl	CH_3	OH	ethyl
	4-pyridylmethyl	CH_3	OH	ethyl
	3-pyridylmethyl	CH_3	OH	ethyl
	2-pyridylmethyl	CH_3	OH	ethyl
	benzyl	CH_3	OH	ethyl
25	4- HO_2C -benzyl	CH_3	OH	ethyl
	4- H_2NCO -benzyl	CH_3	OH	ethyl
	4- CH_3O -benzyl	CH_3	OH	ethyl
	4- HO -benzyl	CH_3	OH	ethyl
	4- Cl -benzyl	CH_3	OH	ethyl
30	4- $(CH_3)_2N$ -benzyl	CH_3	OH	ethyl

-75-

	3-HO ₂ C-benzyl	CH ₃	OH	ethyl
	3-H ₂ NCO-benzyl	CH ₃	OH	ethyl
	3-CH ₃ -benzyl	CH ₃	OH	ethyl
	3-HO-benzyl	CH ₃	OH	ethyl
5	3-Cl-benzyl	CH ₃	OH	ethyl
	3-(CH ₃) ₂ N-benzyl	CH ₃	OH	ethyl
	2-HO-benzyl	CH ₃	OH	ethyl
	2-Cl-benzyl	CH ₃	OH	ethyl
	2-(CH ₃) ₂ N-benzyl	CH ₃	OH	ethyl
10	CH ₃	CH ₃	H	ethyl
	CH ₃ CH ₂	CH ₃	H	ethyl
	CH ₂ =CHCH ₂	CH ₃	H	ethyl
	CH ₃ CH ₂ CH ₂	CH ₃	H	ethyl
	(CH ₃) ₂ CH	CH ₃	H	ethyl
15	HO ₂ CCH ₂ CH ₂	CH ₃	H	ethyl
	H ₂ NCOCH ₂ CH ₂	CH ₃	H	ethyl
	HOCH ₂ CH ₂	CH ₃	H	ethyl
	HOCH ₂ CH ₂ CH ₂	CH ₃	H	ethyl
	(CH ₃) ₂ CH ₂	CH ₃	H	ethyl
20	phenyl	CH ₃	H	ethyl
	4-pyridyl	CH ₃	H	ethyl
	3-pyridyl	CH ₃	H	ethyl
	2-pyridyl	CH ₃	H	ethyl
	4-pyridylmethyl	CH ₃	H	ethyl
25	3-pyridylmethyl	CH ₃	H	ethyl
	2-pyridylmethyl	CH ₃	H	ethyl
	benzyl	CH ₃	H	ethyl
	4-HO ₂ C-benzyl	CH ₃	H	ethyl
	4-H ₂ NCO-benzyl	CH ₃	H	ethyl
30	4-CH ₃ O-benzyl	CH ₃	H	ethyl

-76-

	4-HO-benzyl	CH ₃	H	ethyl
	4-Cl-benzyl	CH ₃	H	ethyl
	4-(CH ₃) ₂ N-benzyl	CH ₃	H	ethyl
	3-HO ₂ C-benzyl	CH ₃	H	ethyl
5	3-H ₂ NCO-benzyl	CH ₃	H	ethyl
	3-CH ₃ O-benzyl	CH ₃	H	ethyl
	3-HO-benzyl	CH ₃	H	ethyl
	3-Cl-benzyl	CH ₃	H	ethyl
	3-(CH ₃) ₂ N-benzyl	CH ₃	H	ethyl
10	2-HO ₂ C-benzyl	CH ₃	H	ethyl
	2-H ₂ NCO-benzyl	CH ₃	H	ethyl
	2-CH ₃ O-benzyl	CH ₃	H	ethyl
	2-HO-benzyl	CH ₃	H	ethyl
	2-Cl-benzyl	CH ₃	H	ethyl
15	2-(CH ₃) ₂ N-benzyl	CH ₃	H	ethyl
	CH ₃	CH ₃	OH	allyl
	CH ₃ CH ₂	CH ₃	OH	allyl
	CH ₂ =CHCH ₂	CH ₃	OH	allyl
	CH ₃ CH ₂ CH ₂	CH ₃	OH	allyl
20	(CH ₃) ₂ CH	CH ₃	OH	allyl
	HO ₂ CCH ₂ CH ₂	CH ₃	OH	allyl
	H ₂ NCOCH ₂ CH ₂	CH ₃	OH	allyl
	HOCH ₂ CH ₂	CH ₃	OH	allyl
	HOCH ₂ CH ₂ CH ₂	CH ₃	OH	allyl
25	(CH ₃) ₂ CH ₂	CH ₃	OH	allyl
	phenyl	CH ₃	OH	allyl
	4-pyridyl	CH ₃	OH	allyl
	3-pyridyl	CH ₃	OH	allyl
	2-pyridyl	CH ₃	OH	allyl
30	4-pyridylmethyl	CH ₃	OH	allyl

-77-


	3-pyridylmethyl	CH ₃	OH	allyl
	2-pyridylmethyl	CH ₃	OH	allyl
	benzyl	CH ₃	OH	allyl
	4-HO ₂ C-benzyl	CH ₃	OH	allyl
5	4-H ₂ NCO-benzyl	CH ₃	OH	allyl
	4-CH ₃ O-benzyl	CH ₃	OH	allyl
	4-HO-benzyl	CH ₃	OH	allyl
	4-Cl-benzyl	CH ₃	OH	allyl
	4-(CH ₃) ₂ N-benzyl	CH ₃	OH	allyl
10	3-HO ₂ C-benzyl	CH ₃	OH	allyl
	3-H ₂ NCO-benzyl	CH ₃	OH	allyl
	3-CH ₃ O-benzyl	CH ₃	OH	allyl
	3-HO-benzyl	CH ₃	OH	allyl
	3-Cl-benzyl	CH ₃	OH	allyl
15	3-(CH ₃) ₂ N-benzyl	CH ₃	OH	allyl
	2-HO ₂ C-benzyl	CH ₃	OH	allyl
	2-H ₂ NCO-benzyl	CH ₃	OH	allyl
	2-CH ₃ O-benzyl	CH ₃	OH	allyl
	2-HO-benzyl	CH ₃	OH	allyl
20	2-Cl-benzyl	CH ₃	OH	allyl
	2-(CH ₃) ₂ N-benzyl	CH ₃	OH	allyl.

25

30


-78-

Representative compounds of the present invention include the compounds of Formula XVIII, XIX, XX and XXI:



XVIII

-79-



XIX

5


10

15

20


25

30



XX

-81-



30

-82-

wherein R^{6a} is H or CH_3 and R^a , R^2 , R^3 and R^5 are selected from the following groups of substituents:

	<u>R^a</u>	<u>R^2</u>	<u>R^3</u>	<u>R^5</u>
5	CH_3	CH_3	OH	ethyl
	CH_3CH_2	CH_3	OH	ethyl
	$CH_2=CHCH_2$	CH_3	OH	ethyl
	$CH_3CH_2CH_2$	CH_3	OH	ethyl
10	$(CH_3)_2CH$	CH_3	OH	ethyl
	$HO_2CCH_2CH_2$	CH_3	OH	ethyl
	$H_2NCOCH_2CH_2$	CH_3	OH	ethyl
	$HOCH_2CH_2$	CH_3	OH	ethyl
	$HOCH_2CH_2CH_2$	CH_3	OH	ethyl
15	$(CH_3)_2CH$	CH_3	OH	ethyl
	phenyl	CH_3	OH	ethyl
	4-pyridyl	CH_3	OH	ethyl
	3-pyridyl	CH_3	OH	ethyl
	2-pyridyl	CH_3	OH	ethyl
20	4-pyridylmethyl	CH_3	OH	ethyl
	3-pyridylmethyl	CH_3	OH	ethyl
	2-pyridylmethyl	CH_3	OH	ethyl
	benzyl	CH_3	OH	ethyl
	4- HO_2C -benzyl	CH_3	OH	ethyl
25	4- H_2NCO -benzyl	CH_3	OH	ethyl
	4- CH_3O -benzyl	CH_3	OH	ethyl
	4- HO -benzyl	CH_3	OH	ethyl
	4- Cl -benzyl	CH_3	OH	ethyl
	4- $(CH_3)_2N$ -benzyl	CH_3	OH	ethyl
30	3- HO_2C -benzyl	CH_3	OH	ethyl
	3- H_2NCO -benzyl	CH_3	OH	ethyl
	3- CH_3O -benzyl	CH_3	OH	ethyl

-83-

	3-HO-benzyl	CH ₃	OH	ethyl
	3-Cl-benzyl	CH ₃	OH	ethyl
	3-(CH ₃) ₂ N-benzyl	CH ₃	OH	ethyl
	2-HO ₂ C-benzyl	CH ₃	OH	ethyl
5	2-H ₂ NCO-benzyl	CH ₃	OH	ethyl
	2-CH ₃ O-benzyl	CH ₃	OH	ethyl
	2-HO-benzyl	CH ₃	OH	ethyl
	2-Cl-benzyl	CH ₃	OH	ethyl
	2-(CH ₃) ₂ N-benzyl	CH ₃	OH	ethyl
10	CH ₃	CH ₃	H	ethyl
	CH ₃ CH ₂	CH ₃	H	ethyl
	CH ₂ =CHCH ₂	CH ₃	H	ethyl
	CH ₃ CH ₂ CH ₂	CH ₃	H	ethyl
	(CH ₃) ₂ CH	CH ₃	H	ethyl
15	HO ₂ CCH ₂ CH ₂	CH ₃	H	ethyl
	H ₂ NCOCH ₂ CH ₂	CH ₃	H	ethyl
	HOCH ₂ CH ₂	CH ₃	H	ethyl
	HOCH ₂ CH ₂ CH ₂	CH ₃	H	ethyl
	(CH ₃) ₂ CH ₂	CH ₃	H	ethyl
20	phenyl	CH ₃	H	ethyl
	4-pyridyl	CH ₃	H	ethyl
	3-pyridyl	CH ₃	H	ethyl
	2-pyridyl	CH ₃	H	ethyl
	4-pyridylmethyl	CH ₃	H	ethyl
25	3-pyridylmethyl	CH ₃	H	ethyl
	2-pyridylmethyl	CH ₃	H	ethyl
	benzyl	CH ₃	H	ethyl
	4-HO ₂ C-benzyl	CH ₃	H	ethyl
	4-H ₂ NCO-benzyl	CH ₃	H	ethyl
30	4-CH ₃ O-benzyl	CH ₃	H	ethyl
	4-HO-benzyl	CH ₃	H	ethyl
	4-Cl-benzyl	CH ₃	H	ethyl
	4-(CH ₃) ₂ N-benzyl	CH ₃	H	ethyl

-84-

	3-HO ₂ C-benzyl	CH ₃	H	ethyl
	3-H ₂ NCO-benzyl	CH ₃	H	ethyl
	3-CH ₃ O-benzyl	CH ₃	H	ethyl
	3-HO-benzyl	CH ₃	H	ethyl
5	3-Cl-benzyl	CH ₃	H	ethyl
	3-(CH ₃) ₂ N-benzyl	CH ₃	H	ethyl
	2-HO ₂ C-benzyl	CH ₃	H	ethyl
	2-H ₂ NCO-benzyl	CH ₃	H	ethyl
	2-CH ₃ O-benzyl	CH ₃	H	ethyl
10	2-HO-benzyl	CH ₃	H	ethyl
	2-Cl-benzyl	CH ₃	H	ethyl
	2-(CH ₃) ₂ N-benzyl	CH ₃	H	ethyl
	CH ₃	CH ₃	OH	allyl
	CH ₃ CH ₂	CH ₃	OH	allyl
15	CH ₂ =CHCH ₂	CH ₃	OH	allyl
	CH ₃ CH ₂ CH ₂	CH ₃	OH	allyl
	(CH ₃) ₂ CH	CH ₃	OH	allyl
	HO ₂ CCH ₂ CH ₂	CH ₃	OH	allyl
	H ₂ NCOCH ₂ CH ₂	CH ₃	OH	allyl
20	HOCH ₂ CH ₂	CH ₃	OH	allyl
	HOCH ₂ CH ₂ CH ₂	CH ₃	OH	allyl
	(CH ₃) ₂ CH ₂	CH ₃	OH	allyl
	phenyl	CH ₃	OH	allyl
	4-pyridyl	CH ₃	OH	allyl
25	3-pyridyl	CH ₃	OH	allyl
	2-pyridyl	CH ₃	OH	allyl
	4-pyridylmethyl	CH ₃	OH	allyl
	3-pyridylmethyl	CH ₃	OH	allyl
	2-pyridylmethyl	CH ₃	OH	allyl
30	benzyl	CH ₃	OH	allyl
	4-HO ₂ C-benzyl	CH ₃	OH	allyl
	4-H ₂ NCO-benzyl	CH ₃	OH	allyl

-85-

	4-CH ₃ O-benzyl	CH ₃	OH	allyl
	4-HO-benzyl	CH ₃	OH	allyl
	4-Cl-benzyl	CH ₃	OH	allyl
	4-(CH ₃) ₂ N-benzyl	CH ₃	OH	allyl
5	3-HO ₂ C-benzyl	CH ₃	OH	allyl
	3-H ₂ NCO-benzyl	CH ₃	OH	allyl
	3-CH ₃ O-benzyl	CH ₃	OH	allyl
	3-HO-benzyl	CH ₃	OH	allyl
	3-Cl-benzyl	CH ₃	OH	allyl
10	3-(CH ₃) ₂ N-benzyl	CH ₃	OH	allyl
	2-HO ₂ C-benzyl	CH ₃	OH	allyl
	2-H ₂ NCO-benzyl	CH ₃	OH	allyl
	2-CH ₃ O-benzyl	CH ₃	OH	allyl
	2-HO-benzyl	CH ₃	OH	allyl
15	2-Cl-benzyl	CH ₃	OH	allyl
	2-(CH ₃) ₂ N-benzyl	CH ₃	OH	allyl.

Representative compounds of the present invention include the compounds of Formula XVIII:

20

25

30

-86-


5

10

15

20

25



XVIII

30

wherein X, R², R³ and R⁵ are selected from the following groups of substituents:

-87-

	<u>X</u>	<u>R²</u>	<u>R³</u>	<u>R⁵</u>
	1-imidazolylmethyl	CH ₃	OH	ethyl
	2-imidazolylmethyl	CH ₃	OH	ethyl
5	3-thiazolylmethyl	CH ₃	OH	ethyl
	2-thiazolylmethyl	CH ₃	OH	ethyl
	2-oxazolylmethyl	CH ₃	OH	ethyl
	5-tetrazolylmethyl	CH ₃	OH	ethyl
	4-pyridylmethyl	CH ₃	OH	ethyl
10	3-pyridylmethyl	CH ₃	OH	ethyl
	2-pyridylmethyl	CH ₃	OH	ethyl
	benzyl	CH ₃	OH	ethyl
	4-HO ₂ C-benzyl	CH ₃	OH	ethyl
	4-H ₂ NCO-benzyl	CH ₃	OH	ethyl
15	4-CH ₃ O-benzyl	CH ₃	OH	ethyl
	4-HO-benzyl	CH ₃	OH	ethyl
	4-R ¹¹ O-benzyl	CH ₃	OH	ethyl
	4-Cl-benzyl	CH ₃	OH	ethyl
	4-(CH ₃) ₂ N-benzyl	CH ₃	OH	ethyl
20	3-HO ₂ C-benzyl	CH ₃	OH	ethyl
	3-H ₂ NCO-benzyl	CH ₃	OH	ethyl
	3-CH ₃ O-benzyl	CH ₃	OH	ethyl
	3-HO-benzyl	CH ₃	OH	ethyl
	3-R ¹¹ O-benzyl	CH ₃	OH	ethyl
25	3-Cl-benzyl	CH ₃	OH	ethyl
	3-(CH ₃) ₂ N-benzyl	CH ₃	OH	ethyl
	2-HO ₂ C-benzyl	CH ₃	OH	ethyl
	2-H ₂ NCO-benzyl	CH ₃	OH	ethyl
	2-CH ₃ O-benzyl	CH ₃	OH	ethyl
30	2-HO-benzyl	CH ₃	OH	ethyl
	2-R ¹¹ O-benzyl	CH ₃	OH	ethyl
	2-Cl-benzyl	CH ₃	OH	ethyl
	2-(CH ₃) ₂ N-benzyl	CH ₃	OH	ethyl

-88-

	3-(4-pyridyl)-imidazol-2-ylmethyl	CH ₃	OH	ethyl
	3-(3-pyridyl)-imidazol-2-ylmethyl	CH ₃	OH	ethyl
	3-(2-pyridyl)-imidazol-2-ylmethyl	CH ₃	OH	ethyl
	3-phenylimidazol-2-ylmethyl	CH ₃	OH	ethyl
5	3-(4-HO ₂ C-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	ethyl
	3-(4-H ₂ NCO-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	ethyl
	3-(4-CH ₃ O-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	ethyl
	3-(4-HO-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	ethyl
	3-(4-R ¹¹ O-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	ethyl
10	3-(4-Cl-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	ethyl
	3-(4-(CH ₃) ₂ N-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	ethyl
	3-(3-HO ₂ C-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	ethyl
	3-(3-H ₂ NCO-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	ethyl
	3-(3-CH ₃ O-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	ethyl
15	3-(3-HO-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	ethyl
	3-(3-R ¹¹ O-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	ethyl
	3-(3-Cl-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	ethyl
	3-(3-(CH ₃) ₂ N-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	ethyl
	3-(2-HO ₂ C-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	ethyl
20	3-(2-H ₂ NCO-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	ethyl
	3-(2-CH ₃ O-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	ethyl
	3-(2-HO-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	ethyl
	3-(2-R ¹¹ O-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	ethyl
	3-(2-Cl-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	ethyl
25	3-(2-(CH ₃) ₂ N-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	ethyl
	1-imidazolylmethyl	CH ₃	H	ethyl
	2-imidazolylmethyl	CH ₃	H	ethyl
	3-thiazolylmethyl	CH ₃	H	ethyl
	2-thiazolylmethyl	CH ₃	H	ethyl
30	2-oxazolylmethyl	CH ₃	H	ethyl
	5-tetrazolylmethyl	CH ₃	H	ethyl
	4-pyridylmethyl	CH ₃	H	ethyl
	3-pyridylmethyl	CH ₃	H	ethyl

-89-

	2-pyridylmethyl	CH ₃	H	ethyl
	benzyl	CH ₃	H	ethyl
	4-HO ₂ C-benzyl	CH ₃	H	ethyl
	4-H ₂ NCO-benzyl	CH ₃	H	ethyl
5	4-CH ₃ O-benzyl	CH ₃	H	ethyl
	4-HO-benzyl	CH ₃	H	ethyl
	4-R ¹¹ O-benzyl	CH ₃	H	ethyl
	4-Cl-benzyl	CH ₃	H	ethyl
	4-(CH ₃) ₂ N-benzyl	CH ₃	H	ethyl
10	3-HO ₂ C-benzyl	CH ₃	H	ethyl
	3-H ₂ NCO-benzyl	CH ₃	H	ethyl
	3-CH ₃ O-benzyl	CH ₃	H	ethyl
	3-HO-benzyl	CH ₃	H	ethyl
	3-R ¹¹ O-benzyl	CH ₃	H	ethyl
15	3-Cl-benzyl	CH ₃	H	ethyl
	3-(CH ₃) ₂ N-benzyl	CH ₃	H	ethyl
	2-HO ₂ C-benzyl	CH ₃	H	ethyl
	2-H ₂ NCO-benzyl	CH ₃	H	ethyl
	2-CH ₃ O-benzyl	CH ₃	H	ethyl
20	2-HO-benzyl	CH ₃	H	ethyl
	2-R ¹¹ O-benzyl	CH ₃	H	ethyl
	2-Cl-benzyl	CH ₃	H	ethyl
	2-(CH ₃) ₂ N-benzyl	CH ₃	H	ethyl
	3-(4-pyridyl)-imidazol-2-ylmethyl	CH ₃	H	ethyl
25	3-(3-pyridyl)-imidazol-2-ylmethyl	CH ₃	H	ethyl
	3-(2-pyridyl)-imidazol-2-ylmethyl	CH ₃	H	ethyl
	3-phenylimidazol-2-ylmethyl	CH ₃	H	ethyl
	3-(4-HO ₂ C-phenyl)-imidazol-2-ylmethyl	CH ₃	H	ethyl
	3-(4-H ₂ NCO-phenyl)-imidazol-2-ylmethyl	CH ₃	H	ethyl
30	3-(4-CH ₃ O-phenyl)-imidazol-2-ylmethyl	CH ₃	H	ethyl
	3-(4-HO-phenyl)-imidazol-2-ylmethyl	CH ₃	H	ethyl
	3-(4-R ¹¹ O-phenyl)-imidazol-2-ylmethyl	CH ₃	H	ethyl
	3-(4-Cl-phenyl)-imidazol-2-ylmethyl	CH ₃	H	ethyl

-90-

	3-(4-(CH ₃) ₂ N-phenyl)-imidazol-2-ylmethyl	CH ₃	H	ethyl
	3-(3-HO ₂ C-phenyl)-imidazol-2-ylmethyl	CH ₃	H	ethyl
	3-(3-H ₂ NCO-phenyl)-imidazol-2-ylmethyl	CH ₃	H	ethyl
	3-(3-CH ₃ O-phenyl)-imidazol-2-ylmethyl	CH ₃	H	ethyl
5	3-(3-HO-phenyl)-imidazol-2-ylmethyl	CH ₃	H	ethyl
	3-(3-R ¹¹ O-phenyl)-imidazol-2-ylmethyl	CH ₃	H	ethyl
	3-(3-Cl-phenyl)-imidazol-2-ylmethyl	CH ₃	H	ethyl
	3-(3-(CH ₃) ₂ N-phenyl)-imidazol-2-ylmethyl	CH ₃	H	ethyl
	3-(2-HO ₂ C-phenyl)-imidazol-2-ylmethyl	CH ₃	H	ethyl
10	3-(2-H ₂ NCO-phenyl)-imidazol-2-ylmethyl	CH ₃	H	ethyl
	3-(2-CH ₃ O-phenyl)-imidazol-2-ylmethyl	CH ₃	H	ethyl
	3-(2-HO-phenyl)-imidazol-2-ylmethyl	CH ₃	H	ethyl
	3-(2-R ¹¹ O-phenyl)-imidazol-2-ylmethyl	CH ₃	H	ethyl
	3-(2-Cl-phenyl)-imidazol-2-ylmethyl	CH ₃	H	ethyl
15	3-(2-(CH ₃) ₂ N-phenyl)-imidazol-2-ylmethyl	CH ₃	H	ethyl
	1-imidazolylmethyl	H	OH	ethyl
	2-imidazolylmethyl	H	OH	ethyl
	3-thiazolylmethyl	H	OH	ethyl
	2-thiazolylmethyl	H	OH	ethyl
20	2-oxazolylmethyl	H	OH	ethyl
	5-tetrazolylmethyl	H	OH	ethyl
	4-pyridylmethyl	H	OH	ethyl
	3-pyridylmethyl	H	OH	ethyl
	2-pyridylmethyl	H	OH	ethyl
25	benzyl	H	OH	ethyl
	4-HO ₂ C-benzyl	H	OH	ethyl
	4-H ₂ NCO-benzyl	H	OH	ethyl
	4-CH ₃ O-benzyl	H	OH	ethyl
	4-HO-benzyl	H	OH	ethyl
30	4-R ¹¹ O-benzyl	H	OH	ethyl
	4-Cl-benzyl	H	OH	ethyl
	4-(CH ₃) ₂ N-benzyl	H	OH	ethyl
	3-HO ₂ C-benzyl	H	OH	ethyl

-91-

	3-H ₂ NCO-benzyl	H	OH	ethyl
	3-CH ₃ O-benzyl	H	OH	ethyl
	3-HO-benzyl	H	OH	ethyl
	3-R ¹¹ O-benzyl	H	OH	ethyl
5	3-Cl-benzyl	H	OH	ethyl
	3-(CH ₃) ₂ N-benzyl	H	OH	ethyl
	2-HO ₂ C-benzyl	H	OH	ethyl
	2-H ₂ NCO-benzyl	H	OH	ethyl
	2-CH ₃ O-benzyl	H	OH	ethyl
10	2-HO-benzyl	H	OH	ethyl
	2-R ¹¹ O-benzyl	H	OH	ethyl
	2-Cl-benzyl	H	OH	ethyl
	2-(CH ₃) ₂ N-benzyl	H	OH	ethyl
	3-(4-pyridyl)-imidazol-2-ylmethyl	H	OH	ethyl
15	3-(3-pyridyl)-imidazol-2-ylmethyl	H	OH	ethyl
	3-(2-pyridyl)-imidazol-2-ylmethyl	H	OH	ethyl
	3-phenylimidazol-2-ylmethyl	H	OH	ethyl
	3-(4-HO ₂ C-phenyl)-imidazol-2-ylmethyl	H	OH	ethyl
	3-(4-H ₂ NCO-phenyl)-imidazol-2-ylmethyl	H	OH	ethyl
20	3-(4-CH ₃ O-phenyl)-imidazol-2-ylmethyl	H	OH	ethyl
	3-(4-HO-phenyl)-imidazol-2-ylmethyl	H	OH	ethyl
	3-(4-R ¹¹ O-phenyl)-imidazol-2-ylmethyl	H	OH	ethyl
	3-(4-Cl-phenyl)-imidazol-2-ylmethyl	H	OH	ethyl
	3-(4-(CH ₃) ₂ N-phenyl)-imidazol-2-ylmethyl	H	OH	ethyl
25	3-(3-HO ₂ C-phenyl)-imidazol-2-ylmethyl	H	OH	ethyl
	3-(3-H ₂ NCO-phenyl)-imidazol-2-ylmethyl	H	OH	ethyl
	3-(3-CH ₃ O-phenyl)-imidazol-2-ylmethyl	H	OH	ethyl
	3-(3-HO-phenyl)-imidazol-2-ylmethyl	H	OH	ethyl
	3-(3-R ¹¹ O-phenyl)-imidazol-2-ylmethyl	H	OH	ethyl
30	3-(3-Cl-phenyl)-imidazol-2-ylmethyl	H	OH	ethyl
	3-(3-(CH ₃) ₂ N-phenyl)-imidazol-2-ylmethyl	H	OH	ethyl
	3-(2-HO ₂ C-phenyl)-imidazol-2-ylmethyl	H	OH	ethyl
	3-(2-H ₂ NCO-phenyl)-imidazol-2-ylmethyl	H	OH	ethyl

-92-

	3-(2-CH ₃ O-phenyl)-imidazol-2-ylmethyl	H	OH	ethyl
	3-(2-HO-phenyl)-imidazol-2-ylmethyl	H	OH	ethyl
	3-(2-R ¹¹ O-phenyl)-imidazol-2-ylmethyl	H	OH	ethyl
	3-(2-Cl-phenyl)-imidazol-2-ylmethyl	H	OH	ethyl
5	3-(2-(CH ₃) ₂ N-phenyl)-imidazol-2-ylmethyl	H	OH	ethyl
	1-imidazolylmethyl	H	H	ethyl
	2-imidazolylmethyl	H	H	ethyl
	3-thiazolylmethyl	H	H	ethyl
	2-thiazolylmethyl	H	H	ethyl
10	2-oxazolylmethyl	H	H	ethyl
	5-tetrazolylmethyl	H	H	ethyl
	4-pyridylmethyl	H	H	ethyl
	3-pyridylmethyl	H	H	ethyl
	2-pyridylmethyl	H	H	ethyl
15	benzyl	H	H	ethyl
	4-HO ₂ C-benzyl	H	H	ethyl
	4-H ₂ NCO-benzyl	H	H	ethyl
	4-CH ₃ O-benzyl	H	H	ethyl
	4-HO-benzyl	H	H	ethyl
20	4-R ¹¹ O-benzyl	H	H	ethyl
	4-Cl-benzyl	H	H	ethyl
	4-(CH ₃) ₂ N-benzyl	H	H	ethyl
	3-HO ₂ C-benzyl	H	H	ethyl
	3-H ₂ NCO-benzyl	H	H	ethyl
25	3-CH ₃ O-benzyl	H	H	ethyl
	3-HO-benzyl	H	H	ethyl
	3-R ¹¹ O-benzyl	H	H	ethyl
	3-Cl-benzyl	H	H	ethyl
	3-(CH ₃) ₂ N-benzyl	H	H	ethyl
30	2-HO ₂ C-benzyl	H	H	ethyl
	2-H ₂ NCO-benzyl	H	H	ethyl
	2-CH ₃ O-benzyl	H	H	ethyl
	2-HO-benzyl	H	H	ethyl

-93-

	2-R ¹¹ O-benzyl	H	H	ethyl
	2-Cl-benzyl	H	H	ethyl
	2-(CH ₃) ₂ N-benzyl	H	H	ethyl
	3-(4-pyridyl)-imidazol-2-ylmethyl	H	H	ethyl
5	3-(3-pyridyl)-imidazol-2-ylmethyl	H	H	ethyl
	3-(2-pyridyl)-imidazol-2-ylmethyl	H	H	ethyl
	3-phenylimidazol-2-ylmethyl	H	H	ethyl
	3-(4-HO ₂ C-phenyl)-imidazol-2-ylmethyl	H	H	ethyl
	3-(4-H ₂ NCO-phenyl)-imidazol-2-ylmethyl	H	H	ethyl
10	3-(4-CH ₃ O-phenyl)-imidazol-2-ylmethyl	H	H	ethyl
	3-(4-HO-phenyl)-imidazol-2-ylmethyl	H	H	ethyl
	3-(4-R ¹¹ O-phenyl)-imidazol-2-ylmethyl	H	H	ethyl
	3-(4-Cl-phenyl)-imidazol-2-ylmethyl	H	H	ethyl
	3-(4-(CH ₃) ₂ N-phenyl)-imidazol-2-ylmethyl	H	H	ethyl
15	3-(3-HO ₂ C-phenyl)-imidazol-2-ylmethyl	H	H	ethyl
	3-(3-H ₂ NCO-phenyl)-imidazol-2-ylmethyl	H	H	ethyl
	3-(3-CH ₃ O-phenyl)-imidazol-2-ylmethyl	H	H	ethyl
	3-(3-HO-phenyl)-imidazol-2-ylmethyl	H	H	ethyl
	3-(3-R ¹¹ O-phenyl)-imidazol-2-ylmethyl	H	H	ethyl
20	3-(3-Cl-phenyl)-imidazol-2-ylmethyl	H	H	ethyl
	3-(3-(CH ₃) ₂ N-phenyl)-imidazol-2-ylmethyl	H	H	ethyl
	3-(2-HO ₂ C-phenyl)-imidazol-2-ylmethyl	H	H	ethyl
	3-(2-H ₂ NCO-phenyl)-imidazol-2-ylmethyl	H	H	ethyl
	3-(2-CH ₃ O-phenyl)-imidazol-2-ylmethyl	H	H	ethyl
25	3-(2-HO-phenyl)-imidazol-2-ylmethyl	H	H	ethyl
	3-(2-R ¹¹ O-phenyl)-imidazol-2-ylmethyl	H	H	ethyl
	3-(2-Cl-phenyl)-imidazol-2-ylmethyl	H	H	ethyl
	3-(2-(CH ₃) ₂ N-phenyl)-imidazol-2-ylmethyl	H	H	ethyl
	1-imidazolylmethyl	CH ₃	OH	allyl
30	2-imidazolylmethyl	CH ₃	OH	allyl
	3-thiazolylmethyl	CH ₃	OH	allyl
	2-thiazolylmethyl	CH ₃	OH	allyl
	2-oxazolylmethyl	CH ₃	OH	allyl

-94-

	5-tetrazolylmethyl	CH ₃	OH	allyl
	4-pyridylmethyl	CH ₃	OH	allyl
	3-pyridylmethyl	CH ₃	OH	allyl
	2-pyridylmethyl	CH ₃	OH	allyl
5	benzyl	CH ₃	OH	allyl
	4-HO ₂ C-benzyl	CH ₃	OH	allyl
	4-H ₂ NCO-benzyl	CH ₃	OH	allyl
	4-CH ₃ O-benzyl	CH ₃	OH	allyl
	4-HO-benzyl	CH ₃	OH	allyl
10	4-R ¹¹ O-benzyl	CH ₃	OH	allyl
	4-Cl-benzyl	CH ₃	OH	allyl
	4-(CH ₃) ₂ N-benzyl	CH ₃	OH	allyl
	3-HO ₂ C-benzyl	CH ₃	OH	allyl
	3-H ₂ NCO-benzyl	CH ₃	OH	allyl
15	3-CH ₃ O-benzyl	CH ₃	OH	allyl
	3-HO-benzyl	CH ₃	OH	allyl
	3-R ¹¹ O-benzyl	CH ₃	OH	allyl
	3-Cl-benzyl	CH ₃	OH	allyl
	3-(CH ₃) ₂ N-benzyl	CH ₃	OH	allyl
20	2-HO ₂ C-benzyl	CH ₃	OH	allyl
	2-H ₂ NCO-benzyl	CH ₃	OH	allyl
	2-CH ₃ O-benzyl	CH ₃	OH	allyl
	2-HO-benzyl	CH ₃	OH	allyl
	2-R ¹¹ O-benzyl	CH ₃	OH	allyl
25	2-Cl-benzyl	CH ₃	OH	allyl
	2-(CH ₃) ₂ N-benzyl	CH ₃	OH	allyl
	3-(4-pyridyl)-imidazol-2-ylmethyl	CH ₃	OH	allyl
	3-(3-pyridyl)-imidazol-2-ylmethyl	CH ₃	OH	allyl
	3-(2-pyridyl)-imidazol-2-ylmethyl	CH ₃	OH	allyl
30	3-phenylimidazol-2-ylmethyl	CH ₃	OH	allyl
	3-(4-HO ₂ C-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	allyl
	3-(4-H ₂ NCO-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	allyl
	3-(4-CH ₃ O-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	allyl

-95-

	3-(4-HO-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	allyl
	3-(4-R ¹¹ O-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	allyl
	3-(4-Cl-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	allyl
	3-(4-(CH ₃) ₂ N-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	allyl
5	3-(3-HO ₂ C-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	allyl
	3-(3-H ₂ NCO-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	allyl
	3-(3-CH ₃ O-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	allyl
	3-(3-HO-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	allyl
	3-(3-R ¹¹ O-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	allyl
10	3-(3-Cl-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	allyl
	3-(3-(CH ₃) ₂ N-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	allyl
	3-(2-HO ₂ C-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	allyl
	3-(2-H ₂ NCO-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	allyl
	3-(2-CH ₃ O-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	allyl
15	3-(2-HO-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	allyl
	3-(2-R ¹¹ O-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	allyl
	3-(2-Cl-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	allyl
	3-(2-(CH ₃) ₂ N-phenyl)-imidazol-2-ylmethyl	CH ₃	OH	allyl
	1-imidazolylmethyl	CH ₃	H	allyl
20	2-imidazolylmethyl	CH ₃	H	allyl
	3-thiazolylmethyl	CH ₃	H	allyl
	2-thiazolylmethyl	CH ₃	H	allyl
	2-oxazolylmethyl	CH ₃	H	allyl
	5-tetrazolylmethyl	CH ₃	H	allyl
-25	4-pyridylmethyl	CH ₃	H	allyl
	3-pyridylmethyl	CH ₃	H	allyl
	2-pyridylmethyl	CH ₃	H	allyl
	benzyl	CH ₃	H	allyl
	4-HO ₂ C-benzyl	CH ₃	H	allyl
30	4-H ₂ NCO-benzyl	CH ₃	H	allyl
	4-CH ₃ O-benzyl	CH ₃	H	allyl
	4-HO-benzyl	CH ₃	H	allyl
	4-R ¹¹ O-benzyl	CH ₃	H	allyl

-96-

	4-Cl-benzyl	CH ₃	H	allyl
	4-(CH ₃) ₂ N-benzyl	CH ₃	H	allyl
	3-HO ₂ C-benzyl	CH ₃	H	allyl
	3-H ₂ NCO-benzyl	CH ₃	H	allyl
5	3-CH ₃ O-benzyl	CH ₃	H	allyl
	3-HO-benzyl	CH ₃	H	allyl
	3-R ¹¹ O-benzyl	CH ₃	H	allyl
	3-Cl-benzyl	CH ₃	H	allyl
	3-(CH ₃) ₂ N-benzyl	CH ₃	H	allyl
10	2-HO ₂ C-benzyl	CH ₃	H	allyl
	2-H ₂ NCO-benzyl	CH ₃	H	allyl
	2-CH ₃ O-benzyl	CH ₃	H	allyl
	2-HO-benzyl	CH ₃	H	allyl
	2-R ¹¹ O-benzyl	CH ₃	H	allyl
15	2-Cl-benzyl	CH ₃	H	allyl
	2-(CH ₃) ₂ N-benzyl	CH ₃	H	allyl
	3-(4-pyridyl)-imidazol-2-ylmethyl	CH ₃	H	allyl
	3-(3-pyridyl)-imidazol-2-ylmethyl	CH ₃	H	allyl
	3-(2-pyridyl)-imidazol-2-ylmethyl	CH ₃	H	allyl
20	3-phenylimidazol-2-ylmethyl	CH ₃	H	allyl
	3-(4-HO ₂ C-phenyl)-imidazol-2-ylmethyl	CH ₃	H	allyl
	3-(4-H ₂ NCO-phenyl)-imidazol-2-ylmethyl	CH ₃	H	allyl
	3-(4-CH ₃ O-phenyl)-imidazol-2-ylmethyl	CH ₃	H	allyl
	3-(4-HO-phenyl)-imidazol-2-ylmethyl	CH ₃	H	allyl
25	3-(4-R ¹¹ O-phenyl)-imidazol-2-ylmethyl	CH ₃	H	allyl
	3-(4-Cl-phenyl)-imidazol-2-ylmethyl	CH ₃	H	allyl
	3-(4-(CH ₃) ₂ N-phenyl)-imidazol-2-ylmethyl	CH ₃	H	allyl
	3-(3-HO ₂ C-phenyl)-imidazol-2-ylmethyl	CH ₃	H	allyl
	3-(3-H ₂ NCO-phenyl)-imidazol-2-ylmethyl	CH ₃	H	allyl
30	3-(3-CH ₃ O-phenyl)-imidazol-2-ylmethyl	CH ₃	H	allyl
	3-(3-HO-phenyl)-imidazol-2-ylmethyl	CH ₃	H	allyl
	3-(3-R ¹¹ O-phenyl)-imidazol-2-ylmethyl	CH ₃	H	allyl
	3-(3-Cl-phenyl)-imidazol-2-ylmethyl	CH ₃	H	allyl

-97-

	3-(3-(CH ₃) ₂ N-phenyl)-imidazol-2-ylmethyl	CH ₃	H	allyl
	3-(2-HO ₂ C-phenyl)-imidazol-2-ylmethyl	CH ₃	H	allyl
	3-(2-H ₂ NCO-phenyl)-imidazol-2-ylmethyl	CH ₃	H	allyl
	3-(2-CH ₃ O-phenyl)-imidazol-2-ylmethyl	CH ₃	H	allyl
5	3-(2-HO-phenyl)-imidazol-2-ylmethyl	CH ₃	H	allyl
	3-(2-R ¹¹ O-phenyl)-imidazol-2-ylmethyl	CH ₃	H	allyl
	3-(2-Cl-phenyl)-imidazol-2-ylmethyl	CH ₃	H	allyl
	3-(2-(CH ₃) ₂ N-phenyl)-imidazol-2-ylmethyl	CH ₃	H	allyl
	1-imidazolylmethyl	H	OH	allyl
10	2-imidazolylmethyl	H	OH	allyl
	3-thiazolylmethyl	H	OH	allyl
	2-thiazolylmethyl	H	OH	allyl
	2-oxazolylmethyl	H	OH	allyl
	5-tetrazolylmethyl	H	OH	allyl
15	4-pyridylmethyl	H	OH	allyl
	3-pyridylmethyl	H	OH	allyl
	2-pyridylmethyl	H	OH	allyl
	benzyl	H	OH	allyl
	4-HO ₂ C-benzyl	H	OH	allyl
20	4-H ₂ NCO-benzyl	H	OH	allyl
	4-CH ₃ O-benzyl	H	OH	allyl
	4-HO-benzyl	H	OH	allyl
	4-R ¹¹ O-benzyl	H	OH	allyl
	4-Cl-benzyl	H	OH	allyl
25	4-(CH ₃) ₂ N-benzyl	H	OH	allyl
	3-HO ₂ C-benzyl	H	OH	allyl
	3-H ₂ NCO-benzyl	H	OH	allyl
	3-CH ₃ O-benzyl	H	OH	allyl
	3-HO-benzyl	H	OH	allyl
30	3-R ¹¹ O-benzyl	H	OH	allyl
	3-Cl-benzyl	H	OH	allyl
	3-(CH ₃) ₂ N-benzyl	H	OH	allyl
	2-HO ₂ C-benzyl	H	OH	allyl

-98-

	2-H ₂ NCO-benzyl	H	OH	allyl
	2-CH ₃ O-benzyl	H	OH	allyl
	2-HO-benzyl	H	OH	allyl
	2-R ¹¹ O-benzyl	H	OH	allyl
5	2-Cl-benzyl	H	OH	allyl
	2-(CH ₃) ₂ N-benzyl	H	OH	allyl
	3-(4-pyridyl)-imidazol-2-ylmethyl	H	OH	allyl
	3-(3-pyridyl)-imidazol-2-ylmethyl	H	OH	allyl
	3-(2-pyridyl)-imidazol-2-ylmethyl	H	OH	allyl
10	3-phenylimidazol-2-ylmethyl	H	OH	allyl
	3-(4-HO ₂ C-phenyl)-imidazol-2-ylmethyl	H	OH	allyl
	3-(4-H ₂ NCO-phenyl)-imidazol-2-ylmethyl	H	OH	allyl
	3-(4-CH ₃ O-phenyl)-imidazol-2-ylmethyl	H	OH	allyl
	3-(4-HO-phenyl)-imidazol-2-ylmethyl	H	OH	allyl
15	3-(4-R ¹¹ O-phenyl)-imidazol-2-ylmethyl	H	OH	allyl
	3-(4-Cl-phenyl)-imidazol-2-ylmethyl	H	OH	allyl
	3-(4-(CH ₃) ₂ N-phenyl)-imidazol-2-ylmethyl	H	OH	allyl
	3-(3-HO ₂ C-phenyl)-imidazol-2-ylmethyl	H	OH	allyl
	3-(3-H ₂ NCO-phenyl)-imidazol-2-ylmethyl	H	OH	allyl
20	3-(3-CH ₃ O-phenyl)-imidazol-2-ylmethyl	H	OH	allyl
	3-(3-HO-phenyl)-imidazol-2-ylmethyl	H	OH	allyl
	3-(3-R ¹¹ O-phenyl)-imidazol-2-ylmethyl	H	OH	allyl
	3-(3-Cl-phenyl)-imidazol-2-ylmethyl	H	OH	allyl
	3-(3-(CH ₃) ₂ N-phenyl)-imidazol-2-ylmethyl	H	OH	allyl
25	3-(2-HO ₂ C-phenyl)-imidazol-2-ylmethyl	H	OH	allyl
	3-(2-H ₂ NCO-phenyl)-imidazol-2-ylmethyl	H	OH	allyl
	3-(2-CH ₃ O-phenyl)-imidazol-2-ylmethyl	H	OH	allyl
	3-(2-HO-phenyl)-imidazol-2-ylmethyl	H	OH	allyl
	3-(2-R ¹¹ O-phenyl)-imidazol-2-ylmethyl	H	OH	allyl
30	3-(2-Cl-phenyl)-imidazol-2-ylmethyl	H	OH	allyl
	3-(2-(CH ₃) ₂ N-phenyl)-imidazol-2-ylmethyl	H	OH	allyl

-99-

	1-imidazolylmethyl	H	H	allyl
	2-imidazolylmethyl	H	H	allyl
	3-thiazolylmethyl	H	H	allyl
	2-thiazolylmethyl	H	H	allyl
5	2-oxazolylmethyl	H	H	allyl
	5-tetrazolylmethyl	H	H	allyl
	4-pyridylmethyl	H	H	allyl
	3-pyridylmethyl	H	H	allyl
	2-pyridylmethyl	H	H	allyl
10	benzyl	H	H	allyl
	4-HO ₂ C-benzyl	H	H	allyl
	4-H ₂ NCO-benzyl	H	H	allyl
	4-CH ₃ O-benzyl	H	H	allyl
	4-HO-benzyl	H	H	allyl
15	4-R ¹¹ O-benzyl	H	H	allyl
	4-Cl-benzyl	H	H	allyl
	4-(CH ₃) ₂ N-benzyl	H	H	allyl
	3-HO ₂ C-benzyl	H	H	allyl
	3-H ₂ NCO-benzyl	H	H	allyl
20	3-CH ₃ O-benzyl	H	H	allyl
	3-HO-benzyl	H	H	allyl
	3-R ¹¹ O-benzyl	H	H	allyl
	3-Cl-benzyl	H	H	allyl
	3-(CH ₃) ₂ N-benzyl	H	H	allyl
25	2-HO ₂ C-benzyl	H	H	allyl
	2-H ₂ NCO-benzyl	H	H	allyl
	2-CH ₃ O-benzyl	H	H	allyl
	2-HO-benzyl	H	H	allyl
	2-R ¹¹ O-benzyl	H	H	allyl
30	2-Cl-benzyl	H	H	allyl
	2-(CH ₃) ₂ N-benzyl	H	H	allyl
	3-(4-pyridyl)-imidazol-2-ylmethyl	H	H	allyl
	3-(3-pyridyl)-imidazol-2-ylmethyl	H	H	allyl

-100-

	3-(2-pyridyl)-imidazol-2-ylmethyl	H	H	allyl
	3-phenylimidazol-2-ylmethyl	H	H	allyl
	3-(4-HO ₂ C-phenyl)-imidazol-2-ylmethyl	H	H	allyl
	3-(4-H ₂ NCO-phenyl)-imidazol-2-ylmethyl	H	H	allyl
5	3-(4-CH ₃ O-phenyl)-imidazol-2-ylmethyl	H	H	allyl
	3-(4-HO-phenyl)-imidazol-2-ylmethyl	H	H	allyl
	3-(4-R ¹¹ O-phenyl)-imidazol-2-ylmethyl	H	H	allyl
	3-(4-Cl-phenyl)-imidazol-2-ylmethyl	H	H	allyl
	3-(4-(CH ₃) ₂ N-phenyl)-imidazol-2-ylmethyl	H	H	allyl
10	3-(3-HO ₂ C-phenyl)-imidazol-2-ylmethyl	H	H	allyl
	3-(3-H ₂ NCO-phenyl)-imidazol-2-ylmethyl	H	H	allyl
	3-(3-CH ₃ O-phenyl)-imidazol-2-ylmethyl	H	H	allyl
	3-(3-HO-phenyl)-imidazol-2-ylmethyl	H	H	allyl
	3-(3-R ¹¹ O-phenyl)-imidazol-2-ylmethyl	H	H	allyl
15	3-(3-Cl-phenyl)-imidazol-2-ylmethyl	H	H	allyl
	3-(3-(CH ₃) ₂ N-phenyl)-imidazol-2-ylmethyl	H	H	allyl
	3-(2-HO ₂ C-phenyl)-imidazol-2-ylmethyl	H	H	allyl
	3-(2-H ₂ NCO-phenyl)-imidazol-2-ylmethyl	H	H	allyl
	3-(2-CH ₃ O-phenyl)-imidazol-2-ylmethyl	H	H	allyl
20	3-(2-HO-phenyl)-imidazol-2-ylmethyl	H	H	allyl
	3-(2-R ¹¹ O-phenyl)-imidazol-2-ylmethyl	H	H	allyl
	3-(2-Cl-phenyl)-imidazol-2-ylmethyl	H	H	allyl
	3-(2-(CH ₃) ₂ N-phenyl)-imidazol-2-ylmethyl	H	H	allyl

25


B. Preparation of Compounds Within the Scope of the Present Invention

The starting materials for the preparation of the compounds of this invention are represented by

30

Formula II:

-101-



II

-102-

wherein:

E is hydrogen or methyl;

W is O or (H, OH);

R³ is hydrogen, hydroxy, or C₁₋₆ alkoxy;

5 R⁴ is hydrogen, or R³ and R⁴ taken together form a double bond;

R⁵ is methyl, ethyl, propyl or allyl; and

n is 1 or 2.

10 The production and characterization of compounds of Formula II is well known in the literature (see U.S. Patent No. 4,894,366 issued January 16, 1990; U.S. Patent No. 4,929,611 issued May 29, 1990; U.S. Patent No. 3,244,592 issued April 15, 1966; EPO Publication No. 0,323,042,; EPO 15 Publication No. 0,356,399; PBJ Disclosure 63-17884; J. Am. Chem. Soc., 1987, 109, 5031; J. Antibiotics, 1987, 40, 1249, J. Antibiotics, 1988, 41(11), 1592; and J. Antibiotics, 1992, 45(1), 118). Both 20 biological fermentation and synthetic processes may be found. A synthetic route to compounds of Formula II can involve modifications of a route described in J. Am. Chem. Soc., 1989, 111, 1157.

25 Biological fermentation followed by synthetic modification is presently favored in the art as the method to produce compounds of Formula II. Organisms belonging to the genus Streptomyces such as Streptomyces tsukubaensis, No. 9993 and Streptomyces hygroscopicus, var. ascomycetis, No. 30 14891 placed in an aqueous nutrient medium will produce desired compounds in isolable amounts. The nutrient medium contains sources of assimilable carbon and nitrogen, preferably under aerobic

- 103 -

conditions. Produced in fermentation are four compounds of Formula II, (A) where E is methyl, W is O, R³ is hydroxyl, R⁴ is hydrogen, R⁵ is allyl and n is 2; (B) where E is methyl, W is O, R³ is hydroxyl, R⁴ is hydrogen, R⁵ is ethyl and n is 2; (C) where E is methyl, W is O, R³ is hydroxyl, R⁴ is hydrogen, R⁵ is methyl and n is 2; and (D) where E is methyl W is O, R³ is hydroxyl, R⁴ is hydrogen, R⁵ is allyl and n is 1.

10 A lyophilized sample of the isolated Streptomyces tsukubaensis, No. 9993 was deposited with the Fermentation Research Institute, Agency of Industrial Science and Technology (No. 1-3, Higashi 1-chome, Yatabemachi Tsukuba-gun, Ibaraki Prefecture, 15 Japan) under the deposit number of FERM P-7886 (deposit date: October 5th, 1984), and then converted to Budapest Treaty route of the same depository on October 19, 1985 under the new deposit number of FERM BP-927.

20 Using the four compounds produced in fermentation above, the remaining compounds of Formula II may be easily produced. The allyl of R⁵ may be conveniently reduced to propyl by well known methods, for example as described in U.S. Patent No. 4,894,366. 25 4,894,366. The hydroxy of R³ may be protected by well known methods, for example as disclosed in EPO Publication No. 0.323.042. Likewise, the hydroxyl at C-4'' may also be protected. In addition, the hydroxy of R³ may be reduced to a hydrogen or 30 eliminated to form a double bond with R⁴ (by methods disclosed in U.S. Patent No. 4,894,366, EPO Publication No. 0.323.042 or EPO Publication No. 0.413.532). The carbonyl of W may be reduced to the

- 104 -

alcohol by methods disclosed in EPO Publication No. 0.323.042 or by methods disclosed in EPO Publication No. 0.445.975.

5 The methyl of E as produced may be replaced
with hydrogen or demethylated and subsequently
protected as desired, if necessary. This
demethylation of compounds wherein E is methyl may be
carried out in a fermentation reaction using the
compounds of Formula II as a feedstock. For
10 instance, compound A named under Formula II above may
be demethylated at E above by using the microorganism
Actinomycetales ATCC No. 53771 (described in U.S.
Patent No. 4.981.792) or by using the microorganism
Streptomyces tsukubaensis, No. 9993 (described in EPO
15 Publication No. 0.353.678). Similarly, compound B
named under Formula II above may be demethylated at E
above using the microorganism Actinoplanacete sp.
ATCC No. 53771 (described in EPO Publication No.
0.349.061). In addition the compound of Formula II
20 wherein E is H, W is O, R³ is hydroxy, R⁴ is
hydrogen, R⁵ is ethyl and n is 2 may be produced
directly by fermentation using the mutant
microorganism Streptomyces hygrosopicus sup.
ascomyceticus, No. 53855 (being a blocked mutant of
25 Streptomyces hygrosopicus sup. ascomyceticus, No.
14891) (as described in EPO Publication No.
0.388.152). Similarly, the compound of Formula II
wherein E is hydrogen, W is O, R³ is hydroxy, R⁴ is
hydrogen, R⁵ is methyl and n is 2 may be produced
30 directly by fermentation using the mutant
microorganism Streptomyces hygrosopicus sup.
ascomyceticus, No. 53855 (being a blocked mutant of
Streptomyces hygrosopicus sup. ascomyceticus, No.

- 105 -


14891) (EPO Publication No. 0.388.153). The hydroxy of C-3" may be protected by methods similar to those known for the protection of the hydroxyl groups of R³ and/or C-4", for example as disclosed in U.S. Patent No. 4.894.366.

Suitable protecting groups for hydroxyl include those groups well known in the art such as: methylthiomethyl, ethylthiomethyl; trisubstituted silyl such as trimethylsilyl, triethylsilyl, tributylsilyl, tri-i-propylsilyl, t-butyldimethylsilyl, tri-t-butylysilyl, methyl-diphenylsilyl, ethyldiphenylsilyl, t-butyldiphenylsilyl, and the like; acyl such as acetyl, pivaloyl benzoyl, 4-methoxybenzoyl, 4-nitrobenzoyl and aliphatic acyl substituted with aromatic group, which are derived from carboxylic acids; and the like.

Compounds A, B, C and D of Formula II, organisms to produce the same, conditions of fermentation, separation techniques, and chemical modification of the products are fully described in U.S. Patent No. 4.894.366, dated January 16, 1990, U.S. Patent No. 4.929.611, issued May 29, 1990 and U.S. Patent No. 5.110.811, issued May 5, 1992.

The novel processes for preparing the novel compounds of the present invention are illustrated as follows, wherein R¹, R², R³, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, E, W and n are as defined above unless otherwise indicated. It will be readily apparent to one of ordinary skill in the art reviewing the synthetic route depicted below that other compounds within Formula I can be synthesized by substitution of appropriate reactants and agents in the synthesis shown below.

- 106 -

REACTION SCHEME A


15

1

20


25

30




2


- 107 -

REACTION SCHEME B


- 108 -

REACTION SCHEME B (CONT.)


- 109 -

REACTION SCHEME B (CONT.)

REACTION SCHEME B (CONT.)



- 111 -

REACTION SCHEME C

- 112 -

REACTION SCHEME D

5


10

15

20

25

30



2b

- 113 -

REACTION SCHEME E

5


10

15

20

25


30




- 114 -

REACTION SCHEME E (CONT.)

3




4b




4c

- 115 -

REACTION SCHEME E (CONT.)





4a'



5a'

- 116 -

REACTION SCHEME E (CONT.)



- 117 -

REACTION SCHEME F

5


10

15


20

25


30




- 118 -

REACTION SCHEME G


- 119 -

REACTION SCHEME G (CONT.)



- 120 -

REACTION SCHEME G. (CONT.)


- 121 -

REACTION SCHEME H

- 122 -

REACTION SCHEME H (CONT'D)

- 123 -

REACTION SCHEME I

- 124 -

REACTION SCHEME J

5


10

15

20

25

30



18

- 125 -

REACTION SCHEME J (CONT'D)

5


10

15


20


25

30



- 126 -

REACTION SCHEME J (CON'T)



- 128 -

REACTION SCHEME A:

As shown in Reaction Scheme A, a solution of a 4"-hydroxy-3"-methoxy macrolide 1 in an inert organic solvent such as methylene chloride, benzene, toluene, chloroform, or the like or mixtures thereof is treated with a triheteroaryl bismuth diacetate reagent (wherein R¹ is heteroaryl) (prepared immediately prior to use by the addition of acetic acid to a suspension of a triheteroaryl bismuth carbonate in an inert organic solvent such as methylene chloride, chloroform or the like or mixture thereof) in the presence of a catalytic amount of copper(II) acetate at a temperature of 20-50°C, preferably room temperature, for a period of one hour to seven days, preferably one day, to give the 4"-O-heteroaryl-3"-methoxy macrolide 2. Alternatively, the triheteroaryl bismuth(V) reagent can be prepared by treatment of a triheteroaryl bismuthine with a suitable oxidant such as peracetic acid, benzoyl peroxide, hydrogen peroxide, iodobenzene diacetate, bis(trifluoroacetoxy) iodobenzene and the like in an inert solvent such as methylene chloride, chloroform, benzene, toluene and the like. The triheteroaryl bismuth(V) reagent can be used without purification or can be purified by silica gel chromatography. Triheteroaryl bismuthines may be prepared by the reaction of an appropriate heteroaryl Grignard reagent or lithiated heteroaryl species with bismuth trichloride in an inert organic solvent such as tetrahydrofuran, diethyl ether, toluene, or 1,4-dioxane, or mixtures thereof, at or near room temperature for a period of 1 to 48 hours. General procedures for the preparation and use of triaryl

- 129 -

bismuth reagents may be found in Barton, D.H.E., et al., J. Chem. Soc. Chem. Commun., 1986, 65 and references cited therein.

5 Reaction Scheme B:

 Similarly, as shown in Reaction Scheme B, a solution of the 3'',4''-dihydroxy macrolide 3 treated with a triheteroaryl bismuth diacetate reagent as described in Reaction Scheme A, to give a mixture of
10 the 3''-hydroxy-4''-O-heteroaryl macrolide 4a, the 3''-O-heteroaryl-4''-hydroxy macrolide 4b, and the 3'',4''-di-O-heteroaryl macrolide 4c. At this stage, a solution of 3''-hydroxy-4''-O-heteroaryl macrolide 4a, or 3''-O-heteroaryl-4''-hydroxy macrolide 4b can be
15 treated with a triaryl bismuth diacetate reagent (prepared immediately prior to use by procedures analogous to those disclosed above), to give 3''-O-aryl-4''-O-heteroaryl macrolide 5a, or 3''-O-heteroaryl-4''-O-aryl macrolide 5a, respectively.
20

Reaction Scheme C:

 As shown in Reaction Scheme C the 14-hydroxy group of a macrolide 5a or 5b (wherein R¹, R², R⁵, R¹⁰, W and n are as defined above) may be eliminated
25 by treatment with p-toluenesulfonic acid, benzenesulfonic acid or methanesulfonic acid in an inert organic solvent such as benzene, or toluene at from 40°C to 60°C, for about 0.5 to 6 hours, or a sufficient period of time to eliminate the 14-hydroxy
30 group. Neutralization with an aqueous solution of a weak base such as aqueous saturated sodium bicarbonate gives the 14,15-dehydro macrolides 6a or

- 130 -

6b. The 14-hydroxy group may also be eliminated by activation followed by basic elimination, as described in U.S. Patent No. 4,894,366.

5 By changing the sequence of synthetic steps, all possible variations of substitution can be achieved.

Reaction Scheme D:

10 AS shown in Reaction Scheme D, a solution of the 4"-hydroxy 3"-methoxy macrolide 1 in an inert organic solvent such as methylene chloride, chloroform, pentane, hexane, cyclohexane, heptane or mixtures thereof is treated with a heteroarylalkyl, heteroarylalkenyl or heteroarylalkynyl
15 trichloroacetimidate reagent (prepared by the reaction of an appropriate sodium alkoxide with trichloroacetonitrile, such as described by Wessel, H.P., Iversen, T., Bundle, D.R., J. Chem. Soc., Perkin Trans. I, 1985, 2247) in the presence of a
20 mild acid catalyst such as trifluoro-methanesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, or mixtures thereof at a temperature of 20-50°C for a period of from one hour to seven days to give the
25 4"-O-heteroarylalkyl-, 4"-O-heteroarylalkenyl- or 4"-O-heteroarylalkynyl-3"-methoxy macrolide 2a.

Reaction Scheme E:

30 Similarly, as shown in Reaction Scheme E, a solution of the 3",4"-dihydroxy macrolide 3 in an inert organic solvent such as methylene chloride, chloroform, pentane, hexane, cyclohexane, heptane or the like or mixtures thereof is treated with a

- 131 -

heteroarylalkyl, heteroarylalkenyl or hetero-
arylalkynyl trichloroacetimidate (prepared as
described in Reaction Scheme D) at a temperature of
20-50°C, preferably 40°C, for a period of one hour to
5 seven days, preferably 6 hours, to give a mixture of
the 4''-O-heteroarylalkyl, 4''-O-heteroarylalkenyl, or
4''-O-heteroarylalkynyl-3-hydroxy macrolide 4a',
3''-O-heteroarylalkyl, 3''-O-heteroarylalkenyl, or
3''-O-heteroarylalkynyl-4''-hydroxymacrolide 4b' and
10 the 3'',4''-di-O-heteroarylalkyl-, heteroarylalkenyl or
-heteroarylalkynyl macrolide 4c'. Subsequently, a
solution of 4''-O-heteroaryl-, 4''-O-heteroarylalkyl,
4''-O-heteroarylalkenyl or 4''-O-heteroarylalkynyl-3-
hydroxy macrolide 4a (from Reaction Scheme B or 4a',
15 or 3''-O-heteroaryl-, 3''-O-heteroarylalkyl,
3''-O-heteroarylalkenyl, 3''-O-heteroarylalkynyl-4''-
hydroxymacrolide 4b from Reaction Scheme B or 4b' can
be treated with an arylalkyl, alkenyl or alkynyl
trichloroacetimidate by procedures described above.)
20 to give macrolides 5a' or 5b'.

The procedures described in Reaction Schemes
C and D may optionally be conducted following the
procedures of Reaction Scheme E or F. Alternatively,
the procedures described in Reaction Scheme F may be
25 performed.

In any of the aforementioned Reaction
Schemes, the macrolide (wherein R^1 and/or R^2 contains
an alkenyl, substituted alkenyl, alkynyl or
substituted alkynyl and wherein R^3 is hydroxy or C_{1-6}
30 alkoxy, R^4 is hydrogen, or R^3 and R^4 taken together
form a double bond) can be reduced with tri-*n*-butyltin
hydride in the presence of tetrakis(triphenylphosp-

- 132 -

hine) palladium (0) catalyst and acetic acid in an organic solvent such as toluene or tetrahydrofuran at or near room temperature for about 2 to 10 hours to give the reduced macrolide.

- 5 The procedures described in Reaction Scheme F may be conducted on the mono-substituted products of Reaction Scheme B (and visa versa) to obtain the mixed disubstituted compounds. In fact, within
10 Reaction Schemes B and F, treatment of the mono-substituted product with a different reagent will afford the mixed disubstituted compounds.

Reaction Scheme F:

- 15 Protection of the C-3", C-4" and/or the C-14 hydroxyl group(s) may be accomplished by methods known in the prior art for compounds of Formula II such as by treatment with: 2,6-lutidine and triisopropylsilyl trifluoromethanesulfonate in a solution of methylene chloride; 2,6-lutidine and
20 t-butyldimethylsilyl trifluoromethanesulfonate in a solution of methylene chloride; pyridine and acetic anhydride in a solution of methylene chloride; pyridine and benzoyl chloride in a solution of dichloromethane; pyridine and p-nitrobenzoyl chloride
25 in a solution of dichloromethane; imidazole and t-butyldiphenylsilyl chloride in a solution of methylene chloride; and the like. For example, as shown in Reaction Scheme F, the C-4",14-dihydroxy-C-3"-methoxy macrolide 7 may be protected at C-14 as
30 the t-butyldimethylsilyl ether by treatment with t-butyldimethylsilyl trifluoromethanesulfonate in methylene chloride to give the C-4",14-di-O-TBDMS

- 133 -

macrolide. Treatment with toluenesulfonic acid in methanol results in selective removal of the C-4'' silyl ether to give the C-14-O-TBDMS macrolide 8.

5 Reaction Scheme G:

As shown in Reaction Scheme G, the 4''-hydroxy-3''-R²O macrolide 9 or alternatively the 3''-hydroxy-4''-R²O macrolide (not depicted) (wherein R³ is protected hydroxy or hydrogen) may be reacted
10 with an alkenyl trichloroacetimidate (wherein alkenyl is C₃₋₁₀ alkenyl) under conditions described in Reaction Scheme E to give the O-alkenyl macrolide 10. Treatment with a stoichiometric amount of osmium tetroxide in an inert organic solvent, such as
15 diethyl ether or tetrahydrofuran, in the presence of an amine base, such as pyridine, at or near room temperature gives the corresponding glycol 11 (wherein A is C₁₋₈ alkyl). Treatment of glycol 11 with sodium metaperiodate in a solution of
20 tetrahydrofuran/water gives aldehyde 12. Alternatively, the alkenyl macrolide 10 may be treated with sodium metaperiodate in the presence of a catalytic amount of osmium tetroxide in an organic solvent to give the aldehyde directly. Aldehyde 12
25 can be further oxidized to carboxylic acid 13 by any number of methods commonly used.

Reaction Scheme H:

A variety of compounds may be prepared from
30 aldehyde 12 as illustrated in Reaction Scheme H. Aldehyde 12 may be reacted with a primary or secondary amine, HNR⁶R⁷ (wherein R⁶ and/or R⁷ are as defined and contain(s) a heteroaryl group) in an

- 134 -

organic solvent such as tetrahydrofuran to give an imine which is reduced in situ with a hydride reducing agent, such as sodium cyanoborohydride, to give macrolide 14 bearing an aminoalkoxy functionality at C-4". Aldehyde 12 may also be reduced to the corresponding alcohol 15 by treatment with a hydride reducing agent, such as potassium triphenyl borohydride or sodium cyanoborohydride in an organic solvent such as tetrahydrofuran. Alcohol 15 may be further modified by utilizing the methods of Reaction Scheme B (wherein R^1 is as defined) or Reaction Scheme E to produce macrolide 16. The procedures described in Reaction Scheme H are readily applicable to the preparation of compounds bearing analogous functionality at C-3".

REACTION SCHEME I:

Amide derivatives may be prepared from the carboxylic acid 13 as illustrated in Reaction Scheme I. The carboxylic acid 13 may be coupled with a primary or secondary amine, HNR^6R^7 (wherein R^6 and/or R^7 are as defined and contain(s) a heteroaryl group) by any of the peptide coupling methods commonly used in the art, such as with BOP reagent or DCC/HOBT.

REACTION SCHEME J:

A hydroxyl or fluoro group may be introduced at C-20 essentially by the procedures of Reaction Scheme J. As shown in Reaction Scheme R the 4",14-dihydroxy macrolide (or the 14-deoxymacrolide) is protected as the di(*t*-butyldimethylsilyl ether) by

- 135 -

treatment with *t*-butyldimethylsilyl triflate in an inert organic solvent such as methylene chloride, chloroform or the like in the presence of a non-nucleophilic base such as 2,6-lutidine. The diprotected macrolide is oxidized at C-20 as further shown in Reaction Scheme J by treatment with selenium dioxide in an alcoholic solvent such as ethanol in the presence of pyridine at solvent reflux temperature to give the 20-hydroxy macrolide (18).

5 The 20-hydroxy macrolide may be further derivatized at C-20 by alkylation, acylation or phosphorylation to give ether, ester or phosphate derivatives by procedures well known to the practitioner of the art. As further illustrated, treatment of the

10 20-hydroxy 4'',14-di-OTBS macrolide with diethylaminosulfur trifluoride in an inert organic solvent such as methylene chloride, chloroform or the like at a temperature of about 0°C to -90°C, preferably about -78°C, gives the 20-fluoro 4'',

15 14-di-OTBS macrolide (19). Removal of the silyl ether protecting groups by treatment with hydrogen fluoride-pyridine complex in tetrahydrofuran gives the 20-fluoro 4'',14-dihydroxy macrolide which may be further derivatized by any of the methods previously

20 described. Reaction Scheme J may also be performed on the 3'', 4'', 14-trihydroxy macrolide to give the 20-fluoro 3'', 4'', 14-trihydroxy macrolide. The procedures of Reaction Scheme J may be conducted prior to, concurrent with, or subsequent to the

25 procedures of Reaction Schemes A-I.

30

- 136 -

The object compounds of Formula I obtained according to the reactions as explained above can be isolated and purified in a conventional manner, for example, extraction, precipitation, fractional
5 crystallization, recrystallization, chromatography, and the like.

In the compounds of Formula I, OR^1 may be substituted at C-4" or C-3", or both C-4" and C-3" (wherein R^2 is independently selected from the
10 definitions of R^1), but it is preferred that $-OR^1$ is substituted at C-4".

It is to be noted that in the aforementioned reactions and the post-treatment of the reaction mixture therein, the stereoisomer(s) of starting and
15 object compounds due to asymmetric carbon atom(s) or double bond(s) of the object compounds of Formula I may occasionally be transformed into the other stereo isomer(s), and such cases are also included within the scope of the present invention.

20 In the present invention, compounds with asymmetric centers may occur as racemates, as diastereomeric mixtures and as individual diastereomers, with all isomeric forms of the compounds being included in the present invention.
25 These may be prepared by methods such as those disclosed in publications which describe synthetic routes to fragments of the macrolide FR-900506 and the total synthesis of the macrolide FR-900506 itself (J. Am. Chem. Soc. 1989, 111, 1157; J. Am. Chem. Soc.
30 1990, 112, 2998; J. Org. Chem. 1990, 55, 2786; J. Am. Chem. Soc. 1990, 112, 5583. Tetrahedron Lett. 1988, 29, 277; Tetrahedron Lett. 1988, 29, 281; Tetrahedron Lett. 1988, 29, 3895; J. Org. Chem. 1988, 53, 4643;

- 137 -

Tetrahedron Lett. 1988, 29, 4245; Tetrahedron Lett. 1988, 29, 4481; J. Org. Chem. 1989, 54, 9; J. Org. Chem. 1989, 54, 11; J. Org. Chem. 1989, 54, 12; J. Org. Chem. 1989, 54, 15; J. Org. Chem. 1989, 54, 17; 5 Tetrahedron Lett. 1989, 30, 919; Tetrahedron Lett. 1989, 30, 1037; J. Org. Chem. 1989, 54, 2785; J. Org. Chem. 1989, 54, 4267; Tetrahedron Lett. 1989, 30, 5235; Tetrahedron Lett. 1989, 30, 6611; Tetrahedron Lett. 1989, 30, 6963; Synlett 1990, 38; J. Org. Chem. 10 1990, 55, 2284; J. Org. Chem. 1990, 55, 2771; J. Org. Chem. 1990, 55, 2776; Tetrahedron Lett. 1990, 31, 1439; Tetrahedron Lett. 1990, 31, 1443; Tetrahedron Lett. 1990, 31, 3007; Tetrahedron Lett. 1990, 31, 3283, 3287).

15 The compounds of the present invention are capable of forming salts with various inorganic and organic acids and bases and such salts are also within the scope of this invention. Examples of such acid addition salts (which are negative counterions 20 defined herein as M^-) include acetate, adipate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, ethanesulfonate, fumarate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 25 methanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, oxalate, pamoate, persulfate, picrate, pivalate, propionate, succinate, tartrate, tosylate, and undecanoate. Base salts (which are positive counterions defined herein as M^+) include 30 ammonium salts, alkali metal salts such as sodium, lithium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with

- 138 -

organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine and so forth. Also, the basic nitrogen-containing groups may be quaternized with such agents as: lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl; diamyl sulfates; long-chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; aralkyl halides like benzyl bromide and others. The non-toxic physiologically acceptable salts are preferred, although other salts are also useful, such as in isolating or purifying the product.

The salts may be formed by conventional means, such as by reacting the free base form of the product with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is removed in vacuo or by freeze drying or by exchanging the anions of an existing salt for another anion on a suitable ion exchange resin.

C. Utility of the compounds within the scope of the invention

The compounds of Formula I may be employed as immunosuppressants or antimicrobial compounds by methods and in dosages known in the prior art for compounds of Formula II. These compounds possess pharmacological activity such as immunosuppressive activity, antimicrobial activity, and the like, and therefore are useful for the treatment and prevention

- 139 -

of the resistance to transplantation or transplan-
tation rejection of organs or tissues (such as heart,
kidney, liver, lung, bone marrow, cornea, pancreas,
intestinum tenue, limb, muscle, nervus, medulla
5 ossium, duodenum, small-bowel, medulla ossium, skin,
pancreatic islet-cell, etc. including xeno
transplantation), graft-versus-host diseases by
medulla ossium transplantation, autoimmune
diseases such as rheumatoid arthritis, systemic lupus
10 erythematosus, nephrotic syndrome lupus, Hashimoto's
thyroiditis, multiple sclerosis, myasthenia gravis,
type I diabetes mellitus, type II adult onset
diabetes, uveitis, nephrotic syndrome, steroid-
dependent and steroid-resistant nephrosis,
15 Palmo-planter pustulosis, allergic encephalomyelitis,
glomerulonephritis, etc., and infectious diseases
caused by pathogenic microorganisms.

The compounds of Formula I are also useful
for treating inflammatory, proliferative and
20 hyperproliferative skin diseases and cutaneous
manifestations of immunologically-mediated illnesses
such as: psoriasis, psoriatic arthritis, atypical
dermatitis, contact dermatitis and further eczematous
dermatitises, seborrhoeic dermatitis, Lichen planus,
25 Pemphigus, bullous Pemphigoid, Epidermolysis bullosa,
urticaria, angioedemas, vasculitides, erythemas,
cutaneous eosinophilias, acne, Alopecia areata,
eosinophilic fasciitis, and atherosclerosis. More
particularly, the compounds of Formula I are useful
30 in hair revitalizing, such as in the treatment of
male or female pattern alopecia or alopecia senilis,
by providing epilation prevention, hair germination,
and/or a promotion of hair generation and hair growth.

- 140 -

The compounds of Formula I are further useful in the treatment of respiratory diseases, for example sarcoidosis, fibroid lung, idiopathic interstitial pneumonia, and reversible obstructive
5 airways disease, including conditions such as asthma, including bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma and dust asthma, particularly chronic or inveterate asthma (for example late asthma and airway hyper-
10 reponsiveness), bronchitis and the like. The compounds of Formula I may also be useful for treating hepatic injury associated with ischemia.

The compounds of the invention are also indicated in certain eye diseases such as
15 keratoconjunctivitis, vernal conjunctivitis, uveitis associated with Behcet's disease, keratitis, herpetic keratitis, conical cornea, dystorpha epithelialis corneae, corneal leukoma, ocular pemphigus, Mooren's ulcer, Scleritis, Graves' ophthalmopathy, severe
20 intraocular inflammation, and the like.

The compounds of Formula I are also useful for treating multidrug resistance of tumor cells, (i.e. enhancing the activity and/or sensitivity of chemotherapeutic agents), preventing or treating
25 inflammation of mucosa or blood vessels (such as leukotriene B₄-mediated diseases, gastric ulcers, vascular damage caused by ischemic diseases and thrombosis, ischemic bowel disease, inflammatory bowel disease (e.g., Crohn's disease and ulcerative
30 colitis) necrotizing enterocolitis), or intestinal lesions associated with thermal burns, cytomegalovirus infection, particularly HCMV infection.

- 141 -

Further, the compounds of Formula I are also useful for treating or preventing renal diseases including interstitial nephritis, Goodpasture's syndrome, hemolytic-uremic syndrome and diabetic nephropathy; nervous diseases selected from multiple myositis, Guillain-Barre syndrome, Meniere's disease and radiculopathy; endocrine diseases including hyperthyroidism and Basedow's disease; hematic diseases including pure red cell aplasia, aplastic anemia, hypoplastic anemia, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, agranulocytosis and anerythroplasia; bone diseases including osteoporosis; respiratory diseases including sarcoidosis, fibroid lung and idiopathic interstitial pneumonia; skin diseases including dermatomyositis, leukoderma vulgaris, ichthyosis vulgaris, photoallergic sensitivity and cutaneous T cell lymphoma; circulatory diseases including arteriosclerosis, aortitis syndrome, polyarteritis nodosa and myocardosis; collagen including scleroderma, Wegener's granuloma and Sjogren's syndrome; adiposis; eosinophilic fasciitis; periodontal disease; nephrotic syndrome; hemolytic-uremic syndrome; and muscular dystrophy.

Further, the compounds of the invention are indicated in the treatment of diseases including intestinal inflammations/allergies such as Coeliac disease, proctitis, eosinophilic gastroenteritis, mastocytosis, Crohn's disease and ulcerative colitis; and food related allergic diseases which have symptomatic manifestation remote from the gastrointestinal tract, for example migraine, rhinitis and eczema.

- 142 -

The compounds of the invention also have liver regenerating activity and/or activity in stimulating hypertrophy and hyperplasia of hepatocytes. Therefore, they are useful for the treatment and prevention of hepatic diseases such as immunogenic diseases (e.g. chronic autoimmune liver diseases including autoimmune hepatitis, primary biliary cirrhosis and sclerosing cholangitis), partial liver resection, acute liver necrosis (e.g. necrosis caused by toxins, viral hepatitis, shock or anoxia), B-virus hepatitis, non-A/non-B hepatitis and cirrhosis.

The compounds of the invention are also indicated for use as antimicrobial agents, and thus may be used in the treatment of diseases caused by pathogenic microorganisms and the like.

The compounds of Formula I may also act as antagonists of macrocyclic immunosuppressive compounds, including derivatives of 12-(2'-cyclohexyl-1'-methylvinyl)-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene, and so be useful in the treatment of immunodepression (such as AIDS, cancer, senile dementia, trauma (including wound healing, surgery and shock), chronic bacterial infection and certain central nervous system disorders), overdosages or toxicity of such immunosuppressive compounds, and as an adjunct to the administration of an antigen in vaccination.

The pharmaceutical compositions of this invention can be used in the form of a pharmaceutical preparation, for example, in solid, semisolid or liquid form, which contains one or more of the

-143 -

compounds of the present invention, as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for external, enteral or parenteral applications. The active ingredient
5 may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable
10 for use. The carriers which can be used are water, glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea and other carriers suitable for use in manu-
15 facturing preparations, in solid, semisolid, or liquid form, and in addition auxiliary, stabilizing, thickening and coloring agents and perfumes may be used. For example, the compounds of Formula I may be
20 utilized with hydroxypropyl methylcellulose essentially as described in U.S. Patent No. 4,916,138, issued April 10, 1990, or with a surfactant
essentially as described in EPO Publication 0,428,169. Oral dosage forms may be prepared
25 essentially as described by T. Hondo, et al., Transplantation Proceedings, 1987, XIX, Supp. 6, 17-22. Dosage forms for external application may be prepared essentially as described in EPO Publication
30 0,423,714. The active object compound is included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the process or condition of diseases.

For the treatment of these conditions and diseases caused by immunoirregularity a compound of Formula I may be administered orally, topically,

- 144 -

parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used
5 herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques.

For the treatment of reversible obstructive
airways disease, it is preferable that the compound
10 of Formula I be administered by inhalation to the lung, especially in the form of a powder.

For modifying the activity and/or toxicity of FK-506-type immunosuppressants, a compound of
Formula I may be administered prior to, in conjunction
15 with or subsequent to the administration of an FK-506-type of a compound.

The compounds of Formula I may optionally be employed in co-therapy with anti-proliferative agents. Particularly preferred is co-therapy with an
20 antiproliferative agent selected from the group consisting of: azathioprine, brequinar sodium, deoxyspergualin, mizaribine, mycophenolic acid morpholino ester, cyclosporin, and rapamycin.

Dosage levels of the compounds of the present
25 invention are of the order from about 0.005 mg to about 50 mg per kilogram of body weight per day, preferably from about 0.1 mg to about 10 mg per kilogram of body weight per day, are useful in the treatment of the above-indicated conditions (from
30 about 0.7 mg to about 3.5 mg per patient per day, assuming a 70 kg patient). In addition, the compounds of the present invention may be

- 145 -

administered on an intermittent basis; i.e. at daily, semiweekly, weekly, semi-monthly or monthly intervals.

5 The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration of humans may contain from 0.5 mg to 5 gm of active agent compounded with an appropriate and
10 convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Dosage unit forms will generally comprise from about 0.01 mg to about 500 mg, and preferably about 0.5 mg to about 100 mg of active ingredient.
15 For external administration the compound of Formula I may be formulated within the range of, for example, 0.0001% to 60% by weight, preferably from 0.001 to 10% by weight, and most preferably from about 0.005 to 0.8% by weight.

20 It will be understood, however, that the specific dose level for any particular patient will depend on a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of
25 administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

The following examples are given for the purpose of illustrating the present invention and shall not be construed as being limitations on the
30 scope or spirit of the instant invention.

- 146 -

PREPARATION OF STARTING INTERMEDIATES

17-Ethyl-1-hydroxy-12-[2'-(4''-hydroxy-3''-methoxycyclo-
hexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-
5 tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]-
octacos-18-ene-2,3,10,16-tetraone

A solution of 500 mg of 17-ethyl-1,14-di-
hydroxy-12-[2'-(4''-hydroxy-3''-methoxycyclohexyl)-1'-
methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-
10 11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-
ene-2,3,10,16-tetraone in 7 ml of benzene was treated
with 10 mg of p-toluenesulfonic acid and the solution
was heated at 60°C for two hours. The reaction
mixture was quenched into saturated sodium
15 bicarbonate solution and extracted with ethyl
acetate. The combined organic layers were washed
with water and saturated sodium chloride solution,
dried with anhydrous magnesium sulfate and
concentrated. The residue was chromatographed on
20 silica gel (66% ethyl acetate: 33% hexane: 1%
methanol) to give 350 mg of product. This material
was dissolved in 10 ml of ethyl acetate and treated
with 15 mg of 5% Rh/C. A balloon containing hydrogen
was placed over the reaction mixture and the mixture
25 stirred until the reaction was complete. The mixture
was filtered through diatomaceous earth, concentrated
and the residue subjected to chromatography (75%
CH₂Cl₂: 5% MeOH: 20% Hexane) to give 294 mg of
30 product.

- 147 -

17-Ethyl-1-hydroxy-12-[2'-(4'',3''-dihydroxyoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

- 5 A solution of 17-ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (210 mg) and a catalytic amount of
- 10 p-toluenesulfonic acid in 40 ml of benzene was refluxed for 4 hours under a nitrogen atmosphere. The solvent was removed under reduced pressure and the dark residue was purified by chromatography (silica gel, 7% i-propanol/CH₂Cl₂) to give
- 15 17-ethyl-1-hydroxy-12-[2'-(4''-hydroxy-3''-isopropoxyloxy-cyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-14,18-diene-2,3,10,16-tetraone (180 mg) as a white solid. This material was
- 20 dissolved in ethanol (20 ml) and treated with 5% Rh/C (40 mg). Hydrogen was introduced via balloon for 30 min. and the mixture was filtered through celite. Removal of solvent followed by chromatography (silica gel) gave 172 mg of the title compound. Mass, ¹H and
- 25 ¹³C NMR data were consistent with the title structure.

17-Ethyl-1-hydroxy-12-[2'-(4''-triisopropylsilyloxy-3''-methoxycyclohexyl)-1'-methylvinyl]-14-triisopropylsilyloxy-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-
2,3,10,16-tetraone

To a cooled solution (0°C) of 17-ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-methoxycyclohexyl)-

- 148 -

1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetra-
methyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-
octacos-18-ene-2,3,10,16-tetraone (120 mg) in dry
methylene chloride (15 ml) was added 2,6-lutidine
5 (64.3 mg) followed by triisopropylsilyl trifluoro-
methanesulfonate (184 mg). Reaction temperature was
raised to r.t. and stirred overnight under nitrogen
atmosphere. The reaction was quenched with 10 ml of
water and extracted with ethyl acetate. Organic
10 layer was washed (water, sat'd NaHCO₃, sat'd NaCl)
and dried (anhydrous MgSO₄). Removal of solvent
followed by chromatography on silica gel (70%
hexane/ethyl acetate) gave 150 mg of product.
MASS: (FAB) 1110 (M⁺ + Li).

15
17-Ethyl-1-hydroxy-12-[2'-(4''-hydroxy-
3''-methoxycyclohexyl)-1'-methylvinyl]-14-triisopropyl-
silyloxy-23,25-dimethoxy-13,19,21,27-tetramethyl-11,-
28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-octacos-18-ene-
20 2,3,10,16-tetraone

The title compound from the previous
preparation (680 mg) was dissolved in methylene
chloride (45 ml) and 10% solution of p-toluene-
sulfonic acid in methanol (45 ml) was added with
25 stirring. The mixture was stirred at room
temperature and the progress was followed by tlc
analysis. After 4 hr, reaction was quenched with
sat'd sodium bicarbonate and extracted with ethyl
acetate three times. Normal work-up and removal of
30 solvent followed by purification on silica gel column
(80% ethyl acetate/hexane) gave 560 mg of the product
(2a) as a white solid. MASS: (FAB) 954 (M⁺ + Li).

- 149 -

17-Ethyl-1-hydroxy-12-[2'-(4"-t-butyl-
dimethylsilyloxy-3"-methoxycyclohexyl)-1'-methyl-
vinyl]-14-t-butyldimethylsilyloxy-23,25-dimethoxy-
13,19,21,27-tetramethyl-11,28-dioxa-4-azatri-cyclo-
5 [22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a cooled solution (0°C) of 17-ethyl-
1,14-dihydroxy-12-[2'-(4"-hydroxy-3"-methoxycyclo-
hexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-
tetra-methyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-
10 octacos-18-ene-2,3,10,16-tetraone (1a) (395 mg) in
dry methylene chloride (15 ml) was added 2,6-lutidine
(160 mg) followed by t-butyldimethylsilyl
trifluoromethanesulfonate (250 mg). Reaction
temperature was raised to r.t. and stirred under
15 nitrogen atmosphere. After 6 hr, the reaction was
quenched with 10 ml of water and extracted with ethyl
acetate. Organic layer was washed (water, saturated
NaHCO₃, saturated NaCl) and dried (anhydrous MgSO₄).
Removal of solvent under reduced pressure gave 500 mg
20 of crude product. MASS: (FAB) 1023 (M⁺ + Li).

17-Ethyl-1-hydroxy-12-[2'-(4"-hydroxy-
3"-methoxycyclohexyl)-1'-methylvinyl]-14-t-butyl-
dimethylsilyloxy-23,25-dimethoxy-13,19,21,27-tetra-
25 methyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-
octacos-18-ene-2,3,10,16-tetraone

The product from the previous example (500
mg) was dissolved in acetonitrile (20 ml) and 100 ml
of hydrogen fluoride (48%) was added. Reaction was
30 stirred for 20 minutes at room temperature, quenched
with saturated sodium bicarbonate, then extracted
with ethyl acetate. Removal of solvent in vacuo
followed by chromatography on silica gel (80% ethyl

- 150 -

acetate/ hexane) gave 300 mg of product (Mass, ^1H and ^{13}C NMR data consistent with the title compound.

17-Ethyl-1-hydroxy-12-[2'-(4''-(tert-butyldimethylsiloxy)-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a solution of 17-ethyl-1-hydroxy-12-[2'-(3'',4''-dihydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (3.01 g) in dry methylene chloride (70 ml) was added an excess of imidazole (809 mg) followed by tert-butyldimethylsilyl chloride (716 mg). After 3 days of stirring at room temperature, the mixture was diluted with ethyl acetate which in turn was washed with 1N HCl, saturated sodium bicarbonate and brine, dried over magnesium sulfate and purified by flash chromatography (ethyl acetate:hexane (1:3)) to give the title compound (941 mg). ^1H NMR consistent with the desired structure.

17-Ethyl-1-hydroxy-12-[2'-(4''-(tert-butyldimethylsilyloxy)-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a solution of 17-ethyl-1-hydroxy-12-[2'-(4''-hydroxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (200 mg) in dry methylene chloride (3 ml) was added an excess of 2,6-lutidine (45 μl) and the

- 151 -

mixture was stirred at room temperature. After 10 minutes, tert-butyldimethylsilyl trifluoromethanesulfonate (64 μ l) was added by syringe. After 15 minutes the reaction mixture was diluted with ethyl acetate, extracted from saturated bicarbonate, washed with brine and the organic phase dried over magnesium sulfate. Removal of solvent in vacuo and flash chromatography on silica gel (ethyl acetate: hexane (1:2) + 1% methanol) gave the title compound (235 mg).

(^1H NMR consistent with the desired structure).

17-Ethyl-1,20-dihydroxy-12-[2'-(4''-tert-butyldimethylsilyloxy)-3''-methoxycyclohexyl)-4''1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a stirred solution of 17-ethyl-1-hydroxy-12-[2'-(4''-(tert-butyldimethylsilyloxy)-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (235 mg) in 95% ethanol (2.2 ml) was added 53 μ l of pyridine followed by selenium dioxide (58 mg). The flask was fitted with a water condenser and heated to 70°C on a mantle. After 20 hours the mixture was cooled to room temperature filtered through diatomaceous earth and the filtrate poured into a saturated sodium bicarbonate solution. This was extracted with ethyl acetate, washed with brine and dried over magnesium sulfate. The solution was concentrated and purified by flash chromatography on silica gel (ethyl acetate: hexane (1:2) + 1% methanol) to give the title compound (89 mg).

(^1H NMR consistent with the desired structure).

- 152 -

17-Ethyl-20-fluoro-1-hydroxy-12-[2'-(4''-(tert-butyl-
dimethylsiloxy)-3''-methoxycyclohexyl)-1'-methylvinyl]-
23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-
4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10.16-
5 tetraone

A solution of 17-ethyl-20-dihydroxy-12-[2'-(
4''-(tert-butyl)dimethylsiloxy)-3''-methoxycyclohexyl)-
1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetra-
methy1-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-
10 18-ene-2,3,10.16-tetraone (30.5 mg) in methylene
chloride (0.5 ml) was cooled to -78°C in a dry
ice/isopropanol bath. To this stirred solution,
diethylaminosulfur trifluoride (4.5 µl) was added.
After 3 minutes, saturated sodium bicarbonate (500
15 µl) was added followed by ethyl acetate (2 ml) and
the mixture was warmed to room temperature.
Extraction from ethyl acetate, drying over magnesium
sulfate and purification by flash chromatography on
silica gel (ethyl acetate: hexane (1:2) + 1% MeOH)
20 gave the title compound (22 mg).
(¹H NMR consistent with the desired structure).

25

30

- 153 -

17-Ethyl-1,20-dihydroxy-12-[2'-(4''-(hydroxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

5 To a solution of 17-ethyl-1,20-dihydroxy-12-[2'-(4''-(tert-butyldimethylsiloxy)-3''-methoxycyclohexyl)-1'-methylvinyl]23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-
10 ~~octacos-18-ene-2,3,10,16-tetraone~~ (7 mg) in acetonitrile (0.3 ml) was added a solution of 2% hydrogen fluoride in aqueous acetonitrile (100 µl), and the mixture stirred at room temperature. After 28 hours the solution was diluted with ethyl acetate, extracted with saturated sodium bicarbonate and the
15 organic phase dried by passage through a magnesium sulfate column. Purification of the concentrate by flash chromatography on silica gel (ethyl acetate: hexane (2:1) + 1% methanol) gave the title compound.

20

25

30

- 154 -

17-Ethyl-20-fluoro-1-hydroxy-12-[2'-(4''-(hydroxy-3''-methoxycyclohexyl)-1'-methylvinyl)-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

- 5 To a solution of 17-ethyl-20-fluoro-1-hydroxy-12-[2'-(4''-(tert-butyldimethylsiloxy)-3''-methoxycyclohexyl)-1'-methylvinyl]23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
10 [22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (7 mg) in acetonitrile (0.3 ml) was added a solution of 2% hydrogen fluoride in aqueous acetonitrile (100 μ l), and the mixture stirred at room temperature. After 2
15 hours the solution was diluted with ethyl acetate, extracted with saturated sodium bicarbonate and the organic phase dried by passage through a magnesium sulfate column. Purification of the concentrate by flash chromatography on silica gel (ethyl acetate: hexane (1:1) + 1% methanol) gave the title compound.
20 MASS: (FAB) 816 (M+Na).
 partial ¹³C NMR δ : 211.5 (C-16); 196.1 (2) 169.3 (10); 165.0 (3); 138.1 (C-19); 135.8 (C-1'); 121.0 (C-18' major); 84.1 (C-3''); 43.1 (C-15); 26.0 (C-21).

25

30

- 155 -

17-Ethyl-1,14,20-trihydroxy-12-[2'-(4''-hydroxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

5

ALTERNATE ROUTE

To a solution of 17-ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
10 tetraone (5.15 gm, 0.065mol) in glacial acetic acid (500 ml) at room temperature, was added a solution of selenium dioxide (9.27 gm, 0.083 mol) in H₂O (90
ml). The reaction mixture was stirred at room
15 temperature for 41 hours whereupon, it was poured into a stirred mixture of H₂O (3 L) and celite. After stirring for 15 minutes, the mixture was
filtered through a pad of celite and extracted with diethyl ether (1x2L, 2x1L). The organic fractions
20 were washed with saturated sodium bicarbonate and brine, dried over magnesium sulfate, filtrated and evaporated in vacuo. The product was purified by
chromatography (silica, acetone:hexanes 2:5) to give the title compound MASS and ¹H NMR were consistent
with the structure.

25

30

- 156 -

EXAMPLE 1

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2-furanyl)methoxy-
3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
5 13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a solution of 17-ethyl-1,14-dihydroxy-12-
[2'-(4''-hydroxy-3''-methoxycyclohexyl)-1'-methylvinyl]-
23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
10 azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone (63 mg in 1.0 ml methylene chloride)
furfuryl trichloroacetimidate (39 μ l neat) was added
and the reagents allowed to mix for 5 minutes.
Camphorsulfonic acid (3.7mg) was added and the
15 mixture stirred at room temperature. After 4.5 hours
the reaction was quenched by the addition of
saturated sodium bicarbonate and extracted with ethyl
acetate (3 x 5 ml). The combined organics were washed
with brine and dried over magnesium sulfate.
20 Purification of the concentrate by flash
chromatography on silica gel (ethyl acetate : hexane
(1:2) + 1% methanol) gave the title compound (20 mg).
MAS: (FAB) 878 (M+Li). Partial ¹H NMR δ :
7.38(brs, 1H); 6.30(m, 3H); 5.32M, 5.19m(brd J =
25 3Hz, 1H); 4.83m, 4.21M(brs, 1H); 4.62(dd J = 15Hz,
2H); 4.41(brd J = 14Hz, 1H).

30

-157-

EXAMPLES 2 and 3

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2-furanyl)methoxy-
3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
5 13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone and
17-Ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-(2-
furanyl)methoxycyclohexyl)-1'-methylvinyl]-23,25-
dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-
10 tricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a solution of 17-ethyl-1,14-dihydroxy-12-
[2'-(3'',4''-dihydroxycyclohexyl)-1'-methylvinyl]-23,25-
dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-
tricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone
15 (52 mg in 0.9 ml methylene chloride) furfuryl
trichloroacetimidate (20 μ l neat) was added and the
reagents allowed to mix for 5 minutes.
Camphorsulfonic acid (2mg) was added and the mixture
stirred at room temperature. After 3.5 hours the
20 reaction was quenched by the addition of saturated
sodium bicarbonate and extracted with ethyl acetate
(3 x 5 ml). The combined organics were washed with
brine and dried over magnesium sulfate. Purification
of the concentrate by flash chromatography on silica
25 gel (ethyl acetate:hexane (1:1) + 1% methanol) gave
the title compounds (16 mg 4'' ether; 13 mg 3'' ether).

4'' ether: MASS: (FAB) 864 (M+Li); Partial ¹H NMR
8: 7.41(brs, 1H); 6.30(m, 2H); 5.32M, 5.19m(brd J =
30 3Hz, 1H); 4.87m, 4.19M(brs, 1H); 4.41(brd J = 14Hz,
1H).

-158-

3" ether: MASS: (FAB) 864 (M+Li); Partial ¹H
NMR δ: 7.44(brs, 1H); 6.37(m, 2H); 5.32M,
5.19m(brd J = 3Hz, 1H); 4.88m, 4.27M(brs, 1H);
4.41(brd J = 14Hz, 1H).

5

EXAMPLE 4

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2-thiophene)-
methoxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-
10 dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-
tricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone

The title compound was prepared essentially as
described in Example 1 using 2-thiophenylmethyl
15 trichloroacetimidate as the alkylating agent.

Partial ¹H NMR δ: 7.27(m, 1H); 6.96(m, 2H);
5.31M, 5.18m(brd J = 3Hz, 1H); 4.81m, 4.22M(brs,
1H); 4.41(brd J = 14Hz, 1H); 3.07(d J = 4Hz, 1H).

20

EXAMPLES 5 and 6

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2-thiophene)-
methoxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-
dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-
25 tricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone
and 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-(2-
thiophene)methoxycyclohexyl)-1'-methylvinyl]-23,25-
dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-
tricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

30

The title compounds were prepared essentially
as described in Examples 2 and 3 using
2-thiophenylmethyl trichloroacetimidate as the
alkylating agent.

-159-

4" ether: MASS: (FAB) 896 (M+Na); Partial ¹H NMR δ: 7.29(m, 1H); 6.97(m, 2H); 5.31M, 5.19m(brd J = 3Hz, 1H); 4.41(brd J = 14Hz, 1H); 3.04(d J = 4Hz, 1H); 2.63M, 2.61m(s, 1H);

5

3" ether: MASS: (FAB) 880 (M+Li); Partial ¹H NMR δ: 7.28 (m, 1H); 6.97 (m, 2H); 5.31 M, 5.19 m (brd J = 3Hz, 1H); 4.41 (brd J = 14 Hz, 1H); 3.08 (d J = 3 Hz, 1H); 2.69 (s, 1H).

10

EXAMPLES 7 and 8

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(3-thiophene)-methoxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone and 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-(3-thiophene)methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

15

20

The title compounds were prepared essentially as described in Examples 2 and 3 using 3-thiophenylmethyl trichloroacetimidate as the alkylating agent.

25

4" ether: MASS: (FAB) 880 (M+Li); Partial ¹H NMR δ: 7.30 (m, 1H); 7.04 (m, 2H); 5.31 M, 5.19 m (brd J = 3Hz, 1H); 4.89 m, 4.19 M (s, 1H); 4.41 (brd J = 14 Hz, 1H); 3.04 (d J = 4Hz, 1H);

30

3" ether: MASS: (FAB) 880 (M+Li); Partial ¹H NMR δ: 7.28 (m, 2H); 7.05 (dd, J = 5, 2 Hz, 1H); 5.31 M, 5.19 m (brd J = 3 Hz, 1H); 4.83 m, 4.25 M (brs, 1H); 4.41 (brd J = 14 Hz, 1H); 3.06 (d J = 3 Hz, 1H); 2.69 (s, 1H).

-160-

EXAMPLE 9

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(benzothien-2-yl)-
oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-di-
5 methoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatri-
cyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a stirred solution of tri(benzothien-2-yl)bismuthine (100mg., 0.164mmol.) in CH₂Cl₂ (2 mL.)
was added peracetic acid (0.050mL., 0.224 mmol., 32%
10 in acetic acid) followed in 10 minutes by 17-ethyl-1,
14-dihydroxy-12-[2'-(4''-hydroxy-3''-methoxycyclo-hexyl)-
1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetrameth
yl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-en
e-2,3,10,16-tetraone (100mg., 0.126 mmol.) and
15 Cu(OAc)₂ (15mg., 0.083 mmol.). The reaction mixture
was stirred for 16 hours at room temperature. The
reaction was then quenched with saturated aqueous
NaHCO₃ and the mixture extracted 3X with CH₂Cl₂. The
extracts were combined, dried with Na₂SO₄, filtered,
20 and concentrated in vacuo. The product was isolated
and purified by preparative TLC 3X on silica gel
(3:1, hexane/acetone) to give 23 mg of
17-ethyl-1,14-dihydroxy-12-[2'-(4''-(benzothien-
2-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-
25 dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-
tricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone.

-161-

EXAMPLE 10

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(thien-2-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
5 13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a stirred solution of tri(thien-2-yl)bis-muthine (80mg., 0.175 mmol.) in CH₂Cl₂ (2 mL.) was added peracetic acid (0.060 mL., 0.253 mmol., 32% in
10 acetic acid) followed in 15 minutes by 17-ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-
octacos-18-ene-2,3,10,16-tetraone (100 mg., 0.126
15 mmol.) and Cu(OAc)₂ (10 mg., 0.055 mmol.). The reaction mixture was allowed to stir at room temperature for 3 days. The reaction was quenched with saturated aqueous NaHCO₃, and the mixture extracted with CH₂Cl₂. The extracts were combined,
20 dried with Na₂SO₄, filtered and concentrated in vacuo. The product was isolated and purified by preparative TLC 2X on silica gel (2:1, hexane/acetone) to give 36 mg of 17-ethyl-1,14-dihydroxy-12-[2'-(4''-(thien-2-yl)oxy-3''-methoxycyclo-
25 hexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-octacos-18-ene-2,3,10,16-tetraone.

30

-162-

EXAMPLE 11

17-Ethyl-1,14-dihydroxy-12-[2'-(4"-5-indolylamino-
carbonylmethoxy-3"-methoxycyclohexyl)-1'-methylvinyl]-
23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone

STEP 11A

17-Ethyl-1-hydroxy-14-(tert-butyldimethylsiloxy)-12-
[2'-(4"-(tert-butyldimethylsiloxy)-3"-methoxycyclo-
hexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-
tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-
octacos-18-ene-2,3,10,16-tetraone

To a solution of 17-ethyl-1,14-dihydroxy-
12-[2'-(4"-hydroxy-3"-methoxycyclohexyl)-1'-methyl-
vinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-
dioxa-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,-
16-tetraone (2.0 g) in dry methylene chloride (25 ml)
was added an excess of 2,6-lutidine (1.2 ml) and the
mixture was stirred at room temperature. After 10
minutes, tert-butyldimethylsilyl
trifluoromethanesulfonate (1.8 ml) was added via
syringe. After 1 hour the reaction mixture was
diluted with ethyl acetate, washed with 1N HCl,
water, saturated sodium bicarbonate and brine. The
organic phase was dried over magnesium sulfate.
Removal of the solvent in vacuo and flash
chromatography on silica gel (ethyl acetate: hexane
(1:6) + 1% methanol) gave the title compound (2.37
g). ¹H NMR consistent with the desired structure.

-163-

STEP 11B

17-Ethyl-1-hydroxy-14-(tert-butyldimethylsiloxy)-12-
[2'-(4''-hydroxy-3''-methoxycyclohexyl)-1'-methylvinyl]-
23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone

To a solution of 17-ethyl-1-hydroxy-14-(tert-butyldimethylsiloxy)-12-[2'-(4''-(tert-butyldimethylsiloxy)-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (2.37 g) (STEP 11A) in dry methylene chloride (25 ml) was added a solution of 10% p-toluenesulfonic acid in methanol (25 ml), and the mixture was stirred at room temperature. After 10 minutes, the mixture was cooled to 0°C and quenched with saturated sodium bicarbonate. The mixture was diluted with ethyl acetate and the layers were separated. The organic layer was washed with saturated sodium bicarbonate and brine and dried over magnesium sulfate. Purification of the concentrate by flash chromatography on silica gel (ethyl acetate: hexane (1:2) + 1% methanol) gave the title compound (2.1 g). ¹H NMR consistent with the desired structure.

STEP 11C

17-Ethyl-1-hydroxy-14-(tert-butyldimethylsiloxy)-12-
[2'-(4''-allyloxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,-
10,16-tetraone

-164-

To a solution of 17-ethyl-1-hydroxy-14-(tert-butyl-
dimethylsiloxy)-12-[2'-(4''-hydroxy-3''-methoxy-
cyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,-
27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-
5 octacos-18-ene-2,3,10,16-tetraone (2.1 g) (STEP 11B)
in 24 ml 33% methylene chloride in cyclohexane, was
added allyl trichloroacetimidate (938 mg neat) and
the reaction mixture was allowed to mix for 5
minutes. Trifluoromethanesulfonic acid (41 μ l neat)
10 was added slowly via syringe and the mixture stirred
at room temperature. After 24 hours, the reaction
mixture was diluted with ethyl acetate and washed
with saturated sodium bicarbonate, water and brine.
The organic layer was dried over magnesium sulfate.
15 Purification of the concentrate by flash
chromatography on silica gel (ethyl acetate: hexane
(1:5)) + 1% methanol) gave the title compound (1.03
g). ¹H NMR consistent with the desired structure.

20 STEP 11D

17-Ethyl-1-hydroxy-14-(tert-butyl-
dimethylsiloxy)-12-[2'-(4''-(2,3-dioxy-1-propoxy)-3''-methoxycyclohexyl)-
1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetra-
25 methyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-
18-ene-2,3,10,16-tetraone

To a solution of 17-ethyl-1-hydroxy-14-(tert-
butyl-
dimethylsiloxy)-12-[2'-(4''-allyloxy-3''-methoxy-
cyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,-
30 27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-
octacos-18-ene-2,3,10,16-tetraone (STEP 11C) (1.03 g)
in 22 ml tetrahydrofuran was added N-methylmorpholine

-165-

N-oxide (883 mg) followed by 0.25M osmium tetroxide solution in THF (871 μ l), and the mixture was stirred at room temperature. After 3 hours, the reaction was quenched by the addition of 20% sodium bisulfite (20 ml), and the precipitate was filtered through Celite and rinsed with ethyl acetate. The combined filtrate was washed with 20% sodium bisulfite (2x), saturated sodium bicarbonate and brine and dried over magnesium sulfate. The concentrate was purified by flash chromatography on silica gel (ethyl acetate:hexane (2:1) + 1% methanol) to give the title compound (705 mg). ¹H NMR consistent with the desired structure.

STEP 11E

15

17-Ethyl-1-hydroxy-14-(tert-butyldimethylsiloxy)-12-[2'-(4''-ethanaloxo-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,-
10,16-tetraone

20

To a solution of 17-ethyl-1-hydroxy-14-(tert-butyldimethylsiloxy)-12-[2'-(4''-(2,3-dioxy-1-propoxy)-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (1.56 g) (STEP 11D) in 20% aqueous tetrahydrofuran (20 ml) was added sodium metaperiodate (510 mg) and the mixture stirred vigorously for 30 minutes. At this time an additional 170 mg of sodium metaperiodate were added. After 30 minutes the mixture was diluted with ethyl acetate, filtered through Celite and the residue rinsed with ethyl acetate. The organic

25

30

-166-

portion was washed with saturated sodium bicarbonate and brine, dried over magnesium sulfate and purified by flash chromatography on silica gel (ethyl acetate:hexane (1:2) + 1% methanol) to give the title compound (1.45 g). ¹H NMR consistent with the desired structure.

STEP 11F

17-Ethyl-1-hydroxy-14-(tert-butyldimethylsiloxy)-12-[2'-(4''-carboxymethoxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a solution of 17-ethyl-1-hydroxy-14-(tert-butyldimethylsiloxy)-12-[2'-(4''-ethanaloxo-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (311 mg) (STEP 11E) in tert-butanol (6.6 ml) and 2-methyl-2-butene (1.65 ml) was added sodium chlorite (273 mg) and sodium dihydrogen phosphate (272 mg) in water (2.7 ml) slowly. After 2 hours, the solvent was removed in vacuo, and the resulting residue was dissolved in water and acidified to pH 3 with 1N HCl. The aqueous portion was extracted with ethyl acetate (3 x 10 ml) and the combined organic portion was washed with brine. This was dried over magnesium sulfate and purified by flash chromatography on silica gel (2% methanol in methylene chloride followed by 2% methanol in methylene chloride + 0.5% acetic acid) to give the title compound (255 mg). ¹H NMR consistent with the desired structure.

-167-

STEP 11G

17-Ethyl-1-hydroxy-14-(tert-butyldimethylsiloxy)-12-
[2'-(4"-5-indolylamino-carbonylmethoxy-3"-methoxy-
5 cyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,-
27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-
octacos-18-ene-2,3,10,16-tetraone

To a solution of 17-ethyl-1-hydroxy-14-(tert-
butyldimethylsiloxy)-12-[2'-(4"-carboxymethoxy-3"-
10 methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (150
mg) (STEP 11F) in methylene chloride (1.6 ml) was
added benzotriazol-1-yloxy-tris(dimethylamino)-
15 phosphonium hexafluorophosphate (103 mg) followed by
triethylamine (43 µl). After 10 minutes,
5-aminoindole (43 mg) was added to the reaction
mixture and stirred for 1 hour. The mixture was
diluted with ethyl acetate and washed with 1N HCl,
20 water, saturated sodium bicarbonate and brine,
respectively. The organic portion was dried over
magnesium sulfate and purified by flash
chromatography on silica gel (ethyl acetate:hexane
(1:2) + 1% methanol) to give the title compound (138
25 mg). ¹H NMR consistent with the desired structure.

STEP 11H

17-Ethyl-1,14-dihydroxy-12-[2'-(4"-5-indolylamino-
30 carbonylmethoxy-3"-methoxycyclohexyl)-1'-methylvinyl]-
23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone

-168-

To a solution of 17-ethyl-1-hydroxy-14-(tert-butylldimethylsiloxy)-12-[2'-(4''-5-indolylaminocarbonyl methoxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (138 mg in 1 ml tetrahydrofuran contained in a polypropylene vial) was added 200 µl of a solution of hydrogen fluoride-pyridine complex (40% in (2:1) tetrahydrofuran:pyridine), and the mixture was stirred at room temperature. After 2 days, the reaction was quenched by the careful addition of saturated sodium bicarbonate and extracted with ethyl acetate. The combined organic portion was washed with brine, dried over magnesium sulfate, concentrated in vacuo and purified by flash chromatography (ethyl acetate:hexane (1:1) + 1% methanol) to give the title compound. MASS (FAB) 971 (M+Li); partial ¹H NMR δ: 9.52 (brs, 1H); 8.15 (brs, 1H); 7.91 (s, 1H); 7.30 (s, 2H); 7.16 (dd, J=3,3Hz, 1H); 6.49 (dd, J=,3Hz, 1H); 4.41 (brd, J=14Hz, 1H).

EXAMPLE 12

17-Ethyl-1-hydroxy-12-[2'-(4''-(methyl-N-tryptophanyl-carbonylmethoxy)-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

STEP 12A

17-Ethyl-1-hydroxy-12-[2'-(4''-allyloxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

-169-

To a solution of 17-ethyl-1-hydroxy-12-[2'-(4''-hydroxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (510 mg) in 6.6 ml 33% methylene chloride in cyclohexane, was added allyl trichloroacetimidate (266 mg neat) and the reaction mixture was allowed to mix for 5 minutes. Trifluoromethanesulfonic acid (12 μ l neat) was added slowly via syringe and the mixture stirred at room temperature. After 24 hours the reaction mixture was diluted with ethyl acetate and washed with saturated sodium carbonate, water and brine. The organic layer was dried over magnesium sulfate. Purification of the concentrate by flash chromatography on silica gel (ethyl acetate: hexane (1:9)) + 1% methanol) gave the title compound (434 mg). ¹H NMR consistent with the desired structure.

STEP 12B

20

17-Ethyl-1-hydroxy-12-[2'-(4''-(2,3-dioxy-1-propoxy)-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

25

To a solution of 17-ethyl-1-hydroxy-12-[2'-(4''-allyloxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (434 mg)(STEP 12A) in 15 ml tetrahydrofuran, was added N-methylmorpholine N-oxide (431 mg) followed by 0.25M osmium tetroxide solution in THF (425 μ l), and the mixture was stirred at room temperature. After

30

-170-

4.5 hours, the reaction was quenched by the addition of 20% sodium bisulfite, and the precipitate was filtered through Celite and rinsed with ethyl acetate. The combined filtrate was washed with 20% sodium bisulfite (2x), saturated sodium bicarbonate and brine and dried over magnesium sulfate. The concentrate was purified by flash chromatography on silica gel (ethyl acetate:hexane (3:1) + 1% methanol) to give the title compound (177 mg). ¹H NMR consistent with the desired structure.

STEP 12C

17-Ethyl-1-hydroxy-12-[2'-(4"-ethanaloxo-3"-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,-21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.-0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a solution of 17-ethyl-1-hydroxy-12-[2'-(4"-(2,3-dioxo-1-propoxy)-3"-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (177 mg) (STEP 12B) in 20% aqueous tetrahydrofuran (2 ml) was added sodium metaperiodate (67 mg) and the mixture stirred vigorously for 30 minutes. At this time an additional 20 mg of sodium metaperiodate were added. After 30 minutes the mixture was diluted with ethyl acetate, filtered through Celite and the residue rinsed with ethyl acetate. The organic portion was washed with saturated sodium bicarbonate and brine, dried over magnesium sulfate and purified by flash chromatography on silica gel (ethyl acetate:hexane (2:3) + 1% methanol) to give the title compound (157 mg). ¹H NMR consistent with the desired structure.

-171-

STEP 12D

17-Ethyl-1-hydroxy-12-[2'-(4''-carboxymethoxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
5 13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a solution of 17-ethyl-1-hydroxy-12-[2'-(4''-ethanaloxo-3''-methoxycyclohexyl)-1'-methylvinyl]-
23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
10 azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone (157 mg) (STEP 12C) in tert-butanol (4 ml)
and 2-methyl-2-butene (1 ml) was added sodium
chlorite (159 mg) and sodium dihydrogen phosphate
(159 mg) in water (1.6 ml) slowly. After 1 hour, the
15 solvent was removed in vacuo, and the resulting
residue was dissolved in water and acidified to pH 3
with 1N HCl. The aqueous portion was with ethyl
acetate (3 x 10 ml), and the combined organic portion
was washed with brine. It was dried over magnesium
20 sulfate and purified by flash chromatography on
silica gel (2% methanol in methylene chloride
followed by 2% methanol in methylene chloride + 0.5%
acetic acid) to give the title compound (114 mg). ¹H
NMR consistent with the desired structure.

25

STEP 12E

17-Ethyl-1-hydroxy-12-[2'-(4''-methoxy-N-tryptophanyl-
carbonylmethoxy-3''-methoxycyclohexyl)-1'-methylvinyl]-
30 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone

-172-

To a solution of 17-ethyl-1-hydroxy-12-[2'-(4"-carboxymethoxy-3"-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (39 mg)(STEP 12D) in methylene chloride (0.5 ml) was added benzotriazol-1-yloxy-tris(dimethyl-amino)phosphonium hexafluorophosphate (31 mg) followed by triethylamine (14 μ l). After 10 minutes, tryptophan methyl ester hydrochloride (24 mg) was added to the reaction mixture and stirred for 1 hour. The mixture was diluted with ethyl acetate and washed with 1N HCl, water, saturated sodium bicarbonate and brine, respectively. The organic portion was dried over magnesium sulfate and purified by flash chromatography on silica gel (ethyl acetate:hexane (1:1) + 1% methanol) to give the title compound (28 mg). MASS (FAB) 1041 (M + Li); Partial ¹H NMR δ : 8.21 (brs, 1H); 8.04 (brd, J=8Hz, 1H); 7.56 (d, J=8Hz, 1H); 7.33 (d, J=8Hz, 1H); 7.11(m, 3H); 4.41 (brd, J=14Hz, 1H); 3.64 (s, 3H).

EXAMPLE 13

17-Ethyl-1-hydroxy-12-[2'-(4"-3-indolylethylamino-carbonylmethoxy-3"-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a solution of 17-ethyl-1-hydroxy-12-[2'-(4"-carboxymethyloxy-3"-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,-

-173-

10,16-tetraone (13 mg) (STEP 12D) in methylene chloride (150 μ l) was added benzotriazol-1-yloxy-tris-(dimethylamino)phosphonium hexafluorophosphate (10.3 mg) followed by triethylamine (4.3 μ l). After 10 minutes, tryptamine (5 mg) was added to the reaction mixture and stirred for 1 hour. The mixture was diluted with ethyl acetate and washed with 1N HCl, water, saturated sodium bicarbonate and brine, respectively. The organic portion was dried over magnesium sulfate and purified by flash chromatography on silica gel (ethyl acetate:hexane (1:1) + 1% methanol) to give the title compound (7.5 mg). MASS (FAB) 983 (M + Li); partial ^1H NMR δ : 8.32 (brs, 1H); 7.89 (m, 1H); 7.58 (d, J=8Hz 1H); 7.31 (m, 1H); 7.10 (m, 3H); 4.51 (brd, J=3Hz, 1H); 4.41 (brd, J=14Hz, 1H).

EXAMPLE 14

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

STEP 14A

1-Methyl-5-bromoindole

A mixture of sodium hydroxide (0.4g., 10 mmol.) in DMSO (20 mL.) was heated to 80-85° C for 6 hours to dissolve most of the solids then allowed to cool to room temperature. To the stirred mixture was

-174-

added 5-bromoindole (2.0 g., 10 mmol.) followed in 1
hour by methyl iodide (0.62 mL., 10 mmol.). After
stirring for an additional 3 hours the reaction was
shown by TLC analysis to be complete. The reaction
5 mixture was diluted with water then extracted with
ether. The extracts were washed 2x with water, dried
with Na₂SO₄, and concentrated in vacuo to give 2.08
g. of 1-methyl-5-bromoindole as a yellow oil which
crystallized on standing.

10

STEP 14BTri(1-methyl-indol-5-yl)bismuthine

To a solution of 1-methyl-5-bromoindole
15 (5.0g., 23.8 mmol.) in ether (100 mL.) at -78°C was
added a 1.7M solution of t-butyllithium in pentane
(28mL. 47.6 mmol.). The mixture was stirred at -78°C
for 1 hour. To this mixture was then added a solution
of bismuth trichloride (2.36g., 7.5 mmol.) in THF (25
20 mL.) via syringe. The cooling bath was maintained for
2 hours then allowed to warm to room temperature
overnight. In the morning the mixture was quenched
with ice water and the product extracted 2X with
toluene. The extracts were combined, washed with
25 water, dried with Na₂SO₄, and concentrated in vacuo
to a volume of about 30mL.. After chilling in the
refrigerator for several hours the solid product was
filtered, washed with cold toluene and vacuum dried
to give tri(1-methyl-indol-5-yl)bismuthine (1.7g.) as
30 a mustard color solid.

-175-

STEP 14C:

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,
5 25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a stirred solution of tri(1-methylindol-5-yl)bismuthine (450 mg., 0.75 mmol.) (STEP 14B) in
10 CH₂Cl₂ (10 mL.) was added peracetic acid (0.158 mL., 0.75 mmol. 32% in acetic acid) followed in 15 minutes by 17-ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
15 [22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (350 mg., 0.442 mmol.) and Cu(OAc)₂. The mixture was stirred at room temperature for 2 days. The reaction was quenched with saturated aqueous NaHCO₃ and the product extracted 3X with CH₂Cl₂. The extracts were
20 combined, dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. The product was isolated and purified 2X by preparative TLC to give 203 mg. of the title compound as a colorless solid. MASS (FAB),
m + Li 927. Partial ¹H NMR (CDCl₃, 200 MHz) δ: 7.19 (bs, 1H); 7.17 (d, J=10Hz, 1H); 6.98 (d, J=4Hz, 1H); 6.91 (dd, J=3 Hz and 10Hz, 1H); 6.34 (d, J=4Hz, 1H); 3.72 (s, 3H); 3.51 (s, 3H).
25

-176-

EXAMPLE 15

17-Ethyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-methyl-
indol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-
5 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone

To a stirred solution of tri(1-methylindol-
5-yl)bismuthine (350 mg., 0.584 mmol.) in CH₂Cl₂ (6
10 mL.) was added peracetic acid (0.15 mL., 0.74
mmol., 32% in acetic acid) followed in 15 minutes by
17-ethyl-1,14,20-trihydroxy-12-[2'-(4''-hydroxy-3''-
methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
15 [22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (250
mg., 0.32 mmol.) and Cu(OAc)₂ (35 mg., 0.138 mmol.).
The reaction mixture was stirred for 2 days at room
temperature. The reaction was quenched with
saturated aqueous NaHCO₃ and the mixture extracted 2X
20 with CH₂Cl₂. The extracts were combined, dried with
Na₂SO₄, filtered and concentrated in vacuo. The
product was isolated by flash column chromatography
on silica gel (3:1 hexane/acetone) followed by
preparative TLC (3% CH₃OH in CH₂Cl₂) to give 111 mg
25 of the title compound. MASS (FAB), M + Li 943.
Partial ¹H NMR (CDCl₃, 200 MHz) δ: 7.21 (bs, 1H); 7.18
(d, J=7.5Hz, 1H); 6.98 (d, J=3Hz, 1H); 6.94 (dd, J=
2.5Hz and 7.5Hz, 1H); 6.37 (d, J=3Hz, 1H); 3.75 (s,
3H); 3.59 (s, 3H).

30

-177-

EXAMPLE 16

17-Ethyl-1-hydroxy-12-[2'-(4''-(1-N-methylindol-5-yl)
oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dime-
5 thoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatri-
cyclo [22.3.1.0^{4,9}]octacos-18-ene-2.3.10.16-tetraone

To a stirred solution of tri(1-methylindol-5-yl)bismuthine (35 mg., 0.058 mmol.) in CH₂Cl₂ (0.7 mL) was added peracetic acid (0.015 mL., 0.074 mmol., 32%
10 in acetic acid) followed in 15 minutes by
17-ethyl-1-hydroxy-12-[2'-(4''-hydroxy-3''-methoxycyclo-
hexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-
tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-
15 octacos-18-ene-2,3,10,16-tetraone (25mg., 0.032
mmol.) and Cu(OAc)₂ (5 mg., 0.03mmol.). The reaction
mixture was stirred for 3 days at room temperature.
The reaction was quenched with saturated aqueous
NaHCO₃ and extracted 2X with CH₂Cl₂. The extracts
20 were combined, dried with Na₂SO₄, filtered and
concentrated in vacuo. The product was isolated and
purified by preparative TLC on silica gel (2:1
hexane/acetone then 5% CH₃OH in CH₂Cl₂) to give 10.2
mg of the title compound. Partial ¹H NMR (CDCl₃, 200
25 MHz) δ : 7.18 (bs, 1H); 7.16 (d, J=7.5Hz, 1H); 6.98
(d, J=3Hz, 1H); 6.92 (dd, J=2.5Hz and 7.5Hz, 1H);
6.33 (d, J=3Hz, 1H); 3.64 (s, 3H); 3.51 (s, 3H).

30

-178-

EXAMPLES 17 AND 18

17-Ethyl-1,14-dihydroxy-12-[2'-(3''-hydroxy-4''-(1-N-methylindol-5-yl)oxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone and 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-(1-N-methylindol-5-yl)oxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a stirred solution of tri(1-methylindol-5-yl)bismuthine (150 mg., 0.25 mmol.) in CH₂Cl₂ (2 mL.) was added peracetic acid (0.05 mL., 0.23 mmol., 32% in acetic acid) followed in 10 minutes by 17-ethyl-1,14-dihydroxy-12-[2'-(3'',4''-dihydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (100 mg, 0.129 mmol) and Cu(OAc)₂ (20 mg., 0.11 mmol.). The reaction mixture was stirred for 2 days at room temperature. The reaction was quenched with saturated aqueous NaHCO₃ and the mixture extracted 2X with CH₂Cl₂. The extracts were combined, dried with Na₂SO₄, filtered and concentrated in vacuo. The products were separated and purified 2X by preparative TLC (2:1 hexane/acetone then 5% CH₃OH in CH₂Cl₂) to give 19mg of 17-ethyl-1,14-dihydroxy-12-[2'-(3''-hydroxy-4''-(1-methylindol-5-yl)oxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone, Partial ¹H NMR (CDCl₃, 200 MHz) δ: 7.19 (d, J=10Hz, 1H); 7.17 (d, J=2.5Hz, 1H); 7.00 (d, J=3Hz, 1H); 6.88 (dd, J=2.5Hz and 10Hz, 1H); 6.35 (d, J=3Hz, 1H); 3.73 (s, 3H).

-179-

and 33mg of 17-ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-(1-methylindol-5-yl)oxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone. Partial ¹H NMR (CDCl₃, 200 MHz) δ: 7.18 (d, J=8Hz, 1H); 7.16 (d, J=2.5Hz, 1H); 6.98 (d, J=3Hz, 1H); 6.88 (dd, J=2.5Hz and 8Hz, 1H); 6.33 (d, J=3Hz, 1H); 3.73 (s, 3H).

10

EXAMPLE 19Tri (indol-5-yl)bismuthine

A solution of 5-bromoindole (5.0 g., 25.5 mmol.) in ether (50 mL.) was slowly added, at 0°C, to a slurry of KH (2.8g., 25 mmol., 35% in oil; washed 3x with hexanes) in ether (40 mL.). The reaction mixture was stirred for 20 minutes then chilled to -78°C. A precooled solution of t-butyllithium (29.7 mL., 50.5 mmol., 1.7M in pentane) was added dropwise via syringe to the mixture followed in 40 minutes by a solution of BiCl₃ (1.89g., 6.0 mmol.) in THF (25 mL.). The cooling bath was maintained for 2 hours then allowed to warm to room temperature overnight. The reaction was quenched with ice water and extracted 3x with toluene. The extracts were combined, dried with Na₂SO₄, filtered and concentrated in vacuo. The residue was diluted with 75 mL. of toluene then stored at 4°C overnight. The solids were filtered and air dried to give 1.53g of tri(indol-5-yl)bismuthine.

-180-

STEP 19B

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(indol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
5 13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a stirred solution of tri(indol-5-yl)bis-muthine (1.3g., 2.33mmol.), prepared by procedures outlined in STEP 14B in CH₂Cl₂ (30mL.) was added
10 peracetic acid (0.50 mL., 2.31 mmol., 32% in acetic acid) followed in 10 minutes by 17-ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-
15 ene-2,3,10,16-tetraone (1.0g., 1.26 mmol.) and Cu(OAc)₂ (100 mg., 0.55 mmol.). The reaction mixture was allowed to stir at room temperature for 3 days. The reaction was quenched with saturated aqueous NaHCO₃ and the mixture extracted 2X with CH₂Cl₂. The
20 extracts were combined, dried with Na₂SO₄, filtered and concentrated in vacuo. The product was isolated and purified by preparative TLC 2X with 2:1 hexane/acetone and once with 2:1 hexane/EtOAc to give
208mg of the title compound. MASS (FAB), M + 906.
25 Partial ¹H NMR (CDCl₃, 200 MHz) δ: 8.12 (bs, 1H); 7.26 (d, J=10Hz, 1H); 7.22 (d, J=2.5Hz, 1H); 7.18 (m, 1H); 6.9 (dd, J=2.5Hz and 10Hz, 1H); 6.44 (m, 1H); 3.53 (s, 3H).

-181-

EXAMPLE 20

17-Allyl-1,14-dihydroxy-12-[2'-(4''-(indol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
5 13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a stirred solution of tri(indol-5-yl)bis-muthine (150 mg., 0.27 mmol.) in CH₂Cl₂ (3 mL.) was added peracetic acid (0.05 mL., 0.23 mmol., 32% in
10 acetic acid) followed in 15 minutes by
17-allyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,-
27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone
15 (100mg., 0.124 mmol.) and Cu(OAc)₂ (20 mg.,
0.11mmol.). The reaction mixture was allowed to stir
at room temperature for 2 days. The reaction was
quenched with saturated aqueous NaHCO₃ and the
mixture extracted with CH₂Cl₂. The extracts were
20 combined, dried with Na₂SO₄, filtered and
concentrated in vacuo. The product was isolated and
purified by preparative TLC 2x (2:1 hexane/acetone
then 5% CH₃OH in CH₂Cl₂) to give 11mg of the title
compound. MASS (FAB), M + Li 925. Partial ¹H NMR
25 (CDCl₃, 200 MHz) δ: 8.12 (bs, 1H); 7.24 (d, J=10Hz,
1H); 7.22 (d, J=2.5Hz, 1H); 7.17 (t, J=3Hz, 1H); 6.9
(dd, J=3Hz and 10Hz, 1H); 6.44 (bs, 1H); 5.70 (m,
1H); 3.53 (s, 3H).

30

-182-

EXAMPLE 21

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-ethylindol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a stirred solution of tri(1-ethylindol-5-yl)bismuthine (150mg., 0.23mmol.), prepared by procedures outlined in STEP 14A & B, in CH₂Cl₂ (3 ml) was added peracetic acid (.063mL., 0.3 mmol., 32% in acetic acid) followed in 15 minutes by 17-ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (100 mg., 0.126 mmol.) and Cu(OAc)₂ (20 mg., 0.11 mmol.). The reaction mixture was allowed to stir at room temperature for 3 days. The reaction was then quenched with saturated aqueous NaHCO₃ and the mixture extracted 2X with CH₂Cl₂. The extracts were combined, dried with Na₂SO₄, filtered, and concentrated in vacuo to a brown oil. The product was isolated and purified by preparative TLC on silica gel (first with 2:1 hexane/acetone followed by 3% CH₃OH in CH₂Cl₂) to give 60 mg of the title compound. MASS (FAB) M + Na 957. Partial ¹H NMR (CDCl₃, 200 MHz) δ: 7.19 (d, J=10Hz, 1H); 7.18 (d, J=3Hz, 1H); 7.05 (d, J=4Hz, 1H); 6.90 (dd, J=3Hz, 10Hz, 1H); 6.35 (d, J=4Hz, 1H); 4.09 (q, J=6.7Hz, 2H); 3.5 (s, 3H); 1.4 (t, J=6.7Hz, 3H).

-183-

EXAMPLE 22

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-ethylindol-5-yl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-
5 dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-
atricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetra-
one

To a solution of tri(1-ethylindol-5-yl)bis-
muthine (0.2 gm) prepared by procedures outlined in
10 Step 14A & B in CH₂Cl₂ (2 ml) at room temperature was
added peracetic acid (37 µL, 0.2 mmol). After
stirring for 15 minutes at room temperature, was
added 17-ethyl-1,14-dihydroxy-12-[2'-(4'',3''-dihydroxy-
cyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,
15 28-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]
octacos-18-ene-2,3,10,16-tetraone (0.2 gm, 0.25 mmol)
followed by Cu(OAc)₂ (20 mg) and the reaction mixture
was stirred for 2 days. To the reaction mixture was
then added saturated NaHCO₃ (approximately 20 ml) and
20 the mixture was extracted twice with CH₂Cl₂. The
combined organic extracts were dried over Na₂SO₄,
filtered and concentrated in vacuo. The mixture of
17-ethyl-1,14-dihydroxy-12-[2'-(4''-(1-ethylindol-5-
yl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-
25 dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone and 17-ethyl-1,14-dihydroxy-12-[2'-(4''-
hydroxy-3''-(1-ethyl-indol-5-yl)oxycyclohexyl)-1'-
methylvinyl]-23,25-dimethoxy-13,19,21,27-tetra-
30 methyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-
octacos-18-ene-2,3,10,16-tetraone were separated by
chromatography (silica, 3:1, hexanes:ethyl acetate)
to give the title compound (0.035 gm).

-184-

TLC (silica, 3:1, hexanes:ethyl acetate) R_F =0.55.
Partial ^1H NMR (CDCl_3 , 200 MHz) δ : 7.21 (d, J =10Hz, 1H); 7.14 (d, J =3Hz, 1H); 7.08 (d, J =4Hz, 1H); 6.85 (dd, J =3Hz and 10Hz, 1H); 6.36 (d, J =4Hz, 1H), 4.10 (q, J =6.7Hz, 2H); 1.42 (t, J =6.7Hz, 3H).

EXAMPLE 23

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-propylindol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a stirred solution of tri(1-propylindol-5-yl)bismuthine (200 mg., 0.29 mmol.), prepared by procedures analogous to STEP 14A and B, in CH_2Cl_2 (3 mL.) was added peracetic acid (0.075 mL., 0.36 mmol., 32% in acetic acid) followed in 10 minutes by 17-ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (150 mg., 0.19 mmol.) and $\text{Cu}(\text{OAc})_2$ (30 mg., 0.17 mmol.). The reaction mixture was stirred for 20 hours at room temperature. The reaction was then quenched with saturated aqueous NaHCO_3 and the mixture extracted with CH_2Cl_2 . The extracts were combined, dried with Na_2SO_4 , filtered and concentrated in vacuo. The product was isolated and purified by preparative TLC 3X on silica gel (2:1, hexane/acetone; 3% CH_3OH in CH_2Cl_2 ; 2:1, hexane/acetone) to give 70mg of the title compound. MASS (FAB) $M + \text{Na}$ 971. Partial ^1H

-185-

NMR (CDCl₃, 200 MHz) δ : 7.17 (d, J=10Hz, 1H); 7.02 (d, J=4Hz, 1H); 6.88 (dd, J=3Hz and 10Hz, 1H); 6.32 (d, J=4Hz, 1H); 3.97 (t, J=7Hz, 2H), 3.50 (s, 3H); 1.80 (m, 2H).

5

EXAMPLE 24

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-propylindol-5-yl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a stirred solution of tri(1-propylindol-5-yl)bismuthine (200 mg., 0.29 mmol.), prepared by procedures analogous to Step 14A and B, in CH₂Cl₂ (3 mL.) is added peracetic acid (0.075 mL., 0.36 mmol., 32% in acetic acid) followed in 10 minutes by 17-ethyl-1,14-dihydroxy-12-[2'-(3'',4''-dihydroxy-3''-cyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (150 mg., 0.19 mmol.) and Cu(OAc)₂ (30 mg., 0.17 mmol.). The reaction mixture is stirred for 20 hours at room temperature. The reaction is then quenched with saturated aqueous NaHCO₃ and the mixture extracted with CH₂Cl₂. The extracts are combined, dried with Na₂SO₄, filtered and concentrated in vacuo. The product is isolated and purified from the C-3'' ether by preparative TLC on silica gel to give the title compound.

-186-

EXAMPLE 25

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-hydroxyethyl-
indol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-
5 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-
4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone

STEP 25A

10

1-(2-Hydroxyethyl)-5-bromoindole

A mixture of NaOH (4.4 gm, 0.011 mol) in DMSO
(175 ml) was stirred at 100°C for 5 hours at which
time it was cooled to 20°C. To this mixture was
15 added 5-bromoindole (20 gm, 0.102 mol) and the
reaction was stirred for 8 hours at room
temperature. A solution of ethylene oxide (5.1 gm,
0.125 mol) in DMSO (20 ml) was prepared by bubbling
the gas into DMSO. To the bromoindole reaction
20 mixture was slowly added the ethylene oxide solution
and stirring was continued for another 2.5 hours.
The reaction mixture was then poured into ice water
and extracted twice with diethyl ether. The combined
-ether-extracts were concentrated in vacuo whereupon
25 -crystallization took place. The crude product was
-recrystallized from diethyl ether:hexanes (3:2) to
afford the title compound (6.25 gm).

30

-187-

STEP 25B1-(2-t-Butyldimethylsilyloxyethyl)-5-bromoindole

5 A solution of 1(2-hydroxyethyl)-5-bromoindole
(6 gm, 0.025 mol), t-butyldimethylsilyl chloride (4.5
gm, 0.03 mol) and triethylamine (4.2 ml, 0.03 mol) in
CH₂Cl₂ (60 ml) was stirred for 12 hours at room
temperature. The reaction mixture was then washed
10 twice with H₂O, dried over Na₂SO₄, filtered and
concentrated in vacuo to provide the title compound
as a yellow oil. ¹H NMR was consistent with the
desired structure.

STEP 25C

15

Tri[1-(2-t-butyldimethylsilyloxyethyl)-indol-5-yl]-
bismuthine

To a solution of 1(2-t-butyldimethylsilyloxy-
ethyl)-5-bromoindole (1.4 gm, 0.004 mol) in diethyl
20 ether (14 ml) at -78°C was added t-butyl lithium (4.7
ml of a 1.7 M solution in pentanes, 0.008 mol).
After stirring for 1.5 hours, a solution of bismuth
trichloride (0.4 gm, 0.013 mol) in THF (4 mL) was
added. The reaction was stirred at -78°C for 2 hours
25 and then allowed to warm slowly to room temperature
and stirring was continued a further 8 hours. The
reaction mixture was then poured into H₂O and
extracted with toluene. The combined organic
extracts were dried over Na₂SO₄, filtered and the
30 filtrate was concentrated in vacuo. Purification by
chromatography (silica, 4:1, hexanes:ethyl acetate)
provided the title compound (1.03 gm) as a semisolid.
¹H NMR was consistent with desired structure.

-188-

STEP 25D

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-t-butyl-di-
methylsilyloxyethyl)indol-5-yl)oxy-3''-methoxycyclo-
5 hexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-
tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-
octacos-18-ene-2,3,10,16-tetraone

To a solution of tri[1-(2-t-butyl-dimethylsilyl-
oxyethyl)-indol-5-yl]bismuthine (1.03 gm, 0.001 mol)
10 in CH₂Cl₂ (10 ml) at room temperature was added
peracetic acid (150 µL). After stirring for 15
minutes, 17-ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-
3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
15 [22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (1 gm)
was added to the reaction mixture followed by Cu(OAc)₂
(0.04 gm) and the reaction mixture was stirred for 20
hours. To the reaction mixture was then added
saturated NaHCO₃ and it was then extracted with
20 CH₂Cl₂. The organic extracts were dried over Na₂SO₄,
filtered and the filtrate was concentrated in vacuo.
The crude product was purified by chromatography
(silica, 3:1, hexanes:ethyl acetate) to provide the
title compound (0.38 gm). ¹H NMR was consistent with
25 desired structure.

-189-

STEP 25E

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-hydroxyethyl-
indol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-
5 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone

To a solution of 17-ethyl-1,14-dihydroxy-12-
[2'-(4''-(1-t-butyldimethylsilyloxyethylindol-5-yl)oxy-
10 3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (0.38
gm) in CH₂Cl₂ (10 ml) at room temperature was added a
solution of para-toluene sulfonic acid (0.05 gm) in
15 CH₃OH (10 ml). The reaction mixture was stirred for
3 hours until TLC (silica, 2:1, hexanes:ethyl
acetate) verified that reaction was complete. The
reaction mixture was poured into saturated NaHCO₃ and
extracted twice with CH₂Cl₂. The combined organic
20 extracts were dried over Na₂SO₄, filtered and
concentrated in vacuo. The crude product was
purified by chromatography (silica, 2:1 hexanes:ethyl
acetate) to provide the title compound 0.245 gm.

MASS (FAB)
25 M + Li 957. Partial ¹H NMR (CDCl₃, 200 MHz) δ: 7.18
(d, J=10Hz, 1H); 7.16 (bs, 1H); 7.06 (d, J=4Hz, 1H);
6.86 (dd, J=3Hz and 10Hz, 1H); 6.33 (d, J=4Hz, 1H);
4.13 (t, J=6.7Hz, 2H); 3.83 (t, J=6.7Hz, 2H); 3.43
(s, 3H).

30

-190-

EXAMPLE 26

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'-allylindol-5'-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-
5 dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-
tricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone

STEP 26A

10

1-Allyl-5-bromoindole

To a stirred mixture of NaOH (204 mg., 5.1
mmol., 1 eq.) in DMSO (10 mL.) was added
5-bromoindole (1.0 g., 5.1 mmol., 1 eq.). The
15 solution was stirred for three hours upon complete
dissolution of the NaOH (approximately 1 h.). To
this solution was added allyl iodide (0.466 mL., 5.1
mmol., 1 eq.) via syringe. After 2 h. the mixture
was diluted with water and extracted 2x with diethyl
20 ether. The organic extracts were combined, dried
over anhydrous MgSO₄, filtered and concentrated in
vacuo. The product was purified by flash column
chromatography on silica gel (4:1 hexanes/acetone)
affording 730 mg 1-allyl-5-bromoindole.

25

STEP 26BTri(1-allylindol-5-yl)bismuthine

To a stirred solution of 1-allyl-5-bromoindole
30 (730 mg., 3.09 mmol., 1 eq.) in diethyl ether (15 mL)
at -78°C under N₂ was added t-butyllithium (1.8mL.,
3.09 mmol., 1 eq., 1.7M solution in pentane). The
mixture was stirred at -78°C under N₂ for 1 h. To

-191-

this mixture was added a solution of bismuth trichloride (292 mg., 0.93 mmol., 0.3 eq.) in dry THF (3 mL.) dropwise via syringe. The ice bath was packed with dry ice and the flask covered. The mixture was allowed to warm slowly to room temperature overnight. The reaction mixture was then diluted with toluene and washed with brine. The layers were separated and the aqueous layer extracted 3x with toluene. The organic extracts were combined, dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. The residue was dissolved in ether and filtered through a 0.4 micron PTFE membrane. The product started to crystallize. Cooled solution in freezer. Collected crystals giving 200 mg. of tris-1-allylindol-5-yl)bismuthine.

STEP 26C

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'-allylindol-5'-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a stirred solution of tri(1-allylindol-5-yl)bismuthine (186 mg., 0.275 mmol., 1.2 eq.) in CH₂Cl₂ (3 mL.) was added peracetic acid (0.064 mL., 0.303 mmol., 1.32 eq., 32% solution in dilute acetic acid). To this solution was added THF (1 mL.), 17-ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (181 mg., 0.229 mmol., 1 eq.) and copper(II)acetate (10

-192-

mg., 0.055 mmol., 0.24 eq.). The mixture was capped and stirred overnight. The reaction was diluted with saturated aqueous NaHCO₃ and extracted 4x with CH₂Cl₂. The organic extracts were combined, dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. The product was isolated and purified by flash column chromatography on silica gel (2:1 hexanes/acetone) followed by preparative TLC (3.5% methanol/CH₂Cl₂) affording 56 mg pure title compound. MASS (FAB) M + Li 953. Partial ¹H NMR (CDCl₃, 200 MHz) δ: 7.17 (bs, 1H); 7.15 (d, J=10Hz, 1H); 7.02 (d, J=3Hz, 1H); 6.88 (dd, J=2Hz and 10Hz, 1H); 6.36 (d, J=3Hz, 1H); 5.95 (m, 1H); 4.63 (bd, J=14Hz, 1H); 3.50 (s, 3H).

EXAMPLE 27

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'-allylindol-5'yl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a stirred solution of tri(1-allylindol-5-yl)bismuthine (1.0 g, 1.48 mmol, 1.2 eq) in CH₂Cl₂ (9 mL) and THF (3 mL) was added peracetic acid (0.315 mL, 1.62 mmol, 1.32 eq, 32% solution in diluted acetic acid). To this solution was added 17-ethyl-1,14-dihydroxy-12-[2'-4(4'',3''-dihydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (956 mg, 1.23 mmol, 1 eq) and copper (II)acetate (22 mg,

-193-

0.123 mmol, 0.1 eq). The mixture was capped and stirred for four days. The reaction was diluted with saturated aqueous NaHCO₃ and extracted 4x with CH₂Cl₂. The organic extracts were combined, dried over anhydrous NaSO₄, filtered and concentrated in vacuo. The product was isolated and purified by flash column chromatography on silica gel (3:1 hexanes/acetone) followed by preparative TLC (3.5% methanol/CH₂Cl₂) affording 163 mg pure 17-ethyl-1,14-dihydroxy-12-[2'-(4''-1'-allylindol-5'yl)oxy-3''-hydroxycyclohexyl]-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetrone.

MASS (FAB), M+Li 953. Partial ¹H NMR (CDCl₃, 200 MHz) δ: 7.17 (d, J=10 Hz, 1H); 7.15 (brs, 1H); 7.05 (d, J=3 Hz, 1H); 6.86 (dd, J=10 Hz, J=2.5 Hz, 1H); 6.39 (d, J=3 Hz, 1H); 6.05-5.85 (m, 1H); 4.66 (brd, J=8.5 Hz, 2H); 4.57 (brd, J=5 Hz, 1H); 4.38 (brd, J=13 Hz, 1H).

EXAMPLE 28

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(9'-methylcarbazol-3'-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

-194-

STEP 28ATri(9-methylcarbazol-3-yl)bismuthine

5 To a stirred mixture of 3-bromo-9-methyl-
carbazole (646 mg., 2.48 mmol., 1 eq.) in diethyl
ether (12 mL) at -78°C (not all carbazole in
solution) under N₂ was added t-butyllithium (3.0 mL.,
4.96 mmol., 2 eq., 1.7M solution in pentane). The
mixture was warmed quickly to room temperature and
10 then quickly cooled to -78°C and stirred under N₂ for
40 minutes. To this mixture was added a solution of
bismuth trichloride (235 mg., 0.744 mmol., 0.3 eq.)
in dry THF (2.5 mL.) dropwise via syringe. The ice
bath was packed with dry ice and the flask covered.
15 The mixture was allowed to warm slowly to room
temperature overnight. The reaction mixture was
poured into a separatory funnel containing brine and
extracted 4x with CH₂Cl₂. The organic extracts were
combined, dried over anhydrous Na₂SO₄, filtered and
20 concentrated in vacuo. The solid residue was
trituated with ether and ether/methanol. The solids
were collected giving 200 mg. of
tri(9-methylcarbazol-3-yl)bismuthine. The supernatant
was saved for further purification.

-25

STEP 28B

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(9'-methylcarbazol-
3'-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-
30 dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-
tricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone

-195-

To a stirred mixture of tri(9-methylcarbazol-3-yl)bismuthine (200 mg., 0.267 mmol., 1.2 eq.) in CH₂Cl₂ (3 mL.) and THF (1 mL.) was added peracetic acid (0.062 mL., .295 mmol., 1.32 eq., 32% solution in dilute acetic acid). To this solution was added 17-ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (175 mg., 0.222mmol., 1 eq.) and copper(II)acetate (10 mg., 0.055 mmol., 0.24 eq.). The mixture was capped and stirred for 48 hours. The reaction was diluted with saturated aqueous NaHCO₃ and extracted 4x with CH₂Cl₂. The organic extracts were combined, dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. The product was isolated and purified by flash column chromatography on silica gel (3:1 hexanes/acetone) followed by preparative TLC (3.5% methanol/CH₂Cl₂) affording 100 mg of the title compound. MASS (FAB) M + Li 977. Partial ¹H NMR (CDCl₃, 200 MHz) δ: 7.68 (d, J=2Hz, 1H); 7.48-7.10 (m, 6H); 4.58 (bd, J=4.8Hz, 1H); 4.39 (bd, J=14Hz, 1H); 3.80 (s, 3H); 3.53 (s, 2H).

25

EXAMPLE 29

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'-benzylindol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

-196-

STEP 29A1-Benzyl-5-bromoindole

To a stirred mixture of NaOH (204 mg., 5.1 mmol., 1 eq.) in DMSO (10 mL.) was added 5-bromoindole (1.0 g., 5.1 mmol., 1 eq.). The solution was stirred for 20 hours upon complete dissolution of the NaOH (approximately 1 h.). To this solution was added benzyl bromide (0.606 mL., 5.1 mmol., 1 eq.) via syringe. After 7 h. the mixture was diluted with water and extracted 4x with diethyl ether. The organic extracts were combined, dried over anhydrous $MgSO_4$, filtered and concentrated in vacuo. The product was purified by crystallization (ether/hexanes) affording 888mg of 1-benzyl-5-bromoindole.

STEP 29B20 Tri(1-benzylindol-5-yl)bismuthine

To a stirred mixture of 1-benzyl-5-bromoindole-3 (888 mg., 3.105 mmol., 1 eq.) in diethyl ether (15 mL) at $-78^{\circ}C$ (not all indole was in solution) under N_2 was added t-butyllithium (3.65 mL., 6.21 mmol., 2 eq., 1.7M solution in pentane). The mixture was stirred at $-78^{\circ}C$ under N_2 for 1 hour. To this mixture was added a solution of bismuth trichloride (294 mg., 0.932 mmol., 0.3 eq.) in dry THF (3 mL.) dropwise via syringe. The ice bath was packed with dry ice and the flask covered. The mixture was allowed to warm slowly to room temperature overnight. The reaction mixture was poured into a

-197-

separatory funnel containing brine and extracted 4x with CH₂Cl₂. The organic extracts were combined, dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. The solid residue was
5 triurated with ether. The solids were collected giving 200 mg. of tri(1-benzylindol-5-yl)-bismuthine. The supernatant was saved for further purification.

10 STEP 29C

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'-benzylindol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-
15 tricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a stirred mixture of tri(1-benzylindol-5-yl)-bismuthine (200 mg., 0.242 mmol., 1.2 eq.) in CH₂Cl₂ (3 mL.) and THF (1 mL.) was added peracetic
20 acid (0.060 mL., .285 mmol., 1.4 eq., 32% solution in dilute acetic acid). To this solution was added 17-ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
25 13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (159 mg., 0.202 mmol., 1 eq.) and copper(II)acetate (10 mg., 0.055 mmol., 0.24 eq.). The mixture was capped and stirred overnight. The reaction was diluted with
30 saturated aqueous NaHCO₃ and extracted 4x with CH₂Cl₂. The organic extracts were combined, dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. The product was isolated and purified by

-198-

flash column chromatography on silica gel (3:1 hexanes/acetone) followed by preparative TLC (3.5% methanol/CH₂Cl₂) affording 100 mg of the title compound. MASS (FAB) M + Li 1003. Partial ¹H NMR (CDCl₃, 200 MHz) δ: 7.3-7.0 (m, 8H); 6.84 (dd, J=9Hz, 1H); 6.40 (d, 3Hz, 1H); 5.23 (bs, 2H); 4.6 (bd, J=6Hz, 1H); 4.38 (bd, J=14Hz, 1H); 3.50 (s, 3H).

EXAMPLE 31

10

17-Ethyl-1-hydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)-oxy-3''-allyloxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

15

STEP 31A

17-Ethyl-1-hydroxy-12-[2'-(4''-(tert-butyldimethylsiloxy)-3''-allyloxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a solution of 17-ethyl-1-hydroxy-12-[2'-(4''-(tert-butyldimethylsiloxy)-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}] octacos-18-ene-2,3,10,16-tetraone (300 mg) in 9 ml 33% methylene chloride in cyclohexane was added allyl trichloroacetimidate (138 mg neat) and the reaction mixture was allowed to mix for 5 minutes.

Trifluoromethanesulfonic acid (18 µl neat) was added slowly via syringe and the mixture stirred at room temperature. After 3 days the reaction was diluted

-199-

with ethyl acetate and quenched with saturated sodium bicarbonate. The layers were separated, and the organic layer was washed with brine then dried over magnesium sulfate. Purification of the concentrate
5 by flash chromatography on silica gel (ethyl acetate: hexane (1:4) + 1% methanol) gave the title compound (230 mg; trichloroacetamide present). ¹H NMR consistent with the desired structure.

10 STEP 31B

17-Ethyl-1-hydroxy-12-[2'-(4''-hydroxy-3''-allyloxy-
cyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,-
21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
15 [22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a solution of 17-ethyl-1-hydroxy-12-[2'-(4''-(tert-butyldimethylsiloxy)-3''-allyloxy)cyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-
20 2,3,10,16-tetraone (115 mg) (STEP 31A) in acetonitrile (2.5 ml) was added a solution of 2% HF in aqueous acetonitrile (40 µl), and the mixture was stirred at room temperature. After 4 hours, the
-solution was diluted with ethyl acetate and quenched
25 with saturated sodium bicarbonate. The layers were separated, and the organic layer was washed with brine and dried over magnesium sulfate. Purification of the concentrate by flash chromatography on silica
gel (ethyl acetate:hexane (1:2)) gave the title
30 compound (42 mg). ¹H NMR consistent with the desired structure.

-200-

STEP 31C

17-Ethyl-1-hydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)-
oxy-3''-allyloxycyclohexyl)-1'-methylvinyl]-23,25-di-
5 methoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatri-
cyclo[22.3.1.0^{4,9}]octacos-18-ene-2.3.10.16-tetraone

To a solution of tri(1-methylindol-5-yl)bis-
muthine (53 mg) in methylene chloride (700 µl) was
added peracetic acid (17 µl), and the mixture was
10 stirred at room temperature for 15 minutes.
17-ethyl-1-hydroxy-12-[2'-(4''-hydroxy-3''-allyloxy-
cyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,-
21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (42
15 mg) was dissolved in methylene chloride (270 µl) and
added to the reaction mixture. After 18 hours the
mixture was diluted with ethyl acetate and washed
with saturated sodium bicarbonate and brine then
dried over magnesium sulfate. Purification of the
20 concentrate by flash chromatography on silica gel
(ethyl acetate:hexane (1:3) + 1% methanol) gave the
title compound (25 mg). MASS (FAB) 938 (M + Li);
Partial ¹H NMR δ: 7.19 (s, 1H); 7.18 (d, J=9Hz, 1H);
6.98 (d, J=3Hz, 1H); 6.92 (dd, J=9,3Hz, 1H); 6.34 (d,
25 J=3Hz, 1H); 5.89 (m, 1H); 4.56 (brd, J=4Hz, 1H); 3.72
(s, 3H).

EXAMPLE 32

30 17-Ethyl-1-hydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)-
oxy-3''-n-propyloxycyclohexyl)-1'-methylvinyl]-23,25-
dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-
tricyclo[22.3.1.0^{4,9}]octacos-18-ene-2.3.10.16-tetraone

-201-

To a solution of 17-ethyl-1-hydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-allyloxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (20 mg) (EXAMPLE 31) in ethyl acetate (500 µl) was added rhodium on carbon (5 mg). The flask was filled with hydrogen, and the mixture was stirred at room temperature. After 1.5 hours the mixture was filtered through Celite then the solvent was removed in vacuo to give the title compound (20 mg). MASS (FAB) 940 (M + Li); Partial ¹H NMR δ: 7.18 (s, 1H); 7.16 (d, J=9Hz, 1H); 6.96 (d, J=3Hz, 1H); 6.92 (dd, J=9,3Hz, 1H); 6.34 (d, J=3Hz, 1H); 4.55 (brd, J=4Hz, 1H); 3.72 (s, 3H).

EXAMPLE 33

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-i-propyloxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

STEP 33A

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-i-propyloxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a solution of 17-ethyl-1,14-dihydroxy-12-[2'-(3'',4''-dihydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-

-202-

tricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone
(300 mg in 4.5 ml 33% methylene chloride in
cyclohexane) isopropyl trichloroacetimidate (142 mg
neat) was added and the reagents allowed to mix for 5
5 minutes. Trifluoromethanesulfonic acid (13.4 μ l
neat) was added slowly via syringe and the mixture
stirred at room temperature. After 5 days the
reaction was diluted with ethyl acetate and quenched
with saturated sodium bicarbonate. The layers were
10 separated, and the organic layer was washed with
brine then dried over magnesium sulfate.
Purification of the concentrate by preparative TLC on
silica gel (ethyl acetate : hexane (1:1) + 1%
methanol) gave the title compound (42 mg). ¹H NMR
15 consistent with the desired structure.

STEP 33B

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-methyl-5-
20 indolyl)oxy-3''-i-propyloxycyclohexyl)-1'-methylvinyl]-
23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone

To a solution of tri(1-methylindol-5-yl)bis-
25 muthine (52 mg) in methylene chloride (700 μ l) was
added peracetic acid (17 μ l), and the mixture was
stirred at room temperature for 15 minutes. 17-
ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-i-
propyloxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
30 13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (42
mg) was dissolved in methylene chloride (450 μ l) and
added to the reaction mixture. After 18 hours the

-203-

mixture was diluted with ethyl acetate and washed with saturated sodium bicarbonate and brine then dried over magnesium sulfate. Purification of the concentrate by preparative TLC on silica gel (ethyl acetate:hexane (1:1 + 1% methanol) gave the title compound (9 mg). MASS (FAB) 956 (M + Li) Partial ¹H NMR δ: 7.19 (s, 1H); 7.16 (d, J=9Hz, 1H); 6.97 (d, J=3Hz, 1H); 6.92 (dd, J=9, 3Hz, 1H); 6.34 (d, J=3Hz, 1H); 4.41 (brd, J=14Hz, 1H); 2.72 (s, 3H).

EXAMPLE 34

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-allyloxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

STEP 34A

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(tert-butyl dimethylsiloxy)-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a solution of 17-ethyl-1,14-dihydroxy-12-[2'-(3'',4''-dihydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (1.0 g) in dry methylene chloride (14 ml) was added 2,6-lutidine (240 μl) and the mixture was stirred at room temperature. After 10 minutes, tert-butyl-

-204-

dimethylsilyl trifluoromethanesulfonate (295 μ l) was added via syringe. After 15 minutes the reaction mixture was diluted with ethyl acetate, washed with 1N HCl, water, saturated sodium bicarbonate and brine. The organic phase was dried over magnesium sulfate. Removal of the solvent in vacuo and flash chromatography on silica gel (ethyl acetate: hexane (1:3) + 1% methanol) gave the title compound (293 mg). ^1H NMR consistent with the desired structure.

STEP 34B

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(tert-butyl dimethylsiloxy)-3''-allyloxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a solution of 17-ethyl-1,14-dihydroxy-12-[2'-(4''-(tert-butyl dimethylsiloxy)-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (290 mg in 3.9 ml 33% methylene chloride in cyclohexane) allyl trichloroacetimidate (131 mg neat) was added and the reagents allowed to mix for 5 minutes. Trifluoromethanesulfonic acid (6 μ l neat) was added slowly via syringe and the mixture stirred at room temperature. After 5 days the reaction was diluted with ethyl acetate and quenched with saturated sodium bicarbonate. The layers were separated, and the organic layer was washed with brine then dried over magnesium sulfate. Purification of the concentrate

-205-

by preparative TLC on silica gel (ethyl acetate : hexane (1:5) + 1% methanol) gave the title compound (150 mg). ¹H NMR consistent with the desired structure.

5

STEP 34C

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-allyl-oxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,-
10 19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a solution of 17-ethyl-1,14-dihydroxy-12-
[2'-(4''-(tert-butyl)dimethylsiloxy)-3''-allyloxycyclo-
hexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-
15 tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-
octacos-18-ene-2,3,10,16-tetraone (150 mg) in
acetonitrile (3 ml) was added a solution of 2% HF in
aqueous acetonitrile (80 µl), and the mixture was
stirred at room temperature. After 2 hours, the
20 solution was diluted with ethyl acetate and quenched
with saturated sodium bicarbonate. The layers were
separated, and the organic layer was washed with
brine and dried over magnesium sulfate. Purification
of the concentrate by flash chromatography on silica
25 gel (ethyl acetate:hexane (1:1) + 1% methanol) gave
the title compound (63 mg). ¹H NMR consistent with
the desired structure.

30

-206-

STEP 34D

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-allyloxycyclohexyl)-1'-methylvinyl]-
5 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a solution of tri(1-methylindol-5-yl)bis-muthine (60 mg) in methylene chloride (1.0 ml) was
10 added peracetic acid (23 μ l), and the mixture was stirred at room temperature for 15 minutes.
17-ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-allyloxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
15 [22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (60 mg) was dissolved in methylene chloride (500 μ l) and added to the reaction mixture. After 20 hours the mixture was diluted with ethyl acetate and washed with saturated sodium bicarbonate and brine then
20 dried over magnesium sulfate. Purification of the concentrate by preparative TLC on silica gel (ethyl acetate:hexane (1:2) + 1% methanol) gave the title compound (26 mg). partial ¹H NMR δ : 7.18 (s, 1H); 7.16 (d, J=9Hz, 1H); 6.97 (d, J=3Hz, 1H); 6.91 (dd, J=9,3Hz, 1H); 6.34 (d, J=3Hz, 1H); 5.89 (m, 1H); 4.57 (brd, J=4 Hz, 1H); 4.41 (brd, J=14Hz, 1H); 3.70 (s, 3H).

30

- 207 -

EXAMPLE 35

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-n-propyloxycyclohexyl)-1'-methylvinyl]-
5 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a solution of 17-ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-allyloxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (14 mg) in ethyl acetate (400 µl) was added rhodium on carbon (4 mg).
10 The flask was filled with hydrogen, and the mixture was stirred at room temperature. After 1.5 hours the mixture was filtered through Celite then the solvent was removed in vacuo. Purification by flash chromatography (ethyl acetate:hexane (1:1) + 1%
15 methanol) gave the title compound (10 mg). partial ¹H NMR d: 7.17 (s, 1H); 7.15 (d, J=9Hz, 1H); 6.97 (d, J=3Hz, 1H); 6.92 (dd, J=9,3Hz, 1H); 6.34 (d, J=3Hz, 1H); 4.56 (brd, J=4 Hz, 1H); 4.40 (brd, J=14Hz, 1H); 3.71 (s, 3H).
20
25

- 208 -

EXAMPLE 36

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-(3-t-butyl-di-
methylsilyloxypropyl)indol-5-yl)oxy-3''-methoxycyclo-
5 hexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-
tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-
octacos-18-ene-2,3,10,16-tetraone

To a solution of tri[1-(3-t-butyl-dimethyl-
silyloxypropyl)-indol-5-yl] bismuthine (0.43 gm,
10 0.4mmol.) in CH₂Cl₂ (4mL.) at room temperature was
added peracetic acid (0.075 mL., 32% in acetic acid)
followed in 15 minutes by 17-ethyl-1,14-dihydroxy-
12-[2'-(4''-hydroxy-3''-methoxycyclohexyl)-1'-methyl-
15 vinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-
dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,
16-tetraone (350 mg., 0.44mmol.) and Cu(OAc)₂ (30
mg.). The reaction mixture was stirred for 2 days.
The reaction was then quenched with saturated NaHCO₃
and the mixture extracted with CH₂Cl₂. The organic
20 extracts were combined, dried over Na₂SO₄, filtered,
and concentrated in vacuo. The product was isolated
and purified by preparative TLC on silica gel (3:1,
hexane/acetone) to give 144 mg. of the title compound.

25

30

- 209 -

EXAMPLE 37

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-(3-hydroxy-
propyl)indol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methyl-
5 vinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-
dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-
2,3,10,16-tetraone

To a solution of 17-ethyl-1,14-dihydroxy-
12-[2'-(4''-(1-(3-t-butyldimethylsilyloxy-propyl)indol-
10 5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-
dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-aza-
tricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone
(144mg) in CH₂Cl₂ (4 mL.) at rt was added a solution
of p-toluene sulfonic acid (20 mg.) in CH₃OH (4 mL.).
15 The reaction mixture was stirred for 3 hr., quenched
with saturated NaHCO₃, then extracted with CH₂Cl₂.
The extracts were combined, dried over Na₂SO₄,
filtered and concentrated in vacuo. The product was
purified by preparative TLC on silica gel (2:1,
20 hexane/acetone) to give 81 mg of the title compound.
Partial ¹H NMR (CDCl₃, 200 MHz) δ: 7.22 (d, J=9 Hz,
1H); 7.18 (d, J=3 Hz, 1H); 7.07 (d, J=3 Hz, 1H); 6.89
(dd, J=3 Hz and J=9 Hz, 1H); 6.34 (d, J=3 Hz, 1H);
4.20 (t, J=6.5 Hz, 2H); 2.00 (m, 2H).

25

30

- 210 -

EXAMPLE 38

17-Ethyl-1,14-dihydroxy-12-[2'-(3''-hydroxy-4''-(1-t-
butyldimethylsilyloxyethylindol-5-yl)oxycyclohexyl)-
5 1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetra-
methyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-
18-ene-2,3,10,16-tetraone

To a solution of tri[1-(2-t-butyldimethyl-
silyloxyethyl)-indol-5-yl] bismuthine (250 mg., 0.24
10 mmol.) in CH₂Cl₂ (2mL.) at rt was added peracetic
acid (0.05 mL., 32% in acetic acid) followed in 15
minutes by 17-ethyl-1,14-dihydroxy-12-[2'-(3'',4''-
dihydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
15 [22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone
(200mg, 0.25 mmol) and Cu(OAc)₂ (20 mg.). The
reaction mixture was stirred for 2 days. The reaction
was then quenched with saturated NaHCO₃ and extracted
with CH₂Cl₂. The organic extracts were combined,
20 dried with Na₂SO₄, filtered and concentrated in
vacuo. The product was isolated and purified by
preparative TLC (3:1, hexane/acetone) to afford 74
mg. of the title compound.

25

30

- 211 -

EXAMPLE 39

17-Ethyl-1,14-dihydroxy-12-[2'-(3''-hydroxy-4''-(1-hydroxyethylindol-5-yl)oxycyclohexyl)-1'-methylvinyl]-
5 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a solution of 17-ethyl-1,14-dihydroxy-12-[2'-(3''-hydroxy-4''-(1-t-butyl-dimethylsilyloxyethylindol-5-yl)oxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone
10 (74mg) in CH₂Cl₂ (2 mL.) at rt was added a solution of p-toluene sulfonic acid (10 mg.) in CH₃OH (2 mL.).
15 The reaction mixture was stirred for 3 hr., quenched with saturated NaHCO₃, then extracted with CH₂Cl₂. The extracts were combined, dried over Na₂SO₄, filtered and concentrated in vacuo.. The product was
20 purified by preparative TLC on silica gel (2:1, hexane/acetone) to give 44.8 mg of the title compound. Partial ¹H NMR (CDCl₃, 200 MHz) δ: 7.24 (d, J=9Hz, 1H); 7.15 (d, J=3Hz, 1H); 7.12 (d, J=3.5Hz, 1H); 6.86 (dd, J=3 and J=9 Hz, 1H); 6.39 (d, J=3.5, 1H); 4.20 (t, J=5, 2H).
25

- 212 -

EXAMPLE 40

Tri[1-2(t-butyldimethylsilyloxyethyl)-indol-
6-yl]-bismuthine

5

Step A: 6-Bromoindole

To a solution of 4-bromo-2-nitrotoluene
(4.3 g., 20 mmol.) in DMF (40 mL.) was added DMF
dimethylacetal (7.15g., 60 mmol.) and pyrrolidine
10 (1.4 g., 20 mmol.). The solution was heated to 110° C
for 4 hr. then cooled to rt. and diluted with ethyl
ether. The mixture was washed 3X with water, dried
with Na₂SO₄, filtered and the solvent evaporated. The
residue was dissolved in 80% aqueous acetic acid (125
15 mL.) and heated to 75° C. Zinc dust (9.75 g., 150
mmol.) was added gradually over 20 min. The reaction
mixture was heated to 85° C for 2 hr. then cooled to
~35° C and filtered to remove unreacted zinc. The
filtrate was diluted with ethyl ether, washed 3X with
20 water then with saturated aqueous NaHCO₃. The
solution was dried with Na₂SO₄, filtered and
concentrated in vacuo to ~30 mL. then diluted with
hexanes and filtered. The filtrate was concentrated
to an off-white solid which was dissolved in hexane,
25 filtered, and concentrated to give 1.65 g. of the
title compound as a light green solid.

Step B: 1-(2-t-Butyldimethylsilyloxyethyl)-6-
bromoindole

30

To a slurry of NaH (192 mg., 4.8 mmol.,
60% oil dispersion) in DMF (4 mL.) was added,
dropwise, a solution of 6-bromoindole (0.85 g., 4.34

- 213 -

mmol.) in DMF (4 mL.). After stirring for 10 min. at
rt., 2-t-butyldimethylsiloxyethyl bromide ((1.15 g.,
4.8 mmol., neat) was added and the mixture stirred
for 1.5 hr. The reaction mixture was partitioned
5 between ice water and hexane. The organics were
washed 2X with water, dried with Na₂SO₄, filtered and
concentrated in vacuo to a dark oil. The product was
isolated by flash column chromatography (silica, 4:1
hexanes/acetone) to give 1.04 g. of the title
10 compound as an oil.

Step C: Tri[1-(2-t-butyldimethylsilyloxyethyl)-
indol-6-yl]-bismuthine

To a solution of 1-(2-t-butyldimethyl-
15 silyloxyethyl)-6-bromoindole (1.0 g., 2.81 mmol.) in
ethyl ether (10 mL.) at -78° C was added
t-butyllithium (3.4 mL., 5.8 mmol., 1.7M in pentane).
After stirring for 10 min. a solution of BiCl₃ (285
mg., 0.9 mmol.) in THF (3 mL.) was added. The
20 reaction mixture was stirred for an additional 10
min. at -78° C then allowed to warm to rt overnight.
The reaction mixture was partitioned between ice
water and CH₂Cl₂. The organic layer was washed with
water, dried with Na₂SO₄ and concentrated to a dark
25 oil. Flash column chromatography (silica, 4:1
hexane/acetone) afforded 630 mg. of the title
compound as a dark oil (~60% pure) which was used
without further purification in Example 41/the next
30 step.

- 214 -

EXAMPLE 41

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-t-butyldimethyl-
silyloxyethyl)indol-6-yl)oxy-3''-methoxycyclohexyl)-1'-
5 methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-
11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-
2,3,10,16-tetraone

To a solution of tri[1-(2-t-butyldimethyl-
silyloxyethyl)-indol-6-yl]-bismuthine (0.60 g.,
10 0.58mmol.) in CH₂Cl₂ (5mL.) at room temperature was
added peracetic acid (0.080 mL., 32% in acetic acid)
followed in 15 minutes by 17-ethyl-1,14-dihydroxy-12-
[2'-(4''-hydroxy-3''-methoxycyclohexyl)-1'-methylvinyl]-
23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
15 azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone (350 mg., 0.44mmol.) and Cu(OAc)₂ (30 mg.).
The reaction mixture was stirred for 20 hr. The
reaction was then quenched with saturated NaHCO₃ and
the mixture extracted with CH₂Cl₂. The organic
20 extracts were combined, dried over Na₂SO₄, filtered,
and concentrated in vacuo. The product was isolated
and purified by preparative TLC on silica gel (3:1,
hexane/acetone) to give 150 mg. of the title compound.

25

30

- 215 -

EXAMPLE 42

5 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-hydroxyethyl-
indol-6-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-
23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone

10 To a solution of 17-ethyl-1,14-dihydroxy-
12-[2'-(4''-(1-t-butyldimethylsilyloxyethylindol-6-yl)-
oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-
dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
15 tetraone (150 mg) in CH₂Cl₂ (4 mL.) at rt was added a
solution of p-toluene sulfonic acid (20 mg.) in CH₃OH
(4 mL.). The reaction mixture was stirred for 2 hr.,
quenched with saturated NaHCO₃, then extracted with
CH₂Cl₂. The extracts were combined, dried over
20 Na₂SO₄, filtered and concentrated in vacuo. The
product was purified by preparative TLC on silica gel
(2:1, hexane/acetone) to give 55 mg of the title
compound.

Partial ¹H NMR (CDCl₃, 200 MHz) δ: 7.47 (d, J=6 Hz,
1H); 7.03 (d, J=3 Hz, 1H); 6.94 (bs, 1H); 6.82 (dd,
25 J=1.5 Hz and J=6 Hz, 1H); 6.41 (d, J=3 Hz, 1H); 6.41
(d, J=3 Hz, 1H); 4.20 (t, J=5 Hz, 2H); 3.93 (t, J=5
Hz, 2H); 3.50 (s, 3H).

30

- 216 -

EXAMPLE 43Tri(1-methylindol-6-yl)bismuthine

5 To a solution of 1-methyl-6-bromoindole
(760 mg., 3.6 mmol.) in ethyl ether (15 mL.) at -78°C
was added t-butyllithium (4.4 mL., 7.5 mmol., 1.7M in
pentane). After 10 min. a solution of BiCl_3 (375 mg.,
1.2 mmol.) in THF (4 mL.) was added and the cooling
10 bath removed. The reaction mixture stirred for 4 hr
then poured into ice water and extracted with CH_2Cl_2 .
The extracts were combined, backwashed with water,
dried with Na_2SO_4 , filtered, and concentrated in
vacuo to a dark oil. The product was crystallized
15 from methanol to afford 290 mg. of the title compound
as a tan solid.

20

25

30

- 217 -

EXAMPLE 44

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-methylindol-6-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-
5 dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-
tricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a solution of tri[1-methylindol-6-yl]-bismuthine (200 mg., 0.33 mmol.) in CH₂Cl₂ (2mL.) at room temperature was added peracetic acid (0.070 mL.,
10 32% in acetic acid) followed in 15 minutes by
17-ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (150
15 mg., 0.19 mmol.) and Cu(OAc)₂ (30 mg.). The reaction mixture was stirred for 4 days. The reaction was then quenched with saturated NaHCO₃ and the mixture extracted with CH₂Cl₂. The organic extracts were combined, dried over Na₂SO₄, filtered, and
20 concentrated in vacuo. The product was isolated and purified by preparative TLC on silica gel (2:1, hexane/acetone) to give 76 mg. of the title compound. Partial ¹H NMR (CDCl₃, 400 MHz) δ: 7.44 (d, J=7Hz, 1H); 6.91 (d, J=3Hz, 1H) 6.88 (d, J=2Hz, 1H); 6.81 (m, 1H); 6.37 (d, J=3, 1H); 3.68 (s, 3H); 3.51 (s, 3H).
25

- 218 -

EXAMPLE 45

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-dibenzyl-
phosphonoxy-ethylindol-5-yl)oxy-3''-methoxycyclohexyl)-
5 1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetra-
methyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-
18-ene-2,3,10,16-tetraone

To a solution of 17-ethyl-1,14-dihydroxy-
12-[2'-(4''-(1-hydroxyethylindol-5-yl)oxy-3''-methoxy-
10 cyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (202
mg, azeotroped with toluene) in dry THF was added
dibenzyl phosphate (88.6 mg) followed by
15 triphenylphosphine (83.5 mg). The reaction mixture
was cooled down to 0°C, then added diethyl
azodicarboxylate (50 mL). The reaction mixture was
stirred at 0°C for 5 minutes, removed the ice bath,
and stirred at room temperature for 2h. The crude
20 reaction mixture was loaded directly onto the silica
gel column and purified (ethyl acetate:hexane (2:3) +
1% MeOH) to give the title compound (197 mg).
Partial ¹H NMR (CDCl₃)δ: 7.29 (m, 6H); 7.18 (m, 5H);
7.12 (d, J = 9Hz, 1H); 7.0 (d, J = 4Hz, 1H); 6.89
25 (dd, J = 9, 2Hz, 1H); 6.36 (d, J = 4Hz, 1H); 4.82 (m,
4H); 4.40 (brd, J = 14Hz, 1H); 4.20 (m, 4H).

- 219 -

EXAMPLE 46

Monopotassium salt of 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-phosphonoxy-ethylindol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,-
21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.-
1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a solution of 17-ethyl-1,14-dihydroxy-12-[2'-(4''-(1-dibenzylphosphate-ethylindol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (197 mg) in methanol (3.2 mL) was added potassium bicarbonate (16.3 mg) dissolved in water (200 mL).
Added palladium hydroxide over carbon, then charged the reaction mixture with hydrogen via balloon. After the reaction was complete (10 min. by TLC analysis) , it was filtered over Celite and rinsed with methanol and small amount of water. The solvent was removed in vacuo, and the crude material was purified on HP-20 column to give the title compound (69 mg).

Partial ¹H NMR (CD₃OD) δ: 7.34 (d, J = 9Hz, 1H); 7.27 (d, J = 4Hz, 1H); 7.12 (d, J = 2Hz, 1H); 6.85 (dd, J = 9, 2Hz, 1H); 6.31 (d, J = 4Hz, 1H); 5.23 (m, 2H); 4.35 (m, 2H); 4.13 (m, 2H).

- 220 -

EXAMPLE 47

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-(N,N-dimethyl-
glycyloxy)ethylindol-5-yl)oxy-3''-methoxycyclohexyl)-
5 1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetra-
methyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-
18-ene-2,3,10,16-tetraone

To a solution of 17-ethyl-1,14-dihydroxy-
12-[2'-(4''-(1-hydroxyethylindol-5-yl)oxy-3''-methoxy-
10 cyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (26.6
mg) in dry methylene chloride (0.3 mL) was added
hydrochloride salt of N,N-dimethylglycine (5.8 mg),
15 DMAP (3.4 mg) and EDC (8 mg), respectively at room
temperature. The reaction mixture was stirred for
4h, then diluted with ethyl acetate and washed with
saturated sodium bicarbonate and brine. The organic
layer was dried over magnesium sulfate, and the
20 solvent was removed in vacuo. The crude material was
purified by flash chromatography
(1:2/acetone:hexane). to give 23mg of the title
compound.

Partial ¹H NMR (CDCl₃) δ: 7.21 (m, 2H); 7.04 (d, J =
25 4Hz, 1H); 6.91 (dd, J = 9, 2Hz, 1H); 6.49 (d, J =
4Hz, 1H); 4.41 (m, 2H); 4.32 (m, 2H); 3.07 (s, 3H);
2.26 (s, 3H).

30

- 221 -

EXAMPLE 48

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-succinyloxy-ethylindol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methyl-
5 vinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a solution of 17-ethyl-1,14-dihydroxy-12-[2'-(4''-(1-hydroxyethylindol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
10 13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (109 mg) in dry methylene chloride was added succinic
anhydride (11.5 mg) and triethylamine (19 ml).
15 Added DMAP (7 mg) to the reaction mixture and followed the reaction by TLC. After 1.5h, the reaction mixture was diluted with ethyl acetate and adjusted to pH 4 with 1N HCl. It was poured into the
separatory funnel and the layers were separated. The
20 aqueous layer was extracted with ethyl acetate, and the combined organic layer was washed with brine. It was dried over magnesium sulfate, and the crude material was purified by flash chromatography (3% methanol/CH₂Cl₂) to give 66 mg of the title compound.
25 Partial ¹H NMR (CDCl₃) δ: 7.19 (m, 2H); 7.04 (d, J = 4Hz, 1H); 6.91 (dd, J = 9, 2Hz, 1H); 6.39 (d, J = 4Hz, 1H); 4.32 (m, 4H); 2.49 (brs, 4H).

- 222 -

EXAMPLE 49

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-methyl-3-phenyl-
indol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-
23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone

Step A: 5-Bromo-3-phenylisatin

To a stirred mixture of 5-bromoisatin
(5g., 22.1 mmol., 1 eq.) in dry THF (150 mL.) was
added phenylmagnesium bromide (14.7 mL., 44.2 mmol.,
2 eq., 3M solution in diethyl ether)(The addition of
Grignard reagent was initiated at -78°C. The
reaction mixture became too viscous to stir after
addition of approximately 5 mL. of the Grignard
reagent. The cooling bath was removed and the
remainder of the Grignard reagent was added by quick
dropwise addition.). The reaction mixture was
stirred overnight. Analysis by TLC showed a small
amount of unreacted starting material. An additional
1.5 mL. of the Grignard reagent was added and the
reaction mixture was stirred an additional 6 hours.
The reaction mixture was poured into a separatory
funnel containing saturated aqueous ammonium chloride
and was extracted 4x with diethyl ether. The organic
extracts were combined, dried over anhydrous MgSO₄,
filtered and concentrated in vacuo. The product was
carried on without further purification.

- 223 -

Step B: 5-Bromo-3-phenylindole

To a stirred solution of 5-bromo-3-phenylisatin (6.39 g., 21 mmol., 1 eq.) in dry THF (50 ml.) at 0°C was added lithium aluminum hydride (2.0g., 52.5 mmol., 2.5 eq.) portionwise over 1.5 hours. The cooling bath was removed and the reaction was allowed to stir overnight. The mixture was cooled to 0°C and carefully quenched with 1N aqueous HCl. The mixture was filtered through Celite™ and the Celite™ was washed with THF. The filtrate was concentrated in vacuo, dissolved in EtOAc and washed with water. The organic layer was dried over anhydrous MgSO₄, filtered and concentrated in vacuo.

Step C: 5-bromo-1-methyl-3-phenylindole

To a stirred solution of 5-bromo-3-phenylindole (2.4 g., 8.78 mmol., 1 eq.) in dimethylformamide (20 mL.) was added NaH (422 mg. of a 60% dispersion in oil, 10.54 mmol., 1.2 eq.). The mixture was stirred 15 minutes. Methyl iodide (0.6 ml, 9.66 mmol, 1.1 eq) was added via syringe and the reaction mixture was stirred 3 hours. The reaction was quenched with water and extracted 4x with EtOAc. The organic extracts were combined, dried over anhydrous MgSO₄, filtered and concentrated in vacuo. The product was purified by flash column chromatography (2:1 hexanes/acetone) giving 1.63 g. 5-bromo-1-methyl-3-phenylindole.

- 224 -

Step D: Tri(1-methyl-3-phenylindol-5-yl)bismuthine

To a stirred solution of 5-bromo-1-methyl-3-phenylindole (1.63 g., 5.7 mmol., 1 eq.) in Et₂O (35 mL.) at -78°C under N₂ atmosphere was added
5 t-buLi (6.7 mL. of a 1.7M solution in hexanes, 11.4 mmol., 2 eq.) dropwise via syringe. The reaction was stirred 10 minutes at -78°C. To this mixture was added a solution of BiCl₃ (540 mg., 1.71 mmol., 0.3 eq.) in THF (7 mL.) dropwise quickly. The reaction
10 was stirred 10 minutes at -78°C and the cooling bath was removed and the mixture allowed to warm to room temperature. After 3 hours the mixture was poured into a separatory funnel containing water and extracted 4x with CH₂Cl₂. The organic extracts were
15 combined, dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. The residue was triturated with Et₂O and the solids collected and washed with Et₂O giving 710 mg of
20 Tri(1-methyl-3-phenylindol-5-yl)bismuthine.

25

30

- 225 -

Step E: 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-methyl-3-phenylindol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a stirred solution of tri(1-methyl-3-phenylindol-5-yl)bismuthine (645 mg., 0.78 mmol., 1.2 eq.) in CH₂Cl₂ (10 mL.) and THF (3 mL.) was added peracetic acid (0.514 mL. of a 32% solution in dilute acetic acid, 0.858 mmol., 1.3 eq.). The mixture was stirred 5 minutes and 17-ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (514 mg., 0.65 mmol., 1 eq.) was added. Cu(OAc)₂ (12 mg., 0.065 mmol., 0.1 eq) was added. The flask was capped and the mixture stirred. After 48 hours the reaction was quenched with saturated aqueous NaHCO₃ and extracted 4x with CH₂Cl₂. The organic extracts were combined, dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. The product was purified by flash column chromatography on silica gel (2:1 hexanes/acetone) and again (3.5% CH₃OH/CH₂Cl₂) giving 78 mg 17-ethyl-1,14-dihydroxy-12-[2'-(4''-(1-methyl-3-phenylindol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone. Mass (FAB) 1003 (M⁺+Li); 996 (M⁺). Partial ¹H NMR (CDCl₃, 400MHz) δ: 7.59 (d, J=7Hz, 2H); 7.50 (m, 1H); 7.41 (t, J=7Hz, 2H); 7.25-7.15 (m, 3H); 6.99 (dd, J=9Hz, J=2Hz, 1H); 4.57 (d, J=6Hz, 1H); 4.39 (bd, J=13 Hz, 1H); 3.78 (s, 3H).

- 226 -

EXAMPLE 50

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-methyl-3-(2-
hydroxyethyl)indol-5-yl)oxy-3''-methoxycyclohexyl)-1'-
5 methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-
11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-
2,3,10,16-tetraone

Step A: 5-Bromo-3-hydroxyethylindole

10 To a stirred solution of
5-bromoindole-3-acetic acid (1.9g., 7.48 mmol., 1
eq.) in dry THF (17 mL.) at 0°C was added lithium
aluminum hydride (570 mg. 14.96 mmol., 2 eq.)
15 portionwise over 30 minutes. The reaction mixture
coagulated. THF (20 mL.) was added and the cooling
bath was removed. The mixture was stirred
vigorously. Let stir overnight. The reaction
mixture was carefully quenched with 1N aqueous HCl
and then acidified with 2N aqueous HCl. The mixture
20 was filtered through Celite™ and the Celite™ was
washed with THF. The filtrate was concentrated in
vacuo, dissolved in EtOAc, and washed with water.
The organic layer was dried over anhydrous MgSO₄,
filtered and concentrated in vacuo. TLC analysis of
25 the residue showed unreacted starting material. The
residue was dissolved in Et₂O and extracted with
0.25N aqueous NaOH. The organic layer was dried over
anhydrous MgSO₄, filtered and concentrated in vacuo
giving 1.16g 5-bromo-3-hydroxyethylindole.

30

- 227 -

Step B: 5-Bromo-3-(2-t-butyldimethylsilyloxy)ethyl-
indole

To a stirred solution of
5-bromo-3-hydroxyethylindole (1.16g., 4.83 mmol., 1
5 eq.) in CH₂Cl₂ (12mL.) was added triethylamine
(1.0mL., 7.25 mmol., 1.5eq.) followed by addition of
t-butyldimethylchlorosilane (875mg., 1.2mmol.,
1.2eq.) and dimethylaminopyridine(catalytic). The
mixture was stirred overnight, poured into a
10 separatory funnel containing water and extracted 4x
with CH₂Cl₂. The organic extracts were combined,
dried over anhydrous Na₂SO₄, filtered and
concentrated in vacuo giving 1.66g. 5-bromo-3-(2-
t-butyldimethylsilyloxy)ethylindole.

15

Step C: 5-Bromo-1-methyl-3-(2-t-butyldimethylsilyl-
oxy)ethylindole

To a stirred solution of 5-bromo-3-(2-
t-butyldimethylsilyloxy)ethylindole (1.66g.,
20 4.66mmol., 1eq.) in DMF (15mL.) was added NaH (225mg.
of a 60% dispersion in oil, 5.6mmol., 1.2eq.). After
15 minutes iodomethane (0.320mL., 5.13mmol., 1.1eq.)
was added. The mixture was stirred 4 hours and then
poured into a separatory funnel containing water and
25 extracted 2x with EtOAc. The organic extracts were
combined, dried over anhydrous MgSO₄, filtered and
concentrated in vacuo giving 1.49g. 5-bromo-1-methyl-
3-(2-t-butyldimethylsilyloxy)ethylindole.

30

- 228 -

Step D: Tri(1-methyl-3-(2-t-butyldimethylsilyloxy)-
ethylindol-5-yl)bismuthine

To a stirred solution of 5-bromo-1-methyl-
3-(2-t-butyldimethylsilyloxy)ethylindole (1.49g.,
5 4.03mmol., 1eq.) in Et₂O (15mL.) at -78°C under
nitrogen atmosphere was added t-butyllithium (4.8mL.
of a 1.7M solution in pentanes, 8.06mmol., 2eq.)
dropwise via syringe. The mixture was stirred 10
minutes at -78°C and then a solution of BiCl₃
10 (381mg., 1.21mmol., 0.3eq.) in THF (5mL.) was added
quickly dropwise via syringe. The mixture was
stirred for 7 minutes at -78°C under nitrogen. The
cooling bath was removed and the mixture was allowed
to warm to room temperature. After 1 hour the
15 mixture was poured into a separatory funnel
containing water and extracted 4x with CH₂Cl₂. The
organic extracts were combined, dried over anhydrous
Na₂SO₄, filtered and concentrated in vacuo giving 554
mg. crude product. ¹H NMR analysis of the residue
20 indicates mixture of approximately 2:1 of the desired
bismuthine to reduced indole. Used the mixture crude
in subsequent reaction.

Step E: 17-Ethyl-1,14-dihydroxy-12-[2'-(4'-(1-
25 methyl-3-(2-t-butyldimethylsilyloxyethyl)-
indol-5-yl)oxy-3''-methoxycyclohexyl)-1'-
methylvinyl]-23,25-dimethoxy-13,19,21,27-
tetramethyl-11,28-dioxa-4-azatricyclo[22.3.
1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone
30 To a stirred solution of tri(1-methyl-3-(2-
t-butyldimethylsilyloxy)ethylindol-5-yl)bismuthine
(554 mg. crude) in CH₂Cl₂ (10 mL.) and THF (3 mL.)

- 229 -

was added peracetic acid (0.120mL. of a 32% solution in dilute acetic acid, 0.571 mmol.). To this mixture was added 17-ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
 5 13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (347mg., 0.439mmol.) followed by addition of Cu(OAc)₂ (24mg., 0.13mmol.). The reaction mixture was allowed to stir overnight. The mixture was poured into a
 10 separatory funnel containing saturated aqueous NaHCO₃ and extracted 4x with CH₂Cl₂. The organic extracts were combined, dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. The product was purified by flash column chromatography on silica gel (2:1
 15 hexanes/acetone) giving 200mg. 17-ethyl-1,14-dihydroxy-12-[2'-(4''-(1-methyl-3-(2-t-butylidimethylsilyloxyethyl)indol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-
 20 2,3,10,16-tetraone as a brown oil.

Step F: 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-methyl-3-(2-hydroxyethyl)indol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-
 25 dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a stirred solution of 17-ethyl-1,14-dihydroxy-12-[2'-(4''-(1-methyl-3-(2-t-butylidimethylsilyloxyethyl)indol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,1
 30

- 230 -

0,16-tetraone (200mg.) in CH_2Cl_2 (6mL.) and CH_3OH (6mL.) was added p-toluenesulfonic acid monohydrate (30mg.). The reaction mixture was allowed to stir 3 hours. The reaction was quenched with saturated aqueous NaHCO_3 and extracted 4x with CH_2Cl_2 . The organic extracts were combined, dried over anhydrous Na_2SO_4 , filtered and concentrated in vacuo. The product was purified by preparative TLC on silica gel (1:1 hexanes/acetone) and again (7% $\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$) giving 75 mg. 17-ethyl-1,14-dihydroxy-12-[2'-(4''-(1-methyl-3-(2-hydroxyethyl)indol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone.

Mass (FAB) 972 ($\text{M}^+ + \text{Li}$).

Partial ^1H NMR (CDCl_3 , 400 MHz) d: 7.17-7.13 (m, 2H); 6.94 (dd, $J=9\text{Hz}$, $J=2\text{Hz}$, 1H); 6.88 (s, 1H); 4.58 (d, $J=6\text{Hz}$, 1H); 4.39 (bd, $J=13\text{Hz}$, 1H); 3.84 (t, $J=6\text{Hz}$, 2H); 3.70 (s, 3H); 2.94 (t, $J=7\text{Hz}$, 2H).

- 231 -

EXAMPLE 51

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1,3-dimethylindol-
5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-
5 dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-
tricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

Step A: 5-Bromo-3-methylindole

10 To a stirred mixture of 5-bromoisatin
(5g., 22.1 mmol., 1 eq.) in dry THF (150 mL.) was
added methylmagnesium bromide (32 mL. of a 1.4M
solution in toluene, 44.2 mmol., 2 eq.) dropwise via
syringe. After 45 minutes TLC analysis showed small
amount of unreacted bromoisatin. Added 3.2 mL. of
15 methylmagnesium bromide solution. Let stir 1 hour.
Cooled reaction mixture to 0°C. Added lithium
aluminum hydride (1.26g., 33.15 mmol., 1.5 eq.)
portionwise. Let stir 30 minutes at 0°C. Removed
cooling bath and let stir overnight. Cooled mixture
20 to 0°C and carefully quenched reaction with 1N
aqueous HCl. Acidified with 2N aqueous HCl. Removed
cooling bath. Let stir for 3 hours. Filtered
mixture through Celite™. Washed Celite™ with THF.
Concentrated filtrate in vacuo. Diluted residue with
25 water and extracted 4x with CH₂Cl₂. The organic
extracts were combined, dried over anhydrous Na₂SO₄,
filtered and concentrated in vacuo. Loaded residue
onto a silica gel plug in a fritted filter and eluted
with 4:1 hexanes/acetone. Collected fractions
30 containing the desired product and concentrated in
vacuo giving 2.85g. 5-bromo-3-methylindole.

- 232 -

Step B: 5-Bromo-1,3-dimethylindole

To a stirred solution of 5-bromo-3-methylindole (2.85g., 13.6 mmol., 1eq.) in DMF (35 mL.) was added NaH (651 mg. of a 60% dispersion in oil, 16.28 mmol., 1.2 eq.). The mixture was stirred 15 minutes. To this mixture was added iodomethane (0.930 mL., 14.93 mmol., 1.1 eq.). The mixture was stirred for 2 hours. The DMF was removed in vacuo. The residue was diluted with water and extracted 4x with Et₂O. The organic extracts were combined, dried over anhydrous MgSO₄, filtered and concentrated in vacuo giving 3.04g. 5-bromo-1,3-dimethylindole as a reddish liquid.

15 Step C: Tri(1,3-dimethylindol-5-yl)bismuthine

To a stirred solution of 5-bromo-1,3-dimethylindole (3.04g., 13.57 mmol., 1 eq.) in Et₂O (50 mL.) at -78°C under nitrogen atmosphere was added t-butyllithium (16 mL. of a 1.7M solution in hexanes, 27.2 mmol., 2 eq.) dropwise via syringe. The mixture was stirred for 10 minutes at -78°C. To the reaction was added a solution of BiCl₃ (1.28g., 4.07mmol., 0.3 eq.) in THF (17 mL.) quickly dropwise via syringe. The mixture was stirred 5 minutes at -78°C. The cooling bath was removed and the reaction was allowed to warm to room temperature. The reaction mixture was poured into a separatory funnel containing ice water and extracted 4x with CH₂Cl₂. The organic extracts were combined, dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. The residue was triturated

- 233 -

with Et₂O. The solids were filtered off. The filtrate was concentrated in vacuo. giving 1.28g. brown oil. ¹H NMR analysis of the residue indicates material is a mixture of approximately 1:2 desired tri(1,3-dimethylindol-5-yl)bismuthine:
5 dimethylindole. Material was used crude in subsequent Step D.

Step D: 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1,3-dimethylindol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,-27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone
10 To a stirred solution of tri(1,3-dimethylindol-5-yl)bismuthine (approximately 420 mg. [based on 1.28 g. of material containing one third bismuthine, .7 mmol., 1.2 eq.) in CH₂Cl₂ (12 mL.) and THF (4 mL.) was added peracetic acid (0.193 mL. of a 32% solution in acetic acid, 0.916 mmol., 1.3 eq.). To this
15 mixture was added 17-ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (464 mg., 0.59 mmol., 1 eq.) followed by
20 addition of Cu(OAc)₂ (30mg., 0.176 mmol., 0.3 eq.). The mixture was stirred 4 days. The reaction was quenched with saturated aqueous NaHCO₃ and extracted 4x with CH₂Cl₂. The organic extracts were combined, dried over anhydrous Na₂SO₄, filtered and
25 concentrated in vacuo. The product was purified by
30

- 234 -

flash column chromatography (2:1 hexanes/acetone) and again (3.5% CH₃OH/CH₂Cl₂) followed by preparative TLC (eluted 6x with 4:1 hexanes/acetone) giving 117 mg. of 17-ethyl-1,14-dihydroxy-12-[2'-(4''-(1,3-dimethyl-
5 indol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone.

Mass (FAB) 934 (M⁺).

10 Partial ¹H NMR (CDCl₃, 400 MHz) δ: 7.14-7.10 (m, 2H); 6.91 (dd, J=9Hz, J=2Hz, 1H); 6.76 (s, 1H); 4.57 (d, J=6Hz, 1H); 4.39 (bd, J=13Hz, 1H); 3.66 (s, 3H); 2.24 (s, 3H).

15

EXAMPLE 52

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-benzylindol-5-yl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatri-
20 cyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a stirred solution of tri(1-benzylindol-5-yl)bismuthine (1.28g., 1.54 mmol., 1.2eq.) in CH₂Cl₂ (9 mL.) and THF (3 mL.) was added peracetic acid (0.357 mL. of a 32% solution in dilute acetic
25 acid, 1.69 mmol., 1.3 eq.). To this mixture was added 17-ethyl-1,14-dihydroxy-12-[2'-(3'',4''-dihydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (1g.,
30 1.28 mmol., 1 eq.) followed by addition of Cu(OAc)₂ (23 mg.). The mixture was stirred 2 days. The

- 235 -

reaction was quenched with saturated aqueous NaHCO_3 and extracted 4x with CH_2Cl_2 . The organic extracts were combined, dried over anhydrous Na_2SO_4 , filtered and concentrated in vacuo. The product was purified

5 by flash column chromatography on silica gel (2:1 hexanes/acetone) and again (3.5% $\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$) and again (2:1 hexanes/acetone) giving 253 mg.

17-ethyl-1,14-dihydroxy-12-[2'-(4''-(1-benzylindol-5-yl)-oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo
10 [22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone.

Mass (FAB) 990($\text{M}^+ + \text{Li}$)..

Partial ^1H NMR (CDCl_3 , 400MHz): 7.30-7.05 (m, 8H);

6.82 (dd, $J=2\text{Hz}$, $J=8\text{Hz}$, 1H); 6.43 (d, $J=3\text{Hz}$, 1H);

15 5.27 (s, 2H); 4.58 (d, $J=6\text{Hz}$, 1H); 4.40 (bd, $J=13\text{ Hz}$, 1H).

EXAMPLE 53

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-(3-hydroxy-propyl)indol-6-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-
20 2.3.10.16-tetraone

25 Step A: 2-t-Butyldimethylsilyloxyethyl bromide

To a solution of 2-bromoethanol (50 g, 0.40 mol) in CH_2Cl_2 (50 mL) was added t-butyldimethylchlorosilane (63.4 g, 0.42 mol), triethylamine (45.4 g, 0.45 mol) and
30 dimethylaminopyridine (0.5 g). After stirring overnight the reaction mixture was washed 3X with water. The organic fraction was dried with Na_2SO_4 , filtered, and concentrated in vacuo to provide 85 g

- 236 -

of the title compound as a light yellow oil.

^1H NMR (CDCl_3) δ : 3.85 (t, 2H); 3.36 (t, 2H); 0.86 (s, 9H); 0.05 (s, 6H).

5 Step B: 1-(2-Butyldimethylsilyloxyethyl)-5-bromoindole

To a slurry of sodium hydride (12 g, 0.3 mol, 60% dispersion in oil) in DMF (200 mL) was added dropwise a solution of 5-bromoindole (50 g, 0.255 mol) in DMF (300 mL). After stirring for 15 minutes 2-t-butyldimethylsilyloxyethyl bromide (60 g, 0.255 mol, neat) was added dropwise and the reaction mixture stirred for 1 hour. The reaction mixture was partitioned between ice water and ethyl ether. The organic fraction was washed with water, dried over Na_2SO_4 , filtered and concentrated in vacuo. The product was purified by column chromatography (silica, 3:1 hexane/acetone) to give 68.6 g of the title compound as a light yellow oil.

20 ^1H NMR (CDCl_3) δ : 7.72 (s, 1H); 7.1-7.3 (m, 3H); 6.4 (d, 1H); 4.18 (t, 2H); 3.86 (t, 2H); 0.8 (s, 9H); -0.18 (s, 6H).

25 Step C: 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-(3-t-butyldimethylsilyloxypropyl)indol-6-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,-25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22,3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

30 To a solution of tri[1-(3-t-butyldimethylsilyloxypropyl)-indol-6-yl]bismuthine (0.917 gm, crude) in CH_2Cl_2 (7 mL) at room temperature was added peracetic acid (0.10 mL, 32% in acetic acid) followed

- 237 -

in 15 minutes by 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (500 mg, . 0.63 mmol) and Cu(OAc)₂ (50 mg). The reaction mixture was stirred for 2 days. The reaction was then quenched with saturated NaHCO₃ and the mixture extracted with CH₂Cl₂. The organic extracts were combined, dried over Na₂SO₄, filtered, and concentrated in vacuo. The product was isolated and purified by preparative TLC on silica gel (3:1, hexane/acetone) to give 318 mg of the title compound.

15 Step D: 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-(3-hydroxypropyl)indol-6-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22,3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

20 To a solution of 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-(3-t-butyldimethylsilyloxypropyl)indol-6-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (318 mg) in CH₂Cl₂ (5 mL) at rt was added a solution of p-toluene sulfonic acid (25 mg) in CH₃OH (5 mL). The reaction mixture was stirred for 3 hours quenched with saturated NaHCO₃, then extracted with

30

- 238 -

CH₂Cl₂. The extracts were combined, dried over Na₂SO₄, filtered and concentrated in vacuo. The product was purified by preparative TLC on silica gel (2:1, hexane/acetone) to give 190 mg of the title compound.

Partial ¹H NMR (CDCl₃, 200 MHz) δ: 7.43 (d, J=9 Hz, 1H); 7.02 (d, J=2 Hz, 1H); 6.98 (d, J=3 Hz, 1H); 6.78 (dd, J=2 Hz and J=9 Hz, 1H); 6.38 (d, J=3 Hz, 1H); 4.20 (t, J=6.5 Hz, 2H); 2.00 (m, 2H).

EXAMPLE 54

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-((2''''-(3''''-diethylaminopropionyloxy)ethyl)indol-5''''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a stirred solution of 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1''''-(2''''-hydroxyethyl)indol-5''''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (200mg., 0.210 mmol., 1 eq.) in CH₂Cl₂ (2 mL.) under nitrogen was added 3-N,N-diethylamino-propionic acid hydrochloride (57 mg., 0.315 mmol., 1.5 eq.), dimethylaminopyridine (26 mg., 0.210 mmol., 1 eq.) and EDC (60 mg., 0.315 mmol., 1.5 eq.). The reaction was stirred for 1 hour. The mixture was diluted with ethyl acetate, washed with 1N aq. HCl, saturated aqueous NaHCO₃ and then brine. The organic layer was dried over anhydrous MgSO₄, filtered and concentrated in vacuo. The product was purified by

- 239 -

flash column chromatography (3:2 hexanes/acetone) to give 194 mg. 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2'''-(3''''-diethylaminopropionyloxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23, 25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone. Mass (FAB) 1079 (M⁺+ 1).

EXAMPLE 55

10

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2'''-(3''''-dimethylaminopropionyloxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
15 [22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

The title compound is prepared in the manner of Example 54 employing 3-N,N-dimethylamino-propionic acid.

20

EXAMPLE 56

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2'''-(3''''-aminopropionyloxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
25 13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

The title compound is prepared in the manner of Example 54 employing 3-aminopropionic acid in suitably protected form followed by deprotection
30 of the amino group.

- 240 -

EXAMPLE 57

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2'''-(3''''-benzyloxycarbonyl-2''''-benzyloxycarbonylamino-
 5 propionyloxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-
octacos-18-ene-2,3,10,16-tetraone

To a stirred solution of 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-hydroxyethyl)indol-
 10 5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (500mg., 0.526 mmol., 1 eq.) in CH₂Cl₂ (5
 15 mL.) under nitrogen was added N-Cbz-aspartic acid -β-benzyl ester (225 mg., 0.631 mmol., 1.2 eq.), dimethyl-aminopyridine (64 mg., 0.526 mmol., 1 eq.) and EDC (120 mg., 0.631 mmol., 1.2 eq.). The reaction was stirred for 2 hours. TLC analysis
 20 indicated reaction complete. The mixture was diluted with ethyl acetate, washed with 1N aq. HCl, saturated aqueous NaHCO₃ and then brine. The organic layer was dried over anhydrous MgSO₄, filtered and concentrated in vacuo. The product was purified by flash column
 25 chromatography (70:30 hexanes/acetone) to give 687 mg 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2'''-(3''''-benzyloxycarbonyl-2''''-benzyloxycarbonyl-aminopropionyloxy)ethyl)indol-5'''-yl)oxy-3''-methoxy-cyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,
 30 27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-octacos-18-ene-2,3,10,16-tetraone.

- 241 -

EXAMPLE 58

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2'''-(aspartyl-
oxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-
5 methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-
11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-
2,3,10,16-tetraone

To a solution of 17-Ethyl-1,14-dihydroxy-
12-[2'-(4''-(2'''-(3''''-benzyloxycarbonyl-2''''-
10 benzyloxy-carbonylamino propionyloxy)ethyl)indol-5'''-
yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-
dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
15 tetraone (125 mg. 0.093 mmol., 1 eq.) in methanol (2
mL.) was added palladium hydroxide on carbon (25
mg.). The flask was charged with hydrogen and
allowed to stir for 30 minutes. The reaction was
filtered through a 0.45 µm PTFE membrane and
concentrated in vacuo. The product was purified by
20 flash column chromatography (100:10:5:0.5 / CHCl₃:
MeOH:formic acid:H₂O) to give 95 mg
17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2'''-(
(aspartyl)oxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclo-
hexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-
25 tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-
octacos-18-ene-2,3,10,16-tetraone. Mass (FAB) 1067
(M⁺).

- 242 -

EXAMPLE 59

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2'''-(1''''-imidazolylcarbonyloxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a stirred solution of 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2'''-hydroxyethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (1.5 g., 1.58 mmol., 1 eq.) in CH₂Cl₂ (15 mL.) under nitrogen was added carbonyl diimidazole (256 mg., 1.58 mmol., 1 eq.). After 45 minutes the reaction mixture was diluted with ethyl acetate, washed with 1N aq. HCl and then brine. The organic layer was dried over anhydrous MgSO₄, filtered and concentrated in vacuo. The residue was used without further purification

EXAMPLE 60

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2'''-(1''''-piperazinocarbonyloxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a stirred solution of 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2'''-(1''''-imidazolyl-

- 243 -

carbonyloxy)ethyl)-indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methyl-vinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-octacos-18-ene-2,3,10,16-tetraone (100 mg., 0.096 mmol., 1 eq.) in THF (1 mL.) at room temperature under nitrogen was added piperazine (82 mg., 0.956 mmol., 10 eq.). The mixture was stirred for 2 hours at room temperature, stored overnight in freezer then stirred for an additional 6 hours at room temperature. The reaction was diluted with ethyl acetate, washed with 1N HCl, saturated NaHCO₃, and brine. The product was purified by flash column chromatography on silica gel (5% methanol/CH₂Cl₂ and then 5% methanol/CH₂Cl₂ plus 1% NH₄OH) to give 74 mg. Mass (FAB) 1064 (M⁺+1).

EXAMPLE 61

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-(2''''-(2''''-hydroxy)ethylaminocarbonyloxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a stirred solution of 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-(1''''-imidazolyl-carbonyloxy)-ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (100 mg., 0.096 mmol., 1 eq.) in THF (1 mL.) at room temperature under nitrogen was added ethanolamine (29 μ L., 0.478

- 244 -

mmol., 5 eq.). The reaction was stirred for 30 minutes at room temperature. The reaction was diluted with ethyl acetate, washed with 1N HCl, saturated NaHCO₃, and brine. The product was
 5 purified by flash column chromatography on silica gel (45/65 acetone/hexanes) to give 50 mg. 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-(2'''''-hydroxy)-ethylaminocarbonyloxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
 10 13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone. Mass (FAB) 1061 (M⁺+Na); 1038 (M⁺+1).

EXAMPLE 62

15

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-(1'''''-imidazolyl-carbonyloxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
 20 13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a stirred solution of 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-(1'''''-imidazolyl-carbonyloxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-
 25 tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-octacos-18-ene-2,3,10,16-tetraone (116 mg., 0.111 mmol., 1 eq.) in THF (1 mL.) at room temperature under nitrogen was added isopropylamine (48 µL., 0.555 mmol., 5 eq.). The reaction was stirred for
 30 overnight. The reaction was diluted with ethyl acetate, washed with 1N HCl and brine. The product

- 245 -

was purified by flash column chromatography on silica gel (2:3 acetone/hexanes) to give 50 mg. 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-(isopropylamino-carbonyloxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-octacos-18-ene-2,3,10,16-tetraone. Mass (FAB) 1043 (M⁺+Li).

10

EXAMPLE 63

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-(1''''''-piperidinocarbonyloxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a stirred solution of 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-(1''''''-imidazolyl-carbonyloxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-octacos-18-ene-2,3,10,16-tetraone (150 mg., 0.143 mmol., 1 eq.) in THF (1 mL.) at room temperature under nitrogen was added piperidine (42 μ L., 0.717 mmol., 5 eq.). The reaction was stirred 1 hour. The reaction was diluted with ethyl acetate, washed with 1N HCl and brine. The product was purified by flash column chromatography on silica gel (4:1 hexanes/acetone) to give 115 mg. 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-(1''''''-piperidinocarbonyl-

- 246 -

oxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone. Mass (FAB) 1062 (M⁺).

5

EXAMPLE 64

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-(1''''''-morphilinocarbonyloxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a stirred solution of 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-(1''''''-imidazolyl-carbonyloxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-octacos-18-ene-2,3,10,16-tetraone (100 mg., 0.096 mmol., 1 eq.) in THF (1 mL.) at room temperature under nitrogen was added morphiline (42 μ L., 0.478 mmol., 5 eq.). The reaction was stirred 4 hours. The reaction was diluted with ethyl acetate, washed with 1N HCl, saturated aqueous NaHCO₃ and brine. The product was purified by preparative TLC on silica gel (4% MeOH/CH₂Cl₂) to give 85 mg. product. The compound was further purified by preparative TLC on silica gel (4% MeOH/CH₂Cl₂) to give 67 mg. 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-(1''''''-morphilinocarbonyloxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone. Mass (FAB) 1064 (M⁺).

- 247 -

EXAMPLE 65

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-(
 (diphenylaminocarbonyloxy)ethyl)indol-5'''-yl)oxy-3''-
 5 methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
 13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a stirred solution of 17-Ethyl-1,14-
 dihydroxy-12-[2'-(4''-(1'''-(2''''-hydroxyethyl)indol-
 10 5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,
 25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
 azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
 tetraone (100mg., 0.105 mmol., 1 eq.) in CH₂Cl₂ (1
 mL.) under nitrogen was added diphenylcarbamy1-
 15 chloride (29 mg., 0.13mmol., 1.2 eq.), triethylamine
 (22μL., 0.16 mmol., 1.5 eq.) and dimethylamino-
 pyridine (3mg., 0.021 mmol., 0.2 eq.). The reaction
 was stirred overnight. More diphenylcarbamy1chloride
 (15 mg.) and triethylamine (11μL.) were added. After
 20 3 hours the reaction mixture was diluted with ethyl
 acetate, washed with 1N aq. HCl, water and then
 brine. The organic layer was dried over anhydrous
 MgSO₄, filtered and concentrated in vacuo. The
 product was purified by preparative TLC (3% MeOH/
 25 CH₂Cl₂) to give 50 mg. 17-Ethyl-1,14-dihydroxy-12-
 [2'-(4''-(1'''-(2''''-(diphenylaminocarbonyloxy)ethyl)-
 indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methyl-
 vinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-
 dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,
 30 16-tetraone. Mass (FAB) 1046 (M⁺).

- 248 -

EXAMPLE 66

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-(
 (diethylaminocarbonyloxy)ethyl)indol-5'''-yl)oxy-3''-
 5 methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
 13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
 [22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a stirred solution of 17-Ethyl-1,14-
 dihydroxy-12-[2'-(4''-(1'''-(2''''-hydroxyethyl)indol-
 10 5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,
 25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
 azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
 tetraone (100mg., 0.105 mmol., 1 eq.) in CH₂Cl₂ (1
 mL.) under nitrogen was added diethylcarbamylochloride
 15 (16 μ L., 0.13 mmol., 1.2 eq.), triethylamine (22 μ L.,
 1.5 eq.), and dimethylaminopyridine (13 mg., 1.0
 eq.). The reaction was stirred overnight. The
 mixture was heated and maintained at reflux for 4
 days. The mixture was cooled, diluted with ethyl
 20 acetate, washed with 1N aq. HCl and then brine. The
 organic layer was dried over anhydrous MgSO₄,
 filtered and concentrated in vacuo. The product was
 purified by preparative TLC (3% MeOH/ CH₂Cl₂) to give
 25 16 mg. 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(
 (2''''-(diethylaminocarbonyloxy)ethyl)indol-5'''-yl)-
 oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-
 dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
 azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
 tetraone. Mass (FAB) 1057 (M⁺+Li).

30

- 249 -

EXAMPLE 67

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-methanesulfonyloxyethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-octacos-18-ene-2,3,10,16-tetraone

To a stirred solution of 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-hydroxyethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (500mg., 0.526 mmol., 1 eq.) in CH₂Cl₂ (20 mL.) under nitrogen at 0°C was added triethylamine (147μL., 1.053 mmol., 2 eq.), followed by methanesulfonylchloride (54μL., 0.579 mmol., 1.1 eq.). The reaction was stirred 10 minutes and the cooling bath was removed. The reaction was stirred at room temperature for three hours. The mixture was stored in the freezer overnight. The solvent was removed in vacuo. The product was used without purification

EXAMPLE 68

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-azidoethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a stirred solution of 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-methanesulfonyloxyethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-

- 250 -

methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-
 11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2
 ,3,10,16-tetraone (0.526 mmol., 1 eq.) in DMF (10
 mL.) under nitrogen was added sodium azide (171 mg.,
 5 2.63 mmol., 5 eq.). The reaction was heated to 60°C
 for 2 hours. The solvent was removed in vacuo. The
 residue was diluted with ethyl acetate and washed
 with brine. The aqueous layer was extracted 3x with
 ethyl acetate. The organic extracts were dried over
 10 anhydrous MgSO₄, filtered and concentrated in vacuo.
 The product was purified by flash column
 chromatography on silica gel (2:1 hexanes/acetone)
 giving 310 mg. 17-Ethyl-1,14-dihydroxy-12-[2'-(4"-
 (1'''-(2''''-azidoethyl)indol-5'''-yl)oxy-3"-methoxy-
 15 cyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,
 27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-
 octacos-18-ene-2,3,10,16-tetraone. Mass (FAB) 975
 (M⁺).

20

EXAMPLE 69

17-Ethyl-1,14-dihydroxy-12-[2'-(4"-(1'''-(2''''-amino-
 ethyl)indol-5'''-yl)oxy-3"-methoxycyclohexyl)-1'-
 methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-
 25 11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-
2,3,10,16-tetraone

To a stirred solution of 17-Ethyl-1,14-
 dihydroxy-12-[2'-(4"-(1'''-(2''''-azidoethyl)indol-
 5'''-yl)oxy-3"-methoxycyclohexyl)-1'-methylvinyl]-23,
 30 25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
 azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-

- 251 -

tetraone (260 mg., 0.27 mmol., 1 eq.) in THF (6 mL.) was added water (7 drops) followed by triphenylphosphine (87 mg., .33 mmol., 1.25 eq.). The reaction was stirred at room temperature for 16 hours. The solvent was removed in vacuo. The product was purified by flash column chromatography on silica gel (10% MeOH/CH₂Cl₂) giving 227 mg. 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2'''-aminoethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23, 25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone. Mass (FAB) 956(M⁺+ Li).

EXAMPLE 70

15

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-t-butyl-dimethylsilyloxyethoxyethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-octacos-18-ene-2,3,10,16-tetraone

20

To a solution of tri[1-(2-t-butyl-dimethylsilyloxy-ethoxyethyl)-indol-5-yl] bismuthine (360 mg., 0.31 mmol.) in CH₂Cl₂ (3mL.) at rt was added peracetic acid (0.05 mL., 32% in acetic acid) followed in 10 minutes by 17-Ethyl-1,14-dihydroxy-12-[2'-(3'',4''-dihydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]-octacos-18-ene-2,3,10,16-tetraone (200mg, 0.25 mmol) and Cu(OAc)₂ (20 mg.). The reaction mixture was stirred for 18 hrs. The reaction

30

- 252 -

was then quenched with saturated NaHCO_3 and extracted with CH_2Cl_2 . The organic extracts were combined, dried with Na_2SO_4 , filtered and concentrated in vacuo. The product was isolated and purified by preparative TLC (3:1, hexane/acetone) to afford 120 mg. of the title compound as a dark oil.

EXAMPLE 71

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-hydroxyethoxyethylindol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a solution of 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-t-butyldimethylsilyloxyethoxy-ethylindol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (120mg) in CH_2Cl_2 (3 mL.) at rt was added a solution of p-toluene sulfonic acid (20 mg.) in CH_3OH (3 mL.). The reaction mixture was stirred for 3 hr., quenched with saturated NaHCO_3 , then extracted with CH_2Cl_2 . The extracts were combined, dried over Na_2SO_4 , filtered and concentrated in vacuo. The product was purified by preparative TLC on silica gel (2:1, hexane/acetone) to give 51 mg of the title compound. Partial ^1H NMR (CDCl_3 , 200 MHz) δ : 7.19 (d, J=9Hz, 1H); 7.17 (d, J=2

30

- 253 -

Hz, 1H); 7.08 (d, J=3.5 Hz, 1H); 6.89 (dd, J=2 and J=9 Hz, 1H); 6.34 (d, J=3.5 Hz, 1H); 4.22 (t, J=5 Hz, 2H); 3.73 (t, J=5 Hz, 2H); 3.57 (t, J=5 Hz, 2H); 3.39 (t, J=5 Hz, 2H).

5

EXAMPLE 72

17-Ethyl-1,14-dihydroxy-12-[2'-(3''-methoxy-4''-(1'''-(1'''-oxoprop-3'''-yl)indol-5'''-yl)oxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone

To a solution of 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(3'''-hydroxypropyl)indol-5'''-yl)-oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone (700 mg., 0.726 mmol.) in CH₂Cl₂ (25 mL) was added DMSO (2 mL.) and diisopropylethylamine (3.7 mL.) followed by pyridine sulfur trioxide (650 mg., 4.1 mmol.). The mixture was stirred for 20 min. then poured into saturated aqueous NaHCO₃. The product was extracted into CH₂Cl₂ which was then dried with Na₂SO₄, filtered, and concentrated in vacuo. The product was purified by column chromatography (silica gel, 4:1 hexane/acetone) to give 457mg. of the title compound. Partial ¹H NMR (CDCl₃, 200 MHz) δ: 9.77 (s, 1H); 7.19 (d, J=2Hz, 1H); 7.15 (d, J=9 Hz, 1H); 7.04 (d, J=3.5 Hz, 1H); 6.89 (dd, J=2 and J=9 Hz, 1H); 6.33 (d, J=3.5 Hz, 1H); 4.39 (t, J=5 Hz, 2H); 2.94 (t, J=5 Hz, 2H).

- 254 -





EXAMPLE 73






17-Ethyl-1,14-dihydroxy-12-[2'-(3''-methoxy-4''-(1'''-(1'''-carboxyeth-2'''-yl)indol-5'''-yl)oxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-octacos-18-ene-2,3,10,16-tetraone

To a stirred solution of 17-Ethyl-1,14-dihydroxy-12-[2'-(3''-methoxy-4''-(1'''-(1'''-oxoprop-3'''-yl)indol-5'''-yl)oxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-octacos-18-ene-2,3,10,16-tetraone (100 mg.), 5-bromoindole (300 mg.) and 2-methyl-2-butene (0.80 mL.) in t-butanol (4mL.) was added a solution of sodium chlorite (15 mg.) and sodium dihydrogen phosphate (15 mg.) in water (0.15 mL.). The reaction mixture was stirred for 0.5 hr. then concentrated in vacuo. The residue was partitioned between 10 ml. water containing 2 drops of 2N HCl and diethyl ether. The organic extract was dried with Na₂SO₄, filtered, and concentrated in vacuo. The product was purified by preparative TLC 2X first with 2:1 hexane/acetone then 7% CH₃OH in CH₂Cl₂ and finally flash column chromatography on C₁₈ column packing with 60% CH₃CN in water to give 11 mg. of the title compound. Mass (FAB) 1001 (M+ Na).

Utilizing the general procedures described in Examples 1 to 73, the following compounds of Formula I (wherein R⁴ is hydrogen, R⁵ is methyl, ethyl, propyl or allyl; R¹⁰ is hydrogen and n is 2) are prepared from the appropriately substituted starting materials and reagents.

- 255 -

EXAMPLE NO.	R ¹	R ²	R ³	R ⁵
74		H	OH	CH ₃ CH ₂
75		CH ₃	OH	CH ₃ CH ₂
76		CH ₃	OH	CH ₃ CH ₂
77		CH ₃	OH	CH ₃ CH ₂

EXAMPLE NO.	R ¹	R ²	R ³	R ⁵
5 78		CH ₃	OH	CH ₃ CH ₂
10 79		CH ₃	OH	CH ₃ CH ₂
15 80		CH ₃	OH	CH ₃ CH ₂
20 81		CH ₃	OH	CH ₃ CH ₂
25 82		CH ₃	OH	CH ₃ CH ₂
30				

- 257 -

EXAMPLE 83T-Cell Proliferation Assay1. Sample Preparation

5 The compounds to be assayed were dissolved
in absolute ethanol at 1 mg/ml.

2. Assay

10 Spleens from C57B1/6 mice were taken under
sterile conditions and gently dissociated in ice-cold
RPMI 1640 culture medium (GIBC), Grand Island, N. Y.)
supplemented with 10% heat-inactivated fetal calf
serum (GIBO)). Cells were pelleted by centrifugation
15 at 1500 rpm for 8 minutes. Contaminating red cells
were removed by treating the pellet with ammonium
chloride lysing buffer (GIBO)) for 2 minutes at 4°C.
Cold medium was added and cells were again
centrifuged at 1500 rpm for 8 minutes. T lymphocytes
20 were then isolated by separation of the cell
suspension on nylon wool columns as follows: Nylon
wool columns were prepared by packing approximately 4
grams of washed and dried nylon wool into 20 ml
plastic syringes. The columns were sterilized by
autoclaving at 25°F for 30 minutes. Nylon wool
25 columns were wetted with warm (37°C) culture medium
and rinsed with the same medium. Washed spleen cells
resuspended in warm medium were slowly applied to the
nylon wool. The columns were then incubated in an
upright position at 37°C for 1 hour. Non-adherent T
30 lymphocytes were eluted from the columns with warm
culture medium and the cell suspensions were spun as
above..

- 258 -

Purified T lymphocytes were resuspended at 2.5×10^5 cells/ml in complete culture medium composed of RPMI 1640 medium with 10% heat-inactivated fetal calf serum, 100 mM glutamine, 1 mM sodium pyruvate, 2×10^{-5} M 2-mercaptoethanol and 50 μ g/ml gentamycin. Ionomycin was added at 250 ng/ml and PMA at 10 ng/ml. The cell suspension was immediately distributed into 96 well flat-bottom microculture plates (Costar) at 200 μ l/well. The various dilutions of the compound to be tested were then added in triplicate wells at 20 μ l/well. The compound 17-allyl-1,14-dihydroxy-12-[2'-(4'-hydroxy-3'-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone was used as a standard. The culture plates were then incubated at 37°C in a humidified atmosphere of 5% CO₂-95% air for 44 hours. The proliferation of T lymphocytes was assessed by measurement of tritiated thymidine incorporation. After 44 hours of culturing, the cells were pulse-labelled with 2 μ Ci/well of tritiated thymidine (NEN, Cambridge, MA). After another 4 hours of incubation, cultures were harvested on glass fiber filters using a multiple sample harvester. Radioactivity of filter discs corresponding to individual wells was measured by standard liquid scintillation counting methods (Betacounter). Mean counts per minute of replicate wells were calculated and the results expressed as concentration of compound required to inhibit tritiated thymidine uptake of T-cells by 50%.

- 259 -

A selection of compounds were tested according to the previous procedure. The title compounds of the following Examples had activity in inhibiting the proliferation of T-cells in the
5 aforementioned assay: 1,2,3,4,5,6,7,8,9,10,11,12,13, 14,15,16,17,18,19,20,21,23,26,28,31,32,33,34, 35, 37, 39, 42, 44, 46, 47, 48, 49, 50, 51, 52, 53, 54, 57, 58, 60, 61, 62, 63, 64, 65, 66, 69, 71, 72 and 73.

The results of this assay are representative
10 of the intrinsic immunosuppressive activity of the compounds of the present invention.


For determining antagonist activity, the foregoing procedure is modified in that dilutions of compounds are cultured with 17-allyl-1,14-dihydroxy-
15 12-[2'-(4"-hydroxy-3"-methoxycyclohexyl)-1'-methyl-vinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10, 16-tetraone (as a standard) at a concentration of 1.2 nM, a concentration which inhibits T cell proliferation by 100%, the concentration of compound
20 required to reverse the inhibition obtained by the standard alone by 50% is measured, and the ED₅₀ value is determined.

While the foregoing specification teaches
25 the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the casual variations, adaptations, modifications, deletions, or additions of procedures
30 and protocols described herein, as come within the scope of the following claims and its equivalents.

- 260 -

WHAT IS CLAIMED IS:

1. A compound of Formula I:



I

or a pharmaceutically acceptable salt thereof,
wherein:

25 R^1 is selected from:

- (1) heteroaryl;
- (2) substituted heteroaryl in which the substituents are X, Y and Z;
- (3) heteroaryl- C_{1-10} alkyl;
- 30 (4) substituted heteroaryl- C_{1-10} alkyl in which the heteroaryl group is substituted by X, Y and Z and the alkyl portion may be substituted with one or more of the substituent(s) selected from:

- 261 -

- (a) hydroxy,
(b) oxo,
(c) C₁₋₆-alkoxy,
(d) aryl-C₁₋₃alkoxy,
5 (e) substituted aryl-C₁₋₃alkoxy, in which
the substituents on aryl are X, Y and Z,
(f) unsubstituted or substituted aryloxy,
in which the substituents on aryl are
X, Y and Z,
10 (g) -OCO-C₁₋₆alkyl,
(h) -NR⁶R⁷, wherein R⁶ and R⁷ are
independently selected from
(i) hydrogen,
(ii) C₁₋₁₀alkyl unsubstituted or
15 substituted with one or more of
the substituent(s) selected from:
(a') aryl, which is unsubstituted
or substituted with X, Y and
Z,
20 (b') heteroaryl, which is
unsubstituted or substituted
with X, Y and Z,
(c') -OH,
(d') C₁₋₆alkoxy,
25 (e') -CO₂H,
(f') -CO₂-C₁₋₆alkyl,
(g') -C₃₋₇cycloalkyl, and
(h') -OR¹¹,
(iii) C₃₋₁₀alkenyl unsubstituted or
30 substituted with one or more of
the substituent(s) selected from:

- 262 -

- (a') aryl, which is unsubstituted or substituted with X, Y and Z,
- (b') heteroaryl, which is unsubstituted or substituted with X, Y and Z,
- (c') -OH,
- (d') C₁₋₆alkoxy,
- (e') -CO₂H,
- (f') -CO₂-C₁₋₆alkyl,
- (g') -C₃₋₇cycloalkyl, and
- (h') -OR¹¹,
- (iv) or where R⁶ and R⁷ and the N to which they are attached may form an unsubstituted or substituted 3-7-membered heterocyclic ring which may include one or two additional heteroatoms independently selected from the group consisting of O, S(O)_p, NR¹⁴, wherein R¹⁴ is hydrogen or C₁₋₆ alkyl unsubstituted or substituted by phenyl, and p is 0, 1 or 2,
- (i) -NR⁶CO-C₁₋₆alkyl-R⁷, wherein R⁶ and R⁷ are as defined above,
- (j) -NR⁶CO₂-C₁₋₆alkyl-R⁷,
- (k) -NR⁶CONR⁶R⁷,
- (l) -OCONR⁶R⁷,
- (m) -COOR⁶,
- (n) -CHO,
- (o) aryl,

- 263 -

- (p) substituted aryl in which the substituents are X, Y and Z,
(q) $-OR^{11}$, and
(r) $-S(O)_p-C_{1-6}alkyl$;
5 (5) heteroaryl- $C_{1-10}alkyl$ wherein one or more of the alkyl carbons is replaced by a group selected from: $-NR^6-$, $-O-$, $-S(O)_p-$, $-CO_2-$, $-O_2C-$, $-CONR^6-$, $-NR^6CO-$, $-NR^6CONR^7-$;
10 (6) substituted heteroaryl- $C_{1-10}alkyl$ wherein one or more of the alkyl carbons is replaced by a group selected from: $-NR^6-$, $-O-$, $-S(O)_p-$, $-CO_2-$, $-O_2C-$, $-CONR^6-$, $-NR^6CO-$, and $-NR^6CONR^7-$, the heteroaryl group is substituted with X, Y, and Z, and the alkyl group may be substituted with one or more of the substituent(s) selected from:
15 (a) hydroxy,
20 (b) oxo,
(c) $C_{1-6}alkoxy$,
(d) aryl- $C_{1-3}alkoxy$,
(e) substituted aryl- $C_{1-3}alkoxy$, in which
25 the substituents on aryl are X, Y and Z,
(f) unsubstituted or substituted aryloxy, in which the substituents on aryl are X, Y and Z,
(g) $-OCO-C_{1-6}alkyl$,
30 (h) $-NR^6R^7$, wherein R^6 and R^7 are as defined above,
(i) $-NR^6CO-C_{1-6}alkyl-R^7$,
(j) $-NR^6CO_2-C_{1-6}alkyl-R^7$.

- 264 -

- (k) $-\text{NR}^6\text{CONR}^6\text{R}^7$,
(l) $-\text{OCONR}^6\text{R}^7$,
(m) $-\text{COOR}^6$,
(n) $-\text{CHO}$,
5 (o) aryl,
(p) substituted aryl in which the
substituents are X, Y and Z,
(q) $-\text{OR}^{11}$, and
(r) $-\text{S(O)}_p\text{-C}_{1-6}\text{alkyl}$;
10 (7) heteroaryl- C_{3-10} alkenyl wherein alkenyl
contains one to four double bonds;
(8) heteroaryl- C_{3-10} alkenyl wherein alkenyl
contains one to four double bonds and
wherein one or more of the alkyl carbons is
15 replaced by a group selected from: $-\text{NR}^6-$,
 $-\text{O}-$, $-\text{S(O)}_p-$, $-\text{CO}_2-$, $-\text{O}_2\text{C}-$, $-\text{CONR}^6-$,
 $-\text{NR}^6\text{CO}-$, and $-\text{NR}^6\text{CONR}^7-$;
(9) substituted heteroaryl- C_{3-10} alkenyl wherein
alkenyl contains one to four double bonds
20 and wherein one or more of the alkyl carbons
may be replaced by a group selected from:
 $-\text{NR}^6-$, $-\text{O}-$, $-\text{S(O)}_p-$, $-\text{CO}_2-$, $-\text{O}_2\text{C}-$, $-\text{CONR}^6-$,
 $-\text{NR}^6\text{CO}-$, and $-\text{NR}^6\text{CONR}^7$, the heteroaryl group
is substituted with X, Y, and Z, and the
25 alkyl group may be substituted with one or
more of the substituent(s) selected from:
(a) hydroxy,
(b) oxo,
(c) C_{1-6} alkoxy,
30 (d) aryl- C_{1-3} alkoxy,
(e) substituted aryl- C_{1-3} alkoxy, in which
the substituents on aryl are X, Y and Z,

- 265 -

- (f) unsubstituted or substituted aryloxy,
in which the substituents on aryl are
X, Y and Z,
- (g) $-\text{OCO}-\text{C}_{1-6}\text{alkyl}$,
- 5 (h) $-\text{NR}^6\text{R}^7$, wherein R^6 and R^7 as defined
above,
- (i) $-\text{NR}^6\text{CO}-\text{C}_{1-6}\text{alkyl}$, wherein R^6 is as
defined above,
- (j) $-\text{NR}^6\text{CO}_2-\text{C}_{1-6}\text{alkyl}$,
- 10 (k) $-\text{NR}^6\text{CONR}^6\text{R}^7$,
- (l) $-\text{OCONR}^6\text{R}^7$,
- (m) $-\text{COOR}^6$,
- (n) $-\text{CHO}$,
- (o) $-\text{aryl}$,
- 15 (p) substituted aryl in which the
substituents are X, Y and Z, and
- (q) $-\text{OR}^{11}$, and
- (r) $-\text{S}(\text{O})_p-\text{C}_{1-6}\text{alkyl}$;

20 R^2 is selected from:

- (1) the definitions of R^1 ;
- (2) hydrogen;
- (3) phenyl;
- (4) substituted phenyl in which the substituents
25 are X, Y and Z;
- (5) 1- or 2-naphthyl;
- (6) substituted 1- or 2-naphthyl in which the
substituents are X, Y and Z;
- (7) biphenyl;
- 30 (8) substituted biphenyl in which the
substituents are X, Y and Z;
- (9) $\text{C}_{1-10}\text{alkyl}$;

- 266 -

(10) substituted-C₁₋₁₀alkyl in which one or more substituent(s) is(are) selected from:

- 5 (a) hydroxy,
(b) oxo,
(c) C₁₋₆alkoxy,
(d) aryl-C₁₋₃alkoxy,
(e) substituted aryl-C₁₋₃alkoxy, in which the substituents on aryl are X, Y and Z,
10 (f) unsubstituted or substituted aryloxy, in which the substituents on aryl are X, Y and Z,
(g) -OCO-C₁₋₆alkyl,
(h) -NR⁶R⁷, wherein R⁶ and R⁷ are as defined above
15 (i) -NR⁶CO-C₁₋₆alkyl-R⁷, wherein R⁶ and R⁷ is as defined above,
(j) -COOR⁶, wherein R⁶ is as defined above,
(k) -CHO,
(l) phenyl,
20 (m) substituted phenyl in which the substituents are X, Y and Z,
(n) 1- or 2-naphthyl,
(o) substituted 1- or 2-naphthyl in which the substituents are X, Y and Z,
25 (p) biphenyl,
(q) substituted biphenyl in which the substituents are X, Y and Z,
(r) -OR¹¹, and
(s) -S(O)_p-C₁₋₆alkyl;
30 (11) C₃₋₁₀alkenyl;
(12) substituted C₃₋₁₀alkenyl in which one or more substituent(s) is(are) selected from:
(a) hydroxy,

- 267 -

- (b) oxo,
(c) C₁₋₆alkoxy,
(d) phenyl-C₁₋₃alkoxy,
(e) substituted phenyl-C₁₋₃alkoxy, in which
5 the substituents on phenyl are
X, Y and Z,
(f) -OCO-C₁₋₆alkyl,
(g) -NR⁶R⁷, wherein R⁶ and R⁷ are as
defined above
10 (h) -NR⁶CO-C₁₋₆alkyl, wherein R⁶ is as
defined above,
(i) -COOR⁶, wherein R⁶ is as defined above,
(j) -CHO,
(k) phenyl,
15 (l) substituted phenyl in which the
substituents are X, Y and Z,
(m) 1- or 2-naphthyl,
(n) substituted 1- or 2-naphthyl in which
the substituents are X, Y and Z,
20 (o) biphenyl,
(p) substituted biphenyl in which the
substituents are X, Y and Z,
(q) -OR¹¹, and
(r) -S(O)_p-C₁₋₆alkyl;
25 (13) C₃₋₁₀alkynyl;
(14) substituted C₃₋₁₀alkynyl in which one or
more substituent(s) is(are) selected from:
(a) hydroxy,
(b) oxo,
30 (c) C₁₋₆alkoxy,
(d) phenyl-C₁₋₃alkoxy,

- 268 -

- (e) substituted phenyl-C₁₋₃alkoxy, in which the substituents on phenyl are X, Y and Z,
- (f) -OCO-C₁₋₆alkyl,
- 5 (g) -NR⁶R⁷, wherein R⁶ and R⁷ are as defined above,
- (h) -NR⁶CO-C₁₋₆alkyl, wherein R⁶ is as defined above,
- (i) -COOR⁶, wherein R⁶ is as defined above,
- 10 (j) -CHO,
- (k) phenyl,
- (l) substituted phenyl in which the substituents are X, Y and Z,
- (m) 1- or 2-naphthyl,
- 15 (n) substituted 1- or 2-naphthyl in which the substituents are X, Y and Z,
- (o) biphenyl,
- (p) substituted biphenyl in which the substituents are X, Y and Z,
- 20 (q) -OR¹¹; and
- (15) -R¹¹;
- R³ is hydrogen, hydroxy, -OR¹¹, or C₁₋₆alkoxy;
- R⁴ is hydrogen, or R³ and R⁴ taken together form a double bond;
- 25 R⁵ is methyl, ethyl, propyl or allyl;
- R¹⁰ is hydrogen, hydroxy, -OR¹¹ or fluoro;
- R¹¹ is selected from:
- (a) -PO(OH)O⁻M⁺, wherein M⁺ is a positively charged inorganic or organic counterion,
- 30 (b) -SO₃⁻M⁺,
- (c) -CO(CH₂)_qCO₂⁻M⁺, wherein q is 1-3, and

- 269 -

- (d) $-\text{CO}-\text{C}_{1-6}\text{alkyl}-\text{NR}^6\text{R}^7$, wherein R^6 and R^7 are as defined above and the alkyl is unsubstituted or substituted with one or more substituents selected from:
- 5 (i) hydroxy,
 - (ii) $\text{C}_{1-6}\text{alkoxy}$,
 - (iii) $-\text{NR}^{16}\text{R}^{17}$, wherein R^{16} and R^{17} are independently selected from:
 - 10 (a') hydrogen, and
 - (b') $\text{C}_{1-6}\text{alkyl}$,
 - (iv) $-\text{COOR}^6$, wherein R^6 is as defined above;
 - (v) phenyl,
 - (iv) substituted phenyl in which the
 - 15 substituents are X, Y and Z,
 - (vii) heteroaryl,
 - (viii) $-\text{SH}$, and
 - (ix) $-\text{S}-\text{C}_{1-6}\text{alkyl}$;
- W is O or (H, OH);
- 20 X, Y and Z independently are selected from:
- (a) hydrogen,
 - (b) $\text{C}_{1-10}\text{alkyl}$, unsubstituted or substituted with one or more substituents selected from:
 - 25 (i) aryl,
 - (ii) substituted aryl in which the substituents are X', Y' and Z',
 - (iii) heteroaryl,
 - (iv) substituted heteroaryl in which
 - 30 the substituents are X', Y', and Z',
 - (v) unsubstituted or substituted aryloxy, in which the substituents

- 270 -

on aryl are X', Y' and Z',

- (vi) $-OR^6$,
- (vii) $-OR^{11}$,
- (viii) $-OCOR^6$,
- (ix) $-OCO_2R^6$,
- (x) $-NR^6R^7$,
- (xi) $-CHO$,
- (xii) $-NR^6COC_{1-6}alkyl-R^7$,
- (xiii) $-NR^6CO_2C_{1-6}alkyl-R^7$,
- (xiv) $-NR^6CONR^6R^7$,
- (xv) $-OCONR^6R^7$,
- (xvi) $-CONR^6R^7$,

(c) $C_{1-10}alkyl$ wherein one or more of the alkyl carbons is replaced by a group selected from $-NR^6-$, $-O-$, $-S(O)_p-$, $-CO_2-$, $-O_2C-$, $-CONR^6-$, $-NR^6CO-$, $-NR^6CONR^7-$, $-CO-$, $-CH(OH)-$, alkenyl or alkynyl and the alkyl may be unsubstituted or substituted with one or more substituents selected from:

- (i) aryl,
- (ii) substituted aryl in which the substituents are X', Y' and Z',
- (iii) heteroaryl,
- (iv) substituted heteroaryl in which the substituents are X', Y', and Z',
- (v) unsubstituted or substituted aryloxy, in which the substituents on aryl are X', Y', and Z',

- (vi) $-OR^6$,
- (vii) $-OR^{11}$,
- (viii) $-OCOR^6$,

- 271 -

- (ix) $-\text{OCO}_2\text{R}^6$,
 (x) $-\text{NR}^6\text{R}^7$,
 (xi) $-\text{CHO}$
 (xii) $-\text{NR}^6\text{COC}_{1-6}\text{alkyl}-\text{R}^7$,
 5 (xiii) $-\text{NR}^6\text{CO}_2\text{C}_{1-6}\text{alkyl}-\text{R}^7$,
 (xiv) $-\text{NR}^6\text{CONR}^6\text{R}^7$,
 (xv) $-\text{OCONR}^6\text{R}^7$,
 (xvi) $-\text{CONR}^6\text{R}^7$,
- 10 (d) halogen,
 (e) $-\text{NR}^6\text{R}^7$,
 (f) $-\text{CN}$,
 (g) $-\text{CHO}$,
 (h) $-\text{CF}_3$,
- 15 (i) $-\text{SR}^8$, wherein R^8 is hydrogen,
 $\text{C}_{1-6}\text{alkyl}$, trifluoromethyl, or phenyl,
 (j) $-\text{SOR}^8$,
 (k) $-\text{SO}_2\text{R}^8$,
 (l) $-\text{CONR}^6\text{R}^7$,
- 20 (m) $\text{R}^9\text{O}(\text{CH}_2)_m-$ wherein R^9 is hydrogen,
 $\text{C}_{1-6}\text{alkyl}$, hydroxy- $\text{C}_{2-3}\text{alkyl}$, $-\text{CF}_3$,
 phenyl, R^{11} or naphthyl and m is 0, 1,
 2, or 3,
 (n) $-\text{CH}(\text{OR}^{12})(\text{OR}^{13})$, wherein R^{12} and R^{13}
 25 are $\text{C}_{1-3}\text{alkyl}$ or taken together form an
 ethyl or propyl bridge, --
- (o) $\overset{\text{O}}{\parallel}\text{R}^9\text{CO}(\text{CH}_2)_m-$ wherein R^9 and m are as
 defined above,
- 30 (p) $\overset{\text{O}}{\parallel}\text{R}^9\text{OC}(\text{CH}_2)_m-$ wherein R^9 and m are as
 defined above, and
 (q) $-\text{R}^{11}$;

- 272 -

or any two of X, Y and Z may be joined to form a saturated ring having 5, 6 or 7 ring atoms, said ring atoms comprising 1 or 2 oxygen atoms, the remaining ring atoms being carbon,

5

X', Y' and Z' independently are selected from:

10

- (a) hydrogen,
- (b) C₁₋₇alkyl,
- (c) C₂₋₆alkenyl,
- (d) halogen,
- (e) $-(CH_2)_m-NR^6R^7$, wherein R⁶, R⁷ and m are as defined above,

15

- (f) -CN,
- (g) -CHO,
- (h) -CF₃,
- (i) -SR⁸, wherein R⁸ is hydrogen, C₁₋₆alkyl, trifluoromethyl, or phenyl,
- (j) -SOR⁸, wherein R⁸ is as defined above,
- (k) -SO₂R⁸, wherein R⁸ is as defined above,
- (l) -CONR⁶R⁷, wherein R⁶ and R⁷ are as defined above,

20

- (m) R⁹O(CH₂)_m- wherein R⁹ and m are as defined above,
- (n) -CH(OR¹²)(OR¹³), wherein R¹² and R¹³ are as defined above,

25

- (o) $R^9\overset{O}{\parallel}CO(CH_2)_m-$ wherein R⁹ and m are as defined above,


30

- (p) $R^9\overset{O}{\parallel}OC(CH_2)_m-$ wherein R⁹ and m are as defined above, and
- (q) -R¹¹;

n is 1 or 2.

- 273 -

2. The compound according to Claim 1
wherein the absolute configuration of Formula I is as
defined in Formula III:




III

- 274 -


3. The compound of Claim 1, wherein the heteroaryl is selected from the group consisting of:

5


10




15




20



25






(Pyridine)




(Pyrimidine)

30




(Pyridazine)




(Pyrazine)

- 275 -


5



10




15



20

25





30 wherein Q is -N(X)-, -O-, or -S-.



- 276 -

4. The compound of Claim 3, wherein the heteroaryl is selected from the group consisting of:



5






10





15



20





25





30

- 277 -


5




10



15



and




20


wherein X is defined in Claim 1.

5. The compound of Claim 1, wherein heteroaryl is:

25



or



;

30

- 278 -

R² is selected from:

- (1) hydrogen,
- (2) methyl,
- (3) ethyl,
- 5 (4) propyl,
- (5) allyl,
- (6) R¹¹,
- (7) -C₂₋₃alkyl-OH; and
- 10 (8) -C₂₋₃alkyl-OR¹¹;

10 R³ is selected from:

- (1) hydrogen,
- (2) hydroxy,
- (3) -OR¹¹, or

R³ and R⁴ taken together form a double bond;

15 R¹⁰ is hydrogen, hydroxy, fluoro, or -OR¹¹;

W is O; and

n is 2.

20

25

30

- 279 -

6. A compound which is selected from the group consisting of:

- 5 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2-furanyl)methoxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 10 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2-furanyl)methoxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 15 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-(2-furanyl)methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 20 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2-thiophene)-methoxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
- 25 tetraone;
- 30 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2-thiophene)-methoxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

- 280 -

- 5 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(3-thiophene)-methoxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 10 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-(2-thiophene)methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 15 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-hydroxy-3''-(3-thiophene)methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 20 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2-thiophene)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 25 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2-benzothienyl)-oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 30 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

- 281 -

5 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

10 17-Ethyl-1,14,20-trihydroxy-12-[2'-(4''-(5-indolyl)-oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

15 17-Ethyl-1,20-dihydroxy-12-[2'-(4''-(5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

20 17-Ethyl-1-hydroxy-12-[2'-(4''-(5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

25 17-Allyl-1,14-dihydroxy-12-[2'-(4''-(5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

30 17-Allyl-1,14-dihydroxy-12-[2'-(4''-(5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Allyl-1,14,20-trihydroxy-12-[2'-(4''-(5-indolyl)-oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

- 282 -

5 17-Allyl-1,20-dihydroxy-12-[2'-(4''-(5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

10 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(5-indolyl)oxy-3''-ethoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

15 17-Allyl-1,14-dihydroxy-12-[2'-(4''-(5-indolyl)oxy-3''-ethoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

20 17-Allyl-1-hydroxy-12-[2'-(4''-(5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

25 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

30 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

- 283 -

5 17-Ethyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

10 17-Ethyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

15 17-Ethyl-1,20-dihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

20 17-Ethyl-1,20-dihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

25 17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

30

- 284 -

5 17-Allyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

10 ~~17-Allyl-1,20-dihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;~~

15 ~~17-Ethyl-1-hydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;~~

20 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-ethoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

25 17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-ethoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

30

- 285 -

5 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-ethyl-5-indolyl)oxy-3''-ethoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

10 17-Allyl-1-hydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)-oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

15 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-allyloxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

20 17-Ethyl-1-hydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)-oxy-3''-allyloxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

25 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-n-propyloxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
30

- 286 -

5 17-Ethyl-1-hydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)-oxy-3''-n-propyloxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

10 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-methyl-5-indolyl)oxy-3''-i-propyloxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

15 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-ethyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

20 17-Ethyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-ethyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

25 17-Ethyl-1,20-dihydroxy-12-[2'-(4''-(1-N-ethyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

30

- 287 -

5 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-ethyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

10 17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-ethyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

15 17-Allyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-ethyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

20 17-Allyl-1,20-dihydroxy-12-[2'-(4''-(1-N-ethyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

25 17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-ethyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
30

- 288 -

5 17-Ethyl-1-hydroxy-12-[2'-(4''-(1-N-ethyl-5-indolyl)-
oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-
dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-
tricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone;

10 17-Allyl-1-hydroxy-12-[2'-(4''-(1-N-ethyl-5-indolyl)-
oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-
dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-
tricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone;

15 17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-ethyl-5-
indolyl)oxy-3''-ethoxycyclohexyl)-1'-methylvinyl]-
23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-
4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone;

20 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-propyl-5-
indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-
23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-
4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone;

25 17-Ethyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-propyl-5-
indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-
23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-
4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
30 tetraone;

- 289 -

5 17-Ethyl-1,20-dihydroxy-12-[2'-(4''-(1-N-propyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxazetetracyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

10 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-propyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxazetetracyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

15 17-Ethyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-propyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxazetetracyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

20 17-Ethyl-1,20-dihydroxy-12-[2'-(4''-(1-N-propyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxazetetracyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

25 17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-propyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxazetetracyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

30

- 290 -

5 17-Allyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-propyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

10 17-Allyl-1,20-dihydroxy-12-[2'-(4''-(1-N-propyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

15 17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-propyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

20 17-Ethyl-1-hydroxy-12-[2'-(4''-(1-N-propyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

25 17-Allyl-1-hydroxy-12-[2'-(4''-(1-N-propyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
30

- 291 -

5 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-propyl-5-indolyl)oxy-3''-ethoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

10 17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-propyl-5-indolyl)oxy-3''-ethoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

15 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-allyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

20 17-Ethyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-allyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

25 17-Ethyl-1,20-dihydroxy-12-[2'-(4''-(1-N-allyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
30

- 292 -

5 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-allyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

10 17-Ethyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-allyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

15 17-Ethyl-1,20-dihydroxy-12-[2'-(4''-(1-N-allyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

20 17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-allyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

25 17-Allyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-allyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

30

- 293 -

- 5 17-Allyl-1,20-dihydroxy-12-[2'-(4''-(1-N-allyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 10 17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-allyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 15 17-Ethyl-1-hydroxy-12-[2'-(4''-(1-N-allyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 20 17-Allyl-1-hydroxy-12-[2'-(4''-(1-N-allyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 25 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-allyl-5-indolyl)oxy-3''-ethoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 30

- 294 -

- 5 17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-allyl-5-indolyl)oxy-3''-ethoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 10 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-2-hydroxyethyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 15 17-Ethyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-2-hydroxyethyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 20 17-Ethyl-1,20-dihydroxy-12-[2'-(4''-(1-N-2-hydroxyethyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 25 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-2-hydroxyethyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-
- 30 2,3,10,16-tetraone;

- 295 -

5 17-Ethyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-2-hydroxy-ethyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methyl-vinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

10 17-Ethyl-1,20-dihydroxy-12-[2'-(4''-(1-N-2-hydroxy-ethyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methyl-vinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

15 17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-2-hydroxy-ethyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methyl-vinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

20 17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-2-hydroxy-ethyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methyl-vinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

25 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-benzyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

30

- 296 -

5 17-Ethyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-benzyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

10 17-Ethyl-1,20-dihydroxy-12-[2'-(4''-(1-N-benzyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

15 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-benzyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

20 17-Ethyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-benzyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

25 17-Ethyl-1,20-dihydroxy-12-[2'-(4''-(1-N-benzyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

30

- 297 -

5 17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-benzyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

10 17-Allyl-1,14,20-trihydroxy-12-[2'-(4''-(1-N-benzyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

15 17-Allyl-1,20-dihydroxy-12-[2'-(4''-(1-N-benzyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

20 17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-benzyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

25 17-Ethyl-1-hydroxy-12-[2'-(4''-(1-N-benzyl-5-indolyl)-oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

30

- 298 -

5 17-Allyl-1-hydroxy-12-[2'-(4''-(1-N-benzyl-5-indolyl)-oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

10 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-benzyl-5-indolyl)oxy-3''-ethoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

15 17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-benzyl-5-indolyl)oxy-3''-ethoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

20 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-cyclopropyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

25 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-cyclopropyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

30

- 299 -

5 17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-cyclopropyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

10 17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-cyclopropyl-5-indolyl)oxy-3''-hydroxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

15 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-N-cyclopropyl-5-indolyl)oxy-3''-ethoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

20 17-Allyl-1,14-dihydroxy-12-[2'-(4''-(1-N-cyclopropyl-5-indolyl)oxy-3''-ethoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

25 17-Ethyl-1-hydroxy-12-[2'-(4''-(1-N-cyclopropyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

30

- 300 -

- 5 17-Allyl-1-hydroxy-12-[2'-(4''-(1-N-cyclopropyl-5-indolyl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 10 17-Ethyl-1-hydroxy-12-[2'-(4''-methoxy-N-tryptophanyl-carbonylmethoxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 15 17-Ethyl-1-hydroxy-12-[2'-(4''-3-indolylethylamino-carbonylmethoxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 20 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-(3-hydroxypropyl)indol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 25 17-Ethyl-1,14-dihydroxy-12-[2'-(3''-hydroxy-4''-(1-hydroxyethylindol-5-yl)oxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;
- 30

- 301 -

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-hydroxyethyl-
indol-6-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-
23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-
5 azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-methylindol-6-
yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-
10 dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-
tricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-dibenzyl-
15 phosphonoxy-ethylindol-5-yl)oxy-3''-methoxycyclohexyl)-
1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetra-
methyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-
18-ene-2,3,10,16-tetraone;

20 Monopotassium salt of 17-Ethyl-1,14-dihydroxy-12-[2'-
(4''-(1-phosphonoxy-ethylindol-5-yl)oxy-3''-methoxy-
cyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,
27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-
octacos-18-ene-2,3,10,16-tetraone;

25 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-(N,N-dimethyl-
glycyloxy)ethylindol-5-yl)oxy-3''-methoxycyclohexyl)-
1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetra-
methyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-
30 18-ene-2,3,10,16-tetraone;

- 302 -

5 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-succinyloxy-ethylindol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

10 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-methyl-3-phenylindol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

15 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1-methyl-3-(2-hydroxyethyl)indol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

20 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1,3-dimethylindol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

25 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1,3-dimethylindol-5-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

30

- 303 -

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(9'-methylcarbazol-3'-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2''''-(3''''-diethylaminopropionyloxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2''''-(3''''-dimethylaminopropionyloxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2''''-(3''''-aminopropionyloxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2''''-(3''''-benzyloxycarbonyl-2''''-benzyloxycarbonylamino-propionyloxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

- 304 -

5 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2'''-(aspartyl-
oxy)ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-
methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-
11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-
2,3,10,16-tetraone;

10 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2'''-(1''''-
imidazolylcarbonyloxy)ethyl)indol-5'''-yl)oxy-3''-
methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

15 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(2'''-(1''''-
piperazinocarbonyloxy)ethyl)indol-5'''-yl)oxy-3''-
methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

20 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-
(2''''-hydroxy)ethylaminocarbonyloxy)ethyl)indol-5'''-
yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-
dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-
tricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-
25 tetraone;

30 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-
(isopropylaminocarbonyloxy)ethyl)indol-5'''-yl)oxy-3''-
methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

- 305 -

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-(
 (1''''-piperidinocarbonyloxy)ethyl)indol-5'''-yl)oxy-
 3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
 5 13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
 [22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-(
 (1''''-morpholinocarbonyloxy)ethyl)indol-5'''-yl)oxy-
 10 3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
 13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
 [22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-(
 (diphenylaminocarbonyloxy)ethyl)indol-5'''-yl)oxy-3''-
 15 methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
 13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
 [22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-(
 (diethylaminocarbonyloxy)ethyl)indol-5'''-yl)oxy-3''-
 20 methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-
 13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-
 [22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-(
 -methanesulfonyloxyethyl)indol-5'''-yl)oxy-3''-methoxy-
 25 cyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,
 27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-
 30 octacos-18-ene-2,3,10,16-tetraone;

- 306 -

5 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-azido-ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

10 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-(2''''-amino-ethyl)indol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

15 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-t-butyl-di-methylsilyloxyethoxyethylindol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

20 17-Ethyl-1,14-dihydroxy-12-[2'-(4''-(1'''-hydroxyethoxyethylindol-5'''-yl)oxy-3''-methoxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone;

25 17-Ethyl-1,14-dihydroxy-12-[2'-(3''-methoxy-4''-(1'''-(1''''-oxoprop-3''''-yl)indol-5'''-yl)oxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetraone; and

30

- 307 -

17-Ethyl-1,14-dihydroxy-12-[2'-(3''-methoxy-4''-(1'''-(1''''-carboxyeth-2''''-yl)indol-5'''-yl)oxycyclohexyl)-1'-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]-octacos-18-ene-2,3,10,16-tetraone;

or a pharmaceutically acceptable salt thereof.

10

7. A pharmaceutical composition comprising a pharmaceutical carrier and a therapeutically effective amount of the compound of Claim 1.

15

8. A method for the treatment of immunoregulatory disorders or diseases comprising the administration to a mammalian species in need of such treatment of an effective amount of the compound of Claim 1.

20


9. A method for the treatment of resistance to transplantation comprising the administration to a mammalian species in need of such treatment of an effective amount of the compound of Claim 1.

25

30

- 308 -

10. A process for the preparation of a compound of structural Formula I:



or a pharmaceutically acceptable salt thereof,
wherein:

25 R^1 is selected from:

- (1) heteroaryl;
- (2) substituted heteroaryl in which the substituents are X, Y and Z;
- (3) heteroaryl- C_{1-10} alkyl;
- 30 (4) substituted heteroaryl- C_{1-10} alkyl in which the heteroaryl group is substituted by X, Y and Z and the alkyl portion may be substituted with one or more of the substituent(s) selected from:

- 309 -

- (a) hydroxy,
(b) oxo,
(c) C₁₋₆-alkoxy,
(d) aryl-C₁₋₃alkoxy,
5 (e) substituted aryl-C₁₋₃alkoxy, in which
the substituents on aryl are X, Y and Z,
(f) unsubstituted or substituted aryloxy,
in which the substituents on aryl are
X, Y and Z,
10 (g) -OCO-C₁₋₆alkyl,
(h) -NR⁶R⁷, wherein R⁶ and R⁷ are
independently selected from
(i) hydrogen,
(ii) C₁₋₁₀alkyl unsubstituted or
15 substituted with one or more of
the substituent(s) selected from:
(a') aryl, which is unsubstituted
or substituted with X, Y and
Z,
20 (b') heteroaryl, which is
unsubstituted or substituted
with X, Y and Z,
(c') -OH,
(d') C₁₋₆alkoxy,
25 (e') -CO₂H,
(f') -CO₂-C₁₋₆alkyl,
(g') -C₃₋₇cycloalkyl, and
(h') -OR¹¹,
(iii) C₃₋₁₀alkenyl unsubstituted or
30 substituted with one or more of
the substituent(s) selected from:

- 310 -

- (a') aryl, which is unsubstituted or substituted with X, Y and Z,
- 5 (b') heteroaryl, which is unsubstituted or substituted with X, Y and Z,
- (c') -OH,
- (d') C₁₋₆alkoxy,
- 10 (e') -CO₂H,
- (f') -CO₂-C₁₋₆alkyl,
- (g') -C₃₋₇cycloalkyl, and
- (h') -OR¹¹,
- (iv) or where R⁶ and R⁷ and the N to which they are attached may form
- 15 an unsubstituted or substituted 3-7-membered heterocyclic ring which may include one or two additional heteroatoms independently selected from the
- 20 group consisting of O, S(O)_p, NR¹⁴, wherein R¹⁴ is hydrogen or C₁₋₆ alkyl unsubstituted or substituted by phenyl, and p is 0, 1 or 2,
- 25 (i) -NR⁶CO-C₁₋₆alkyl-R⁷, wherein R⁶ and R⁷ are as defined above,
- (j) -NR⁶CO₂-C₁₋₆alkyl-R⁷,
- (k) -NR⁶CONR⁶R⁷,
- (l) -OCONR⁶R⁷,
- 30 (m) -COOR⁶,
- (n) -CHO,
- (o) aryl,

- 311 -

- (p) substituted aryl in which the substituents are X, Y and Z,
(q) $-OR^{11}$, and
(r) $-S(O)_p-C_{1-6}alkyl$;
5 (5) heteroaryl- $C_{1-10}alkyl$ wherein one or more of the alkyl carbons is replaced by a group selected from: $-NR^6-$, $-O-$, $-S(O)_p-$, $-CO_2-$, $-O_2C-$, $-CONR^6-$, $-NR^6CO-$, $-NR^6CONR^7-$;
10 (6) substituted heteroaryl- $C_{1-10}alkyl$ wherein one or more of the alkyl carbons is replaced by a group selected from: $-NR^6-$, $-O-$, $-S(O)_p-$, $-CO_2-$, $-O_2C-$, $-CONR^6-$, $-NR^6CO-$, and
15 $-NR^6CONR^7-$, the heteroaryl group is substituted with X, Y, and Z, and the alkyl group may be substituted with one or more of the substituent(s) selected from:
20 (a) hydroxy,
(b) oxo,
(c) $C_{1-6}alkoxy$,
(d) aryl- $C_{1-3}alkoxy$,
(e) substituted aryl- $C_{1-3}alkoxy$, in which
25 the substituents on aryl are X, Y and Z,
(f) unsubstituted or substituted aryloxy, in which the substituents on aryl are X, Y and Z,
(g) $-OCO-C_{1-6}alkyl$,
30 (h) $-NR^6R^7$, wherein R^6 and R^7 are as defined above,
(i) $-NR^6CO-C_{1-6}alkyl-R^7$,
(j) $-NR^6CO_2-C_{1-6}alkyl-R^7$.

- 312 -

- (k) $-\text{NR}^6\text{CONR}^6\text{R}^7$,
(l) $-\text{OCONR}^6\text{R}^7$,
(m) $-\text{COOR}^6$,
(n) $-\text{CHO}$,
5 (o) aryl,
(p) substituted aryl in which the substituents are X, Y and Z,
(q) $-\text{OR}^{11}$, and
(r) $-\text{S}(\text{O})_p\text{-C}_{1-6}\text{alkyl}$;
10 (7) heteroaryl- C_{3-10} alkenyl wherein alkenyl contains one to four double bonds;
(8) heteroaryl- C_{3-10} alkenyl wherein alkenyl contains one to four double bonds and wherein one or more of the alkyl carbons is
15 replaced by a group selected from: $-\text{NR}^6-$, $-\text{O}-$, $-\text{S}(\text{O})_p-$, $-\text{CO}_2-$, $-\text{O}_2\text{C}-$, $-\text{CONR}^6-$, $-\text{NR}^6\text{CO}-$, and $-\text{NR}^6\text{CONR}^7-$;
(9) substituted heteroaryl- C_{3-10} alkenyl wherein alkenyl contains one to four double bonds
20 and wherein one or more of the alkyl carbons may be replaced by a group selected from: $-\text{NR}^6-$, $-\text{O}-$, $-\text{S}(\text{O})_p-$, $-\text{CO}_2-$, $-\text{O}_2\text{C}-$, $-\text{CONR}^6-$, $-\text{NR}^6\text{CO}-$, and $-\text{NR}^6\text{CONR}^7$, the heteroaryl group is substituted with X, Y, and Z, and the
25 alkyl group may be substituted with one or more of the substituent(s) selected from:
(a) hydroxy,
(b) oxo,
(c) C_{1-6} alkoxy,
30 (d) aryl- C_{1-3} alkoxy,
(e) substituted aryl- C_{1-3} alkoxy, in which the substituents on aryl are X, Y and Z,

- 313 -

- (f) unsubstituted or substituted aryloxy,
in which the substituents on aryl are
X, Y and Z,
(g) $-\text{OCO}-\text{C}_{1-6}\text{alkyl}$,
5 (h) $-\text{NR}^6\text{R}^7$, wherein R^6 and R^7 as defined
above,
(i) $-\text{NR}^6\text{CO}-\text{C}_{1-6}\text{alkyl}$, wherein R^6 is as
defined above,
(j) $-\text{NR}^6\text{CO}_2-\text{C}_{1-6}\text{alkyl}$,
10 (k) $-\text{NR}^6\text{CONR}^6\text{R}^7$,
(l) $-\text{OCONR}^6\text{R}^7$,
(m) $-\text{COOR}^6$,
(n) $-\text{CHO}$,
(o) aryl,
15 (p) substituted aryl in which the
substituents are X, Y and Z, and
(q) $-\text{OR}^{11}$, and
(r) $-\text{S}(\text{O})_p-\text{C}_{1-6}\text{alkyl}$;

20 R^2 is selected from:

- (1) the definitions of R^1 ;
(2) hydrogen;
(3) phenyl;
(4) substituted phenyl in which the substituents
25 are X, Y and Z;
(5) 1- or 2-naphthyl;
(6) substituted 1- or 2-naphthyl in which the
substituents are X, Y and Z;
(7) biphenyl;
30 (8) substituted biphenyl in which the
substituents are X, Y and Z;
(9) $\text{C}_{1-10}\text{alkyl}$;

- 314 -

- (10) substituted-C₁₋₁₀alkyl in which one or more substituent(s) is(are) selected from:
- (a) hydroxy,
 - (b) oxo,
 - 5 (c) C₁₋₆alkoxy,
 - (d) aryl-C₁₋₃alkoxy,
 - (e) substituted aryl-C₁₋₃alkoxy, in which the substituents on aryl are X, Y and Z,
 - (f) unsubstituted or substituted aryloxy,
 - 10 ~~in which the substituents on aryl are~~
X, Y and Z,
 - (g) -OCO-C₁₋₆alkyl,
 - (h) -NR⁶R⁷, wherein R⁶ and R⁷ are as
~~defined above~~
 - 15 (i) -NR⁶CO-C₁₋₆alkyl-R⁷, wherein R⁶ and R⁷
is as defined above,
 - (j) -COOR⁶, wherein R⁶ is as defined above,
 - (k) -CHO,
 - (l) phenyl,
 - 20 (m) substituted phenyl in which the
substituents are X, Y and Z,
 - (n) 1- or 2-naphthyl,
 - (o) substituted 1- or 2-naphthyl in which
the substituents are X, Y and Z,
 - 25 ~~(p) biphenyl,~~
 - ~~(q) substituted biphenyl in which the~~
~~substituents are X, Y and Z,~~
 - (r) -OR¹¹, and
 - (s) -S(O)_p-C₁₋₆alkyl;
 - 30 (11) C₃₋₁₀alkenyl;
 - (12) substituted C₃₋₁₀alkenyl in which one or
more substituent(s) is(are) selected from:
 - (a) hydroxy,

- 315 -

- (b) oxo,
(c) C₁₋₆alkoxy,
(d) phenyl-C₁₋₃alkoxy,
(e) substituted phenyl-C₁₋₃alkoxy, in which
5 the substituents on phenyl are
X, Y and Z,
(f) -OCO-C₁₋₆alkyl,
(g) -NR⁶R⁷, wherein R⁶ and R⁷ are as
defined above
10 (h) -NR⁶CO-C₁₋₆alkyl, wherein R⁶ is as
defined above,
(i) -COOR⁶, wherein R⁶ is as defined above,
(j) -CHO,
(k) phenyl,
15 (l) substituted phenyl in which the
substituents are X, Y and Z,
(m) 1- or 2-naphthyl,
(n) substituted 1- or 2-naphthyl in which
the substituents are X, Y and Z,
20 (o) biphenyl,
(p) substituted biphenyl in which the
substituents are X, Y and Z,
(q) -OR¹¹, and
(r) -S(O)_p-C₁₋₆alkyl;
25 (13) C₃₋₁₀alkynyl;
(14) substituted C₃₋₁₀alkynyl in which one or
more substituent(s) is(are) selected from:
(a) hydroxy,
(b) oxo,
30 (c) C₁₋₆alkoxy,
(d) phenyl-C₁₋₃alkoxy,

- 316 -

- (e) substituted phenyl-C₁₋₃alkoxy, in which the substituents on phenyl are X, Y and Z,
- (f) -OCO-C₁₋₆alkyl,
- 5 (g) -NR⁶R⁷, wherein R⁶ and R⁷ are as defined above,
- (h) -NR⁶CO-C₁₋₆alkyl, wherein R⁶ is as defined above,
- (i) -COOR⁶, wherein R⁶ is as defined above,
- 10 (j) -CHO,
- (k) phenyl,
- (l) substituted phenyl in which the substituents are X, Y and Z,
- (m) 1- or 2-naphthyl,
- 15 (n) substituted 1- or 2-naphthyl in which the substituents are X, Y and Z,
- (o) biphenyl,
- (p) substituted biphenyl in which the substituents are X, Y and Z,
- 20 (q) -OR¹¹; and
- (15) -R¹¹;
- R³ is hydrogen, hydroxy, -OR¹¹, or C₁₋₆alkoxy;
- R⁴ is hydrogen, or R³ and R⁴ taken together form a double bond;
- 25 R⁵ is methyl, ethyl, propyl or allyl;
- R¹⁰ is hydrogen, hydroxy, -OR¹¹ or fluoro;
- R¹¹ is selected from:
- (a) -PO(OH)O⁻M⁺, wherein M⁺ is a positively charged inorganic or organic counterion,
- 30 (b) -SO₃⁻M⁺,
- (c) -CO(CH₂)_qCO₂⁻M⁺, wherein q is 1-3, and

- 317 -

(d) $-\text{CO}-\text{C}_{1-6}\text{alkyl}-\text{NR}^6\text{R}^7$, wherein R^6 and R^7 are as defined above and the alkyl is unsubstituted or substituted with one or more substituents selected from:

5

(i) hydroxy,

(ii) $\text{C}_{1-6}\text{alkoxy}$,

(iii) $-\text{NR}^{16}\text{R}^{17}$, wherein R^{16} and R^{17} are independently selected from:

(a') hydrogen, and

10

(b') $\text{C}_{1-6}\text{alkyl}$,

(iv) $-\text{COOR}^6$, wherein R^6 is as defined above,

(v) phenyl,

15

(iv) substituted phenyl in which the substituents are X, Y and Z,

(vii) heteroaryl,

(viii) $-\text{SH}$, and

(ix) $-\text{S}-\text{C}_{1-6}\text{alkyl}$;

W is O or (H, OH);

20

X, Y and Z independently are selected from:

(a) hydrogen,

(b) $\text{C}_{1-10}\text{alkyl}$, unsubstituted or substituted with one or more substituents selected from:

25

(i) aryl,

(ii) substituted aryl in which the substituents are X', Y' and Z',

(iii) heteroaryl,

30

(iv) substituted heteroaryl in which the substituents are X', Y', and Z',

(v) unsubstituted or substituted aryloxy, in which the substituents

- 318 -

on aryl are X', Y' and Z',

- (vi) $-OR^6$,
- (vii) $-OR^{11}$,
- (viii) $-OCOR^6$,
- (ix) $-OCO_2R^6$,
- (x) $-NR^6R^7$,
- (xi) $-CHO$,
- (xii) $-NR^6COC_{1-6}alkyl-R^7$,
- (xiii) $-NR^6CO_2C_{1-6}alkyl-R^7$,
- (xiv) $-NR^6CONR^6R^7$,
- (xv) $-OCONR^6R^7$,
- (xvi) $-CONR^6R^7$,

(c) $C_{1-10}alkyl$ wherein one or more of the alkyl carbons is replaced by a group selected from $-NR^6-$, $-O-$, $-S(O)_p-$, $-CO_2-$, $-O_2C-$, $-CONR^6-$, $-NR^6CO-$, $-NR^6CONR^7-$, $-CO-$, $-CH(OH)-$, alkenyl or alkynyl and the alkyl may be unsubstituted or substituted with one or more substituents selected from:

- (i) aryl,
 - (ii) substituted aryl in which the substituents are X', Y' and Z',
 - (iii) heteroaryl,
 - (iv) substituted heteroaryl in which the substituents are X', Y', and Z',
 - (v) unsubstituted or substituted aryloxy, in which the substituents on aryl are X', Y', and Z',
- (vi) $-OR^6$,
 - (vii) $-OR^{11}$,
 - (viii) $-OCOR^6$,

- 319 -

- (ix) $-\text{OCO}_2\text{R}^6$,
 (x) $-\text{NR}^6\text{R}^7$,
 (xi) $-\text{CHO}$
 (xii) $-\text{NR}^6\text{COC}_{1-6}\text{alkyl}-\text{R}^7$,
 5 (xiii) $-\text{NR}^6\text{CO}_2\text{C}_{1-6}\text{alkyl}-\text{R}^7$,
 (xiv) $-\text{NR}^6\text{CONR}^6\text{R}^7$,
 (xv) $-\text{OCONR}^6\text{R}^7$,
 (xvi) $-\text{CONR}^6\text{R}^7$,
- 10 (d) halogen,
 (e) $-\text{NR}^6\text{R}^7$,
 (f) $-\text{CN}$,
 (g) $-\text{CHO}$,
 (h) $-\text{CF}_3$,
- 15 (i) $-\text{SR}^8$, wherein R^8 is hydrogen,
 $\text{C}_{1-6}\text{alkyl}$, trifluoromethyl, or phenyl,
 (j) $-\text{SOR}^8$,
 (k) $-\text{SO}_2\text{R}^8$,
 (l) $-\text{CONR}^6\text{R}^7$,
- 20 (m) $\text{R}^9\text{O}(\text{CH}_2)_m-$ wherein R^9 is hydrogen,
 $\text{C}_{1-6}\text{alkyl}$, hydroxy- $\text{C}_{2-3}\text{alkyl}$, $-\text{CF}_3$,
 phenyl, R^{11} or naphthyl and m is 0, 1,
 2, or 3,
 (n) $-\text{CH}(\text{OR}^{12})(\text{OR}^{13})$, wherein R^{12} and R^{13}
 25 are $\text{C}_{1-3}\text{alkyl}$ or taken together form an
 ethyl or propyl bridge,
- (o) $\text{R}^9\overset{\text{O}}{\overset{||}{\text{C}}}(\text{CH}_2)_m-$ wherein R^9 and m are as
 defined above,
- 30 (p) $\text{R}^9\overset{\text{O}}{\overset{||}{\text{C}}}(\text{CH}_2)_m-$ wherein R^9 and m are as
 defined above, and
 (q) $-\text{R}^{11}$;

- 320 -

or any two of X, Y and Z may be joined to form a saturated ring having 5, 6 or 7 ring atoms, said ring atoms comprising 1 or 2 oxygen atoms, the remaining ring atoms being carbon,

X', Y' and Z' independently are selected from:

- (a) hydrogen,
- (b) C₁₋₇alkyl,
- (c) C₂₋₆alkenyl,
- (d) halogen,
- (e) $-(CH_2)_m-NR^6R^7$, wherein R⁶, R⁷ and m are as defined above,
- (f) -CN,
- (g) -CHO,
- (h) -CF₃,
- (i) -SR⁸, wherein R⁸ is hydrogen, C₁₋₆alkyl, trifluoromethyl, or phenyl,
- (j) -SOR⁸, wherein R⁸ is as defined above,
- (k) -SO₂R⁸, wherein R⁸ is as defined above,
- (l) -CONR⁶R⁷, wherein R⁶ and R⁷ are as defined above,
- (m) R⁹O(CH₂)_m- wherein R⁹ and m are as defined above,
- (n) -CH(OR¹²)(OR¹³), wherein R¹² and R¹³ are as defined above,
- (o) $R^9\overset{O}{\overset{||}{C}}(CH_2)_m-$ wherein R⁹ and m are as defined above,
- (p) $R^9\overset{O}{\overset{||}{OC}}(CH_2)_m-$ wherein R⁹ and m are as defined above, and
- (q) -R¹¹;

n is 1 or 2;

- 321 -

which comprises:


contacting a compound of structural Formula IIa:

5

10

15

20



IIa

wherein:

25

E is hydrogen, methyl or R²;

W is O or (H, OH);

R³ is hydrogen, hydroxy, or C₁₋₆ alkoxy;R⁴ is hydrogen, or R³ and R⁴ taken together form a double bond;

30

R⁵ is methyl, ethyl, propyl or allyl; and

n is 1 or 2;

- 322 -

with a triheteroaryl bismuth diacetate reagent of the
formula: $(R^1)_3Bi(OAc)_2$ or $(R^2)_3Bi(OAc)_2$
(wherein R^1 and R^2 are as defined above) in an
5 organic solvent at a temperature of $0^\circ C$ to solvent
reflux temperature in the presence of an oxidant and
a catalytic amount of a copper(II) salt;

or with a trichloroacetimidate reagent of the formula:
10 $(R^1O)C=NH(CCl_3)$ or $(R^2O)C=NH(CCl_3)$
(wherein R^1 and R^2 are as defined above) in an
organic solvent at a temperature of $0^\circ C$ to solvent
reflux temperature in the presence of a catalytic
amount of an organic or inorganic acid;

15 or with an alkylating agent of the formula:



(wherein LG is an appropriate leaving group and R^1
and R^2 are as defined above) in an organic solvent at
20 a temperature of $0^\circ C$ to solvent reflux temperature in
the presence of an amine base.

25

30

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 92/07508

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl. 5 C07H19/01; A61K31/70		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	C07H ; A61K ; C07D	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
P,X	GB,A,2 245 891 (FUJISAWA PHARMACEUTICAL CO. LTD) 15 January 1992 cited in the application see page 13, line 20 - page 14, line 10; claims	1-10
A	EP,A,0 428 365 (MERCK AND CO., LTD.) 22 May 1991 cited in the application see claims; examples	1-10
<p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
07 DECEMBER 1992	21.12.92	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	DAY G.J.	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 92/07508

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 8 and 9 are directed to a method of treatment of the human/
animal body, the search has been carried out and based on the alleged
effects of the compound/composition (ART 17(2) + Rule 39.1(iv)PCT)
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such
an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. US 9207508
SA 64867**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 07/12/92

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB-A-2245891	15-01-92	None	
EP-A-0428365	22-05-91	CA-A- 2029860	14-05-91
		JP-A- 3209386	12-09-91

EPO FORM P0479

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82